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SCIENTIFIC OPINION 
Scientific Opinion on the essential composition of infant and follow-on 
formulae
1
 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2,3
 
European Food Safety Authority (EFSA), Parma, Italy 
This scientific output, published on 05 August 2014, replaces the earlier version published on 24 July 2014* 
ABSTRACT 
Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition and 
Allergies (NDA) was asked to deliver a scientific opinion on the essential composition of infant and follow-on 
formula. This opinion reviews the opinion provided by the Scientific Committee on Food in 2003 on the 
essential requirements of infant and follow-on formulae in light of more recent evidence and by considering the 
Panel’s opinion of October 2013 on nutrient requirements and dietary intakes of infants and young children in 
the European Union. The minimum content of a nutrient in formula proposed in this opinion is derived from the 
intake levels the Panel had considered adequate for the majority of infants in the first six months of life in its 
previous opinion and an average amount of formula consumed during this period. From a nutritional point of 
view, the minimum contents of nutrients in infant and follow-on formula proposed by the Panel cover the 
nutritional needs of virtually all healthy infants born at term and there is no need to exceed these amounts in 
formulae, as nutrients which are not used or stored have to be excreted and this may put a burden on the infant’s 
metabolism. Therefore, the Panel emphasises that maximum amounts should be interpreted not as target values 
but rather as upper limits of a range which should not be exceeded. 
© European Food Safety Authority, 2014 
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SUMMARY 
Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition 
and Allergies (NDA) was asked to deliver a scientific opinion on the essential composition of infant 
and follow-on formula. This opinion reviews the opinion provided by the Scientific Committee on 
Food (SCF) in 2003 on the essential requirements of infant and follow-on formulae in the light of 
more recent evidence and by considering the Panel’s opinion of October 2013 on nutrient 
requirements and dietary intakes of infants and young children in the European Union. 
There is scientific consensus that breast milk is the preferred food for all healthy infants and provides 
an adequate supply of all nutrients to support growth and development (with the exception of vitamin 
K during the first weeks of life and of vitamin D). Whereas the composition of infant formula remains 
stable over time, breast milk composition changes continuously and therefore infant formula cannot 
imitate breast milk. 
All formulae intended for infants must be safe and suitable to meet the nutritional requirements and 
promote growth and development of infants born at term when used as a sole source of nutrition 
during the first months of life, and when used as the principal liquid element in a progressively 
diversified diet after the introduction of appropriate complementary feeding. Nutrients and substances 
should be added to formulae for infants only in amounts that serve a nutritional or other benefit. The 
addition in amounts higher than those serving a benefit or the inclusion of unnecessary substances in 
formulae may put a burden on the infant’s metabolism and/or on other physiological functions, as 
substances which are not used or stored have to be excreted. 
The minimum content of a nutrient in formula proposed in this opinion is derived from the intake 
levels the Panel had considered adequate for the majority of infants in the first half of the first year of 
life in its previous opinion and an average amount of daily energy intake from formula during this 
period (500 kcal/day). These minimum amounts should be understood as target values which cover the 
nutritional needs of virtually all infants born at term for optimal growth and development, whereas 
maximum amounts are driven by safety aspects and also taking into account technological 
considerations and should not be interpreted as target values but rather as upper limits of a range, 
which should not be exceeded. 
Specifications for the currently permitted maximum amounts of micronutrients in formulae were 
mostly calculated as three to five times the minimum amounts established at the time and took into 
account the established history of apparent safe use (Codex Stan 72-1981, Codex Stan 156-1987, the 
Directive 2006/141/EC, and the SCF) and were not based on scientific evidence for adverse effects 
owing to the lack of such evidence for most nutrients. 
There are no reports on any adverse effects associated with the use of formulae complying with the 
current specifications for micronutrients as laid down in Directive 2006/141/EC, although there are no 
studies available which were designed to investigate the short- or long-term health consequences of 
consumption of formulae containing the currently permitted maximum amounts of micronutrients in 
infant or follow-on formula. Assuming an energy intake from formula of 500 kcal/day (average of the 
average requirement for energy of boys and girls aged three to four months), regular consumption of a 
formula by an infant containing the currently permitted maximum amounts of zinc, iodine, vitamin A 
and folate (if the whole amount is provided in the form of folic acid) would imply that the Tolerable 
Upper Intake Levels (ULs) are exceeded for these nutrients. When assuming an energy intake from 
formula of 700 kcal/day (highest observed mean energy intakes in infants below six months of age), 
also intakes of selenium would exceed the UL. The Panel acknowledges that the ULs used in this 
estimation were those derived for young children and there is uncertainty with respect to their 
extrapolation to infants. 
Cow’s milk, goat’s milk and isolated soy protein are safe and suitable protein sources for use in infant 
and follow-on formulae based on intact protein. The use of other protein sources in infant and follow-
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on formulae and/or the introduction of new technologies need clinical evaluation and their safety and 
suitability should be established in the target population prior to their general use in infant and follow-
on formulae. 
Formulae containing protein hydrolysates are insufficiently characterised by the declared protein 
content even though they fulfil regulatory criteria concerning amino acid patterns; therefore, the safety 
and suitability of each specific infant and follow-on formula containing protein hydrolysates have to 
be established by clinical evaluation in the target population. 
The use of a default conversion factor of 6.25 is proposed to calculate the protein content from the 
total nitrogen content, irrespective of the protein source. 
Infant and follow-on formulae should provide on an energy basis indispensable and conditionally 
indispensable amino acids in amounts at least equal to the reference protein (i.e. breast milk), 
irrespective of the protein source. 
There is no necessity to add arachidonic acid, eicosapentaenoic acid, non-digestible oligosaccharides, 
“probiotics” or “synbiotics”, chromium, fluoride, taurine and nucleotides to infant and follow-on 
formulae. There is also no necessity to use phospholipids as a source of long-chain polyunsaturated 
fatty acids instead of triacylglycerols in infant and follow-on formulae or to use triacylglycerols with 
palmitic acid predominantly esterified in the sn-2 position in infant and follow-on formulae instead of 
triacylglycerols from other fat sources. For follow-on formulae, in contrast to infant formulae, the 
addition of L-carnitine, inositol and choline is not necessary. 
The Panel did not consider it necessary to propose specific compositional criteria for formulae 
consumed after one year of age, as formulae consumed during the first year of life can continue to be 
used by young children. 
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BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION 
Directive 2009/39/EC on foodstuffs intended for particular nutritional uses lays down general rules
4
 on 
the composition of such foods that are specially designed to meet the particular nutritional 
requirements of the persons to whom they are intended, including infants and young children in good 
health. 
One of the measures adopted under that framework legislation is Commission Directive 2006/141/EC 
on infant formulae and follow-on formulae
5
. That Directive was adopted originally in 1991 and 
revised globally in 2006. 
The Directive defines ‘infants’ as “children under the age of 12 months” and ‘young children’ as 
“children aged between one and three years”. 
The Directive also defines ‘infant formulae’ as “foodstuffs for particular nutritional use by infants 
during the first months of life and satisfying by themselves the nutritional requirements of such infants 
until the introduction of appropriate complementary feeding” and ‘follow-on formulae’ as “foodstuffs 
intended for particular nutritional use by infants when appropriate complementary feeding is 
introduced and constituting the principal liquid element in a progressively diversified diet of such 
infants”. 
The Directive sets essential requirements for the composition of infant formula and follow-on formula, 
which are based on a number of opinions of the Scientific Committee on Food, the latest one being the 
“Report of the Scientific Committee on Food on the Revision of Essential Requirements of Infant 
Formulae and Follow-on Formulae”, adopted on 4 April 20036. In the last ten years, scientific and 
technological developments on the essential composition of these products have progressed and there 
are increasing calls for a review of the legislation to reflect such developments. 
The Commission’s proposal for a Regulation of the European Parliament and the Council on foods 
intended for infants and young children and on food for special medical purposes
7
 aims at revising the 
legal framework applicable to food for particular nutritional uses and, among others, at repealing 
Directive 2009/39/EC. Negotiations on the proposal are reaching their conclusion and it is expected 
that such Regulation will be adopted in the next months. 
Once the new Regulation is adopted, the Commission will need to adopt delegated acts setting specific 
rules for the categories of food covered by the Regulation, including infant formulae and follow-on 
formulae. 
In the last years, increasing numbers of milk-based drinks and similar products are marketed in 
different Member States with the denomination of ‘growing-up milks’ or ‘toddlers’ milks’ or with 
similar terminology. The composition of these products varies with respect to the protein origin (they 
can be derived from protein of animal or vegetable origin such as cows’ milk, goats’ milk, soy or rice) 
and other ingredients. They are promoted as being particularly suitable for young children and, as 
such, under the current rules, may be considered as foodstuffs for particular nutritional uses. However, 
no composition requirements for these products are set in EU legislation. 
Different views exist in the scientific community and among stakeholders on whether these products 
are necessary to satisfy the nutritional requirements of young children or have any nutritional benefits 
when compared to other foods that can constitute the normal diet of young children. In this context, 
                                                     
4 Directive 2009/39/EC of the European Parliament and of the Council of 6 May 2009 on foodstuffs intended for particular 
nutritional uses, OJ L 124, 20.5.2009, p. 21. 
5 Commission Directive 2006/141/EC of 22 December 2006 on infant formulae and follow-on formulae and amending 
Directive 1999/21/EC, OJ L 401, 30.12.2006, p. 1. 
6 Report of the Scientific Committee on Food on the Revision of Essential Requirements of Infant Formulae and Follow-on 
Formulae, adopted on 4 April 2003, SCF/CS/NUT/IF/65 Final, 18 May 2003. 
7 COM (2011) 353. 
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some would argue that, given the potential variability of weaning diets that may result in different 
nutrient intakes for this group of the population, these products are convenient, as a liquid element in 
the diet of young children, in contributing to meeting their nutritional requirements. Taking all these 
elements into account, the European Parliament and the Council agreed that these products should be 
subject of a specific reflection. Therefore, in the abovementioned revision of the legal framework, the 
Commission will be requested, after consulting the European Food Safety Authority, to draft a report 
on the necessity, if any, of special provisions for milk-based drinks and similar products intended for 
young children (hereinafter ‘growing-up milks’). 
In the meantime, at international level, the Codex Committee on Nutrition and Food for Special 
Dietary Uses (CCNFSDU) agreed at its 34th session in December 2012 to revise their existing 
standard for follow-up formulae
8
, which dates back to 1987 and applies to food intended for use as a 
liquid part of the weaning diet for the infant from the 6th month on and for young children up to three 
years of age. Such review will cover all aspects of the existing standard and will include consideration 
of issues such as technological and scientific developments in follow-up formula production and 
composition over the past 25 years, the age range of the intended population, product definition and 
the role of such products in the diet of infants and young children. Furthermore, following comments 
by WHO and some Codex Member Countries and observers, the review may also consider whether 
this standard is still necessary at all. The first discussion on this subject has taken place at the session 
of the CCNFSDU held on 4-8 November 2013. 
Taking into account the developments described above, it is considered necessary to request the EFSA 
to provide a scientific opinion on all milk-based drinks and similar products intended for infants and 
young children. 
TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
In accordance with Article 29(1) (a) of Regulation (EC) No 178/2002
9
, the European Commission asks 
EFSA to: 
 Provide advice on the nutritional requirements of infants and young children and, in particular, 
on those requirements that may be satisfied by breast milk, milk-based drinks and similar 
products. In this context it will also be important to provide advice to the Commission on how 
these nutritional requirements evolve during the age period 0-3 years. 
 Provide advice on the essential composition requirements of infant formulae and follow-on 
formulae by updating the relevant opinions of the SCF on the matter. 
 Provide advice on the importance of the role that ‘growing-up milks’ may have as a liquid 
element in the diet of young children, with respect to elements such as the pattern of 
consumption, the nutritional intake and any other relevant aspect related to exposure to 
substances that may be present in their diet. In this context it would be useful to take into 
account that different products are on the market which may have a considerably varied 
composition. 
 Provide advice on whether ‘growing-up milks’ are necessary to satisfy the nutritional 
requirements of young children or have any nutritional benefits when compared to other foods 
that may be included in the normal diet of young children (such as breast milk, infant 
formulae, follow-on formulae, cows’ milk and other similar products). 
 If considered appropriate, advise the Commission with respect to the appropriate age range 
and the essential composition of ‘growing-up milks’. 
                                                     
8 CODEX STAN 156-1987. 
9 OJ L 31, 01.02.2002. p. 1. 
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ASSESSMENT 
1. Introduction 
The period of infancy is characterised by special needs in nutrition, with respect to requirements for 
energy and for nutrient amounts per kilogram body mass, which must not only maintain the body but 
also support a rapid growth rate and the appropriate synthesis and deposition of body tissue. A special 
feature of young infancy is that, as a rule, one liquid food is the sole source of nutrition and must 
supply appropriate amounts of energy, water and nutrients. 
Comparative studies in affluent countries have indicated important health advantages of breast-feeding 
over formula-feeding for the recipient infants, such as lower incidence of gastrointestinal and 
respiratory tract infections (Ip et al., 2007; Agostoni et al., 2009; Hörnell et al., 2013b) and of otitis 
media (Hörnell et al., 2013b) and a lower risk of overweight and obesity (von Kries et al., 1999; 
Toschke et al., 2002; Owen et al., 2005; Hörnell et al., 2013b). 
Infant formulae (IF) and follow-on formulae (FOF) have been regulated as foods for particular 
nutritional uses under Directive 2009/39/EC
10
 and its implementing Directive 2006/141/EC
11
 based 
upon a series of reports from the Scientific Committee on Food (SCF, 1983, 1989, 1991, 1993a, 1995, 
2003b) and EFSA (EFSA, 2005f; EFSA NDA Panel, 2012a). No revision of the SCF reports in the 
light of new available evidence has been undertaken since then, and such review in the context of the 
revision of the implementation of Regulation (EU) No 609/2013
12
 is part of the present Terms of 
Reference (ToR). 
Owing to the limited time frame given, the Panel has decided, in agreement with the European 
Commission, to produce two separate opinions. Of the five parts of the ToR: 
 nutritional requirements of infants and young children and their coverage by human milk and 
milk-based products, 
 advice on the essential composition requirements of IF and FOF by updating the relevant 
opinions of the SCF on the matter, 
 the potential role of milk-based drinks designed, manufactured and advertised to be used in the 
diets of infants and young children other than IF and FOF, 
 a comparison of the nutritional role of such other milk-based drinks in the diet of young 
children with other formulae, human milk or cow’s milk, 
 eventually advice on the essential composition of such other milk-based drinks and their target 
groups, 
the Panel will provide in this second opinion 
1) advice on the essential composition requirements of IF and FOF by updating the relevant 
opinions of the SCF on the matter, and 
                                                     
10 Directive 2009/39/EC of the European Parliament and of the Council of 6 May 2009 on foodstuffs intended for particular 
nutritional uses, OJ L 124, 20.5.2009, p. 21–29. 
11 Commission Directive 2006/141/EC of 22 December 2006 on infant formulae and follow-on formulae and amending 
Directive 1999/21/EC, OJ L 401, 30.12.2006, p. 1–33. 
12 Regulation (EU) No 609/2013 of the European Parliament and of the Council of 12 June 2013 on food intended for infants 
and young children, food for special medical purposes, and total diet replacement for weight control and repealing Council 
Directive 92/52/EEC, Commission Directives 96/8/EC, 1999/21/EC, 2006/125/EC and 2006/141/EC, Directive 
2009/39/EC of the European Parliament and of the Council and Commission Regulations (EC) No 41/2009 and (EC) No 
953/2009, OJ L 181, 29.6.2013, p. 35–56. 
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2) advice on the appropriateness to propose compositional requirements for formulae consumed 
after one year of life. 
Advice on the dietary requirements of infants and young children, an evaluation of dietary intakes of 
infants and young children living in Europe in comparison with requirements and advice on the 
potential role of milk-based drinks designed, manufactured and advertised to be used in the diets of 
infants and young children, including an evaluation whether they have any nutritional benefits when 
compared with other foods (such as breast milk, IF, FOF and cow’s milk) that may be included in the 
normal diet of infants and young children, has been given by the Panel in a previous opinion (EFSA 
NDA Panel, 2013a). 
This opinion will not address compositional requirements of formulae intended for pre-term infants, 
for very low- or low-birth-weight infants or for infants with specific nutritional requirements. Also, the 
dietary management of cow’s milk allergy in infants is outside the scope of this opinion. 
However, the general considerations and the specifications with respect to nutrients or other 
ingredients proposed in the present opinion may serve as a basis for defining compositional 
requirements for foods for special medical purposes for infants, unless the disease conditions for 
which such foods are to be used necessitate other compositional aspects. 
2. Definitions 
For this opinion the following definitions apply: 
 Infants means children under the age of 12 months (Article 2(2)(a) of Regulation (EU) No 
609/2013). 
 Young children means children aged between one and three years (36 months) (Article 2(2)(b) 
of Regulation (EU) No 609/2013). 
 IF means food intended for use by infants during the first months of life and satisfying by 
itself the nutritional requirements of such infants until the introduction of appropriate 
complementary feeding (Article 2(2)(c) of Regulation (EU) No 609/2013 and Codex Stan 72-
1981).
13
 
 FOF means food intended for use by infants when appropriate complementary feeding is 
introduced and which constitutes the principal liquid element in a progressively diversified 
diet of such infants (Article 2(2)(d) of Regulation (EU) No 609/2013). 
 “Growing-up milk” or “toddlers’ milk” are formulae intended specifically for young children. 
No compositional criteria have been laid down in EU legislation. They may or may not be 
based on milk. In the latter case they would have to contain other animal or plant protein. The 
Panel proposes not to use the term “growing-up milk” because this would imply a particular 
effect on growth. The Panel will also not use the term “toddlers’ milk” because it considers 
that a “young child” is better defined by age. Young-child formula is the term proposed by the 
Panel for formulae intended for young children. This term includes also formulae based on 
protein sources other than cow’s milk. 
 Complementary feeding, as defined by the World Health Organization (WHO) in 2002, is “the 
process starting when breast milk alone is no longer sufficient to meet the nutritional 
requirements of infants” so that “other foods and liquids are needed, along with breast milk” 
(WHO, 2002). In the Panel’s opinion on the appropriate age for the introduction of 
complementary food (EFSA NDA Panel, 2009) “complementary feeding” means the period, 
                                                     
13 Codex-Stan 72-1981 (Codex Alimentarius), 2011. Standard for infant formula and formulas for special medical purposes 
intended for infants. Adopted 1981, amended 1983, 1985, 1987, revised 2007, amended 2011. 
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when complementary foods are given together with either human milk or a breast milk 
substitute. The Panel notes that this definition differs from the definition of “complementary 
feeding” provided by WHO. 
 Complementary food in this opinion comprises, therefore, all liquid, semisolid and solid foods 
other than breast milk and IF or FOF that are fed to infants. Complementary food can be 
beverages, spoon-fed foods or finger food (EFSA NDA Panel, 2009). Cereal-based foods and 
baby foods are regulated in Directive 2006/125/EC.
14
 
3. General aspects of infant feeding 
There is scientific consensus that breast milk is the preferred food for all healthy infants and provides 
an adequate supply of all nutrients to support growth and development (with the exception of 
vitamin K, during the first weeks of life, and of vitamin D), besides providing protection against 
infection and immunostimulatory components (EFSA NDA Panel, 2013a). When complementary food 
is introduced into the infant’s diet, breast milk remains the most appropriate liquid part of a 
progressively diversified diet (EFSA NDA Panel, 2009, 2013a). 
4. Methodological considerations 
All formulae intended for infants must be safe and suitable to meet the nutritional requirements and 
promote growth and development of infants born at term when used as a sole source of nutrition 
during the first months of life, and when used as the principal liquid element in a progressively 
diversified diet after the introduction of appropriate complementary feeding. The safety and suitability 
of such formulae should be demonstrated by generally accepted scientific evidence. 
Even though human milk composition of healthy, well-nourished mothers can provide guidance for 
the composition of formulae intended for infants, compositional similarity to human milk is not the 
only appropriate determinant or indicator of safety and nutritional suitability of such formulae. The 
mere presence of a substance in human milk does not necessarily indicate a specific benefit of this 
substance for the infant, nor do the concentrations of nutrients in human milk necessarily reflect 
infants’ dietary requirements because they may mirror maternal intakes rather than infants’ needs or 
because absorption efficiency of certain nutrients differ between breast milk and formula. A more 
suitable approach to evaluate the compositional suitability of formulae intended for infants is to relate 
health outcomes, including physiological parameters (including growth and development) and 
biochemical parameters, in formula-fed infants to those of healthy term infants who have been 
exclusively breast fed for four to six months. The Panel also notes that nutrients and substances should 
be added to formulae for infants only in amounts that serve a nutritional or other benefit. The addition 
in amounts higher than those serving a nutritional or other benefit or the inclusion of unnecessary 
substances in formulae may put a burden on the infant’s metabolism or on other physiological 
functions, as substances which are not used or stored have to be excreted. 
The compositional requirements of IF and FOF as laid down by Directive 2006/141/EC have been set 
by specifying the minimum and maximum content of nutrients and other substances in formulae as 
ready for consumption, including the contribution of water used to reconstitute powdered formulae. 
The Panel notes that, whereas minimum amounts should be understood as target values which cover 
the nutritional needs of the majority of infants born at term for optimal growth and development, 
maximum amounts are driven by safety aspects while also taking into account technological 
considerations and should not be interpreted as target values but rather as upper limits of a range 
which should not be exceeded. 
                                                     
14 Commission Directive 2006/125/EC of 5 December 2006 on processed cereal-based foods and baby foods for infants and 
young children (Codified version). OJ L 339, 6.12.2006, p. 16–35. 
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4.1. Minimum content of nutrients and other substances in IF and FOF 
Minimum amounts of nutrients in formulae should be based on generally accepted scientific evidence 
which establishes the nutrient requirements of virtually all infants in the target population. The Panel 
considers that the minimum content of a nutrient in formula can be derived from the intake levels the 
Panel had considered adequate for the majority of infants in the first half of the first year of life (EFSA 
NDA Panel, 2013a) and an average amount of formula consumed during this period. The average 
amount of formula consumed in the first six months of life is taken to be equivalent to 500 kcal/day by 
averaging the Average Requirements (ARs) for energy of boys and girls aged three to less than four 
months (i.e. 479 kcal/day) (EFSA NDA Panel, 2013a) and rounding up. The Panel notes that observed 
mean energy intakes at this age are generally above the AR. Therefore, the Panel considers observed 
mean energy intakes not to be a suitable basis for deriving the minimum content of nutrients in 
formulae. Bearing in mind that the levels the Panel had considered adequate for the majority of infants 
in the first half of the first year of life take into account inter-individual variability in nutrient 
requirements and are designed to cover the dietary requirements of at least 97.5 % of infants and that 
observed formula intakes are generally above the intakes assumed by the Panel, the minimum content 
derived on that basis can be assumed to be adequate for virtually all infants below six months of age 
and there is no necessity to provide nutrients in amounts higher than the amounts proposed by the 
Panel. 
The Panel notes that the intake levels of micronutrients the Panel had considered adequate for the 
majority of infants in the first six months of life were mostly derived from observed mean nutrient 
intakes from breast milk. These Adequate Intakes (AIs) are less precise estimators of recommended 
intakes than an AR or a Population Reference Intake (PRI). AIs are used when available data are 
insufficient to derive an AR and a subsequent PRI. For other substances with a physiological role, 
which can be synthesised endogenously, a temporarily insufficient synthesising capacity of the infant 
needs to be taken into account when proposing minimum contents of these substances in IF or FOF. 
As data are sparse, especially in the very young infant, the evidence for the estimate of the adequate 
amount of those substances to be supplied to infants in formula is less strong than for essential 
nutrients. Whenever a recommendation of the Panel is made purely on the basis of expert judgement, 
this is stated in the appropriate section. 
The Panel also notes that while for a food which is the sole source of energy and nutrients, such as IF, 
compositional requirements can be based on energy and nutrient needs of the targeted population, the 
evidence for proposing compositional requirements for foods which are not the sole source of energy 
and nutrients, such as FOF, is less strong, as other foods contribute to nutrient and energy intakes in 
variable amounts. For the present opinion, the Panel assumes that energy and nutrient intakes from 
complementary foods will compensate for the higher requirements of infants and for the potentially 
lower feeding volume of formulae in infants receiving complementary foods, unless otherwise 
specified in the appropriate section. 
4.2. Maximum content of nutrients and other substances in IF and FOF 
As the different protein and fat sources used in the manufacture of formula and the water used to 
reconstitute powdered formula contribute to the total nutrient content of a formula in varying amounts, 
maximum contents of nutrients have been established in order to ensure the safe use of formulae while 
limiting technological alterations of the initial nutrient contents of food constituents used in the 
production of formulae. 
The Panel notes that specifications for the currently permitted maximum amounts of micronutrients in 
formulae were mostly calculated as three to five times the minimum amounts established at the time 
and took into account the established history of apparent safe use (Codex Stan 72-1981, Codex Stan 
156-1987, the Directive 2006/141/EC, and the SCF (2003b)) and were not based on scientific evidence 
for adverse effects owing to the lack of such evidence for most nutrients. 
Essential composition of infant and follow-on formulae  
 
EFSA Journal 2014;12(7):3760 12 
The Panel acknowledges that scientific data available to derive Upper Tolerable Intake Levels (UL) 
for infants remain scarce for most micronutrients, and there are no reports on any adverse effects 
associated with the use of formulae complying with the current specifications as laid down in 
Directive 2006/141/EC. However, there is a lack of studies designed to investigate the short- or long-
term health consequences of consumption of formulae containing the currently permitted maximum 
amounts of nutrients in IF or FOF. Whenever a UL has been established for a specific nutrient for 
infants or young children, the Panel will note if the continuous consumption of formulae containing 
the currently permitted maximum amount of that micronutrient could lead to intakes exceeding the 
UL. 
5. Minimum and maximum content of energy and macronutrients in IF and FOF 
5.1. Energy 
5.1.1. Current compositional requirements of IF and FOF 
Based on the opinion of SCF (2003b), Directive 2006/141/EC lays down a minimum energy content of 
60 kcal/100 mL and a maximum energy content of 70 kcal/100 mL. These minimum and maximum 
values apply both to IF and to FOF and were based on the energy content of breast milk. 
5.1.2. Energy density of human milk 
The average energy density of human milk has been shown by Butte et al. (2001) to be about 
65 kcal/100 mL. 
Since then, this value has been confirmed by several recent studies on donor breast milk or own 
mother’s milk (mean ± standard deviation (SD)): 65  11 kcal/100 mL for donor breast milk (Wojcik 
et al., 2009); 67.3  6.5 kcal/100 mL for own mother’s milk, 64.1  5.9 kcal/100 mL for single-donor 
pooled breast milk, 63.6  4.5 kcal/100 mL for multiple-donor pooled breast milk (de Halleux and 
Rigo, 2013); 62 ± 9.6 kcal/100 mL to 65 ± 9.1 kcal/100 mL for own mother’s milk (Nielsen et al., 
2011) and 66 ± 12 kcal/100 mL for donor breast milk (Cooper et al., 2013). 
5.1.3. Energy requirements of infants 
The energy content of human milk can provide some guidance for the composition of IF and FOF. 
However, the energy content of human milk changes within one feed. Because the lipid content 
increases markedly with emptying of the breast, hindmilk has a significantly higher energy content 
than foremilk (Stam et al., 2013), while formula is of stable composition. Therefore, the knowledge of 
energy requirements of infants is a key factor to determine the optimal composition of IF and FOF. 
Energy requirement is the amount of food energy needed to balance energy expenditure in order to 
maintain body mass, body composition and a level of physical activity consistent with long-term good 
health. This requirement includes the energy needed for growth and development. Dietary Reference 
Values (DRVs) for energy are provided as ARs (EFSA NDA Panel, 2013d). Table 1 summarises the 
energy intakes considered adequate for infants in the Panel’s previous opinion on nutrient 
requirements and dietary intakes of infants and young children in the European Union (EFSA NDA 
Panel, 2013a). 
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Table 1:  Intakes of energy considered adequate for infants (EFSA NDA Panel, 2013a) 
Age (months) AR (kcal (MJ)/day) AR (kcal (MJ)/kg body weight per day) 
Boys Girls Boys Girls 
0 to < 1 359 (1.5) 329 (1.4) 109 (0.45) 103 (0.43) 
1 to < 2 505 (2.1) 449 (1.9) 112 (0.47) 107 (0.45) 
2 to < 3 531 (2.2) 472 (2.0) 95 (0.40) 92 (0.39) 
3 to < 4 499 (2.1) 459 (1.9) 78 (0.33) 79 (0.33) 
4 to < 5 546 (2.3) 503 (2.1) 78 (0.33) 79 (0.33) 
5 to < 6 583 (2.4) 538 (2.3) 78 (0.33) 78 (0.33) 
6 to < 7 599 (2.5) 546 (2.3) 76 (0.32) 75 (0.31) 
7 to < 8 634 (2.7) 572 (2.4) 76 (0.32) 76 (0.32) 
8 to < 9 661 (2.8) 597 (2.5) 77 (0.32) 76 (0.32) 
9 to < 10 698 (2.9) 628 (2.6) 77 (0.32) 76 (0.32) 
10 to < 11 724 (3.0) 655 (2.7) 79 (0.33) 77 (0.32) 
11 to < 12 742 (3.1) 674 (2.8) 79 (0.33) 77 (0.32) 
 
These ARs are generally lower than the ones used by the SCF (2003b), with the exception of those for 
male infants at the age of one month (+1.9 %) and two months (+4.7 %) and for female infants at the 
age of two months (+4.7 %). From three months of age onwards, the differences range between -6.2 % 
and -3.2 %. This is a result of more refined equations used to calculate total energy expenditure, 
different assumptions made with respect to energy needs for growth and the use of updated reference 
body weights. 
5.1.4. Energy intakes of infants 
Data on energy intakes were available from four surveys for mostly formula-fed infants aged from 
zero to less than six months (Hilbig, 2005; Noble and Emmett, 2006; Fantino and Gourmet, 2008; 
Lennox et al., 2013) in which mean/median energy intakes of about 550-700 kcal/day were reported. 
In exclusively breast-fed infants, mean energy intakes at 15 and 25 weeks of age were reported to be 
590 kcal/day and 620 kcal/day, respectively (Nielsen et al., 2011). For infants in the second half of the 
first year of life mean/median energy intakes in the range of 650-980 kcal/day were observed 
(Lagström et al., 1997; Noble and Emmett, 2001; Hilbig, 2005; de Boer et al., 2006; DGE, 2008; 
Fantino and Gourmet, 2008; Marriott et al., 2008; Thorsdottir et al., 2008; Lennox et al., 2013). 
Only one study from a representative sample of French infants (Fantino and Gourmet, 2008) reported 
on the contribution of formula to energy intakes in formula-fed infants over the first year of life. 
Energy from formula intakes represented the following percentages of the total energy intakes (E %): 
95.5 E % at one to three months; 91.0 E % at four months; 77.8 E % at five months; 63.8 E % at six 
months; 58.6 E % at seven months; 54 E % at eight to nine months; and 36.7 E % at 10-12 months of 
age. 
5.1.5. Health consequences 
Several studies have observed slight differences in growth patterns of formula-fed infants compared 
with breast-fed infants, with formula-fed infants growing at a faster rate over the first year of life 
(Koletzko et al., 2009a; Hörnell et al., 2013a). The higher energy and protein content of IF compared 
with breast milk has been suggested as an explanation for these differences. A number of studies have 
found associations between a high growth velocity during the first months of life and an increased risk 
of non-communicable diseases later in life. Systematic reviews found that upwards percentile crossing 
for weight and length in infancy was associated with a higher risk of later obesity (Baird et al., 2005; 
Monteiro and Victora, 2005). 
The Panel notes that the composition of IF has evolved over the last decade, and the energy and 
protein contents of current IF resemble more closely those of human milk. It should also be noted, 
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however, that, whereas composition of IF remains stable over time, breast milk composition changes 
continuously, and therefore IF cannot imitate breast milk with respect to its energy and protein 
content. 
5.1.6. Recommendations 
IF and FOF should ensure that the growth and development of infants fed IF are similar to those of 
infants who are exclusively breast fed during the first four to six months of life, and that the growth 
and development of infants fed FOF in association with appropriate complementary feeding are 
similar to those of infants who continue to be breast fed while complementary food is introduced into 
their diet. Since IF and FOF can be used instead of breast milk, there is no reason to set different 
minimum and maximum energy contents for IF and FOF. 
There is no scientific evidence suggesting that the mean energy content of breast milk or the energy 
requirements of infants up to the age of one year are markedly different from the values used by the 
SCF (2003b) to determine the minimum and maximum energy content of IF and FOF. An energy 
density of IF and FOF considerably higher than that of human milk may increase total energy intakes 
beyond the energy intakes considered adequate for infants and may play a role in the development of a 
higher than desirable weight gain. 
The Panel therefore proposes a minimum energy content of IF and FOF of 60 kcal (250 kJ)/100 mL 
and a maximum energy content of 70 kcal (293 kJ)/100 mL. However, the Panel considers it desirable 
if IF and FOF are designed in a way that their energy content tends towards the lower bound of the 
range provided that infants are fed ad libitum. 
5.2. Protein 
5.2.1. Current compositional requirements of IF and FOF 
Permitted sources of protein in IF and FOF as laid down in Directive 2006/141/EC include cow’s milk 
protein, goat’s milk protein, isolated soy protein (ISP) and protein hydrolysates of unspecified origin 
and unspecified degree of hydrolysis. Currently permitted minimum and maximum amounts of protein 
in IF and FOF as laid down in Directive 2006/141/EC and compared with the recommendations by the 
SCF (2003b) are shown in Table 2. 
Table 2:  Currently permitted minimum and maximum amounts of protein in IF and FOF from 
different sources as laid down by Directive 2006/141/EC in comparison to the 
recommendations by the SCF (2003b) and by the EFSA NDA Panel (2012a) 
Formula with IF FOF 
 Directive 2006/141/EC SCF (2003b) Directive 2006/141/EC SCF (2003b) 
(g per 100 kcal) min max min max min max min max 
Cow’s milk protein 1.80(a) 3.00 1.80 3.00 1.80 3.50 1.80 3.00 
Goat’s milk protein 1.80(a) 3.00    1.80(c)    3.00(c) 1.80 3.50    1.80(c)    3.00(c) 
Protein hydrolysates 1.80
(b)
 3.00 2.25 3.00    1.80
(b)
 3.50 2.25 3.00 
ISP     2.25 3.00 2.25 3.00 2.25 3.50 2.25 3.00 
(a): Formulae with a protein content between 1.80 and 2.00 g per 100 kcal currently require that their safety and suitability is 
demonstrated by clinical evaluation. 
(b): Formulae with a protein content between 1.80 and 2.25 g per 100 kcal currently require that their safety and suitability is 
demonstrated by clinical evaluation. To date, only one specific formulation of whey protein hydrolysates that provides 
1.86 g protein per 100 kcal is authorised for use in IF and FOF following an evaluation by the Panel (EFSA, 2005f). 
(c): EFSA NDA Panel (2012a). 
5.2.2. Protein content of human milk 
Protein concentrations in human milk change during the first days of life. In a meta-analysis of 21 
studies reporting on energy and macronutrient composition of breast milk from mothers of healthy 
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singleton infants born at term and who were exclusively breast fed at the time of breast milk sampling 
(Hester et al., 2012), crude protein content expressed as mean (range) was reported as follows: for 
colostrum (1-5 days),  2.5 (1.4-6.5) g/100 mL (3.8 (2.2-10.0) g/100 kcal, n = 433); for transitional milk 
(6-14 days), 1.7 (1.3-2.5) g/100 mL (2.6 (2.0-3.8) g/100 kcal, n = 308); and, for mature human milk 
(> 14 days), 1.3 (0.8-2.1) g/100 mL (2.0 (1.2-3.2) g/100 kcal, n = 415). Protein accounts for around 
17 E % in colostrum and 7 E % in mature human milk (Räihä, 1994). The concentrations of different 
proteins also change with duration of lactation. Casein is low or absent in early lactation, then 
increases rapidly and subsequently decreases. The concentration of whey proteins decreases from 
early lactation and continues to fall. These changes result in a whey protein–casein ratio of about 
90:10 in the first three to four days post partum, 55:45 in mature milk and 50:50 in late lactation (at 
around six months) (Kunz and Lönnerdal, 1992). 
5.2.3. Protein requirements of infants 
Estimating true protein intakes from breast milk is difficult because of the non-protein nitrogen (NPN) 
fraction, which represents about 25 % of total nitrogen and is made up of urea (up to 50 % of NPN), 
free amino acids and other nitrogenous compounds. How and how much of NPN is utilised by the 
body is not entirely understood (WHO/FAO/UNU, 2007). Moreover, the composition of the protein 
fraction of breast milk changes with time, and no data are available on the true digestibility of the 
different fractions. Therefore, in previous opinions (EFSA NDA Panel, 2012c, 2013a) the Panel 
decided to derive an AR and subsequently a PRI for protein for infants based on a factorial approach 
as the sum of the requirement for maintenance and the requirement for growth adjusted for efficiency 
of dietary protein utilisation. 
Table 3 summarises the protein intakes considered adequate for the majority of infants in the Panel’s 
previous opinion on nutrient requirements and dietary intakes in infants and young children in the 
European Union (EFSA NDA Panel, 2013a). 
Table 3:  Intakes of protein considered adequate for the majority of infants (EFSA NDA Panel, 
2013a) 
Age (months) PRI  
(g/kg body weight per day)
 
Body weight (kg)
(a) 
PRI (g/day) 
Boys Girls Boys Girls 
1 to < 2 1.77 4.5 4.2 8 7 
2 to < 3 1.50 5.6 5.1 8 8 
3 to < 4 1.36 6.4 5.8 9 8 
4 to < 5 1.27 7.0 6.4 9 8 
5 to < 6 1.21 7.5 6.9 9 8 
6 to < 7 1.15 7.9 7.3 9 8 
7 to < 8 1.27 8.3 7.6 11 10 
8 to < 9 1.23 8.6 7.9 11 10 
9 to < 10 1.19 8.9 8.2 11 10 
10 to < 11 1.16 9.2 8.5 11 10 
11 to < 12 1.14 9.4 8.7 11 10 
(a): 50th percentile of WHO Growth Standards. 
No PRI has been proposed by the Panel for the age group zero to less than one month owing to the 
lack of data for the first month of life. However, the Panel considers it safe to assume that 
requirements for protein intakes in the first month of life do not differ significantly from those of the 
second month of life. 
5.2.4. Protein intakes of infants 
Protein intakes in mostly formula-fed infants in Europe have been reported to be around 9-10 E % in 
infants less than six months of age (Hilbig, 2005; Noble and Emmett, 2006; Fantino and Gourmet, 
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2008; Lennox et al., 2013) and around 10-15 E % in infants in the second half of the first year of life 
(Lagström et al., 1997; Noble and Emmett, 2001; Hilbig, 2005; de Boer et al., 2006; DGE, 2008; 
Fantino and Gourmet, 2008; Marriott et al., 2008; Thorsdottir et al., 2008; Lennox et al., 2013). 
5.2.5. Health consequences 
5.2.5.1. Protein intakes to ensure adequate growth and development 
Several studies which investigated the safety and suitability of IF based on intact cow’s milk protein 
with protein contents of 1.8-1.9 g/100 kcal have been reviewed by the Panel previously (EFSA, 
2005f). These studies have generally shown that protein concentrations in formula of 
1.8-1.9 g/100 kcal when derived from intact milk protein are adequate to promote normal growth 
when these formulae are fed ad libitum. In a study of infants (Koletzko et al., 2009b) consuming a low 
protein IF with 1.77 g protein per 100 kcal and subsequently FOF providing 2.2 g protein per 100 kcal 
for the first year of life and who were followed up until 24 months of age, no statistically significant 
differences between the group consuming low-protein formula and the breast-fed reference group with 
respect to weight-for-length and body mass index (BMI) were found at 24 months of follow-up. 
Another study (Trabulsi et al., 2011) investigated the effect on infant growth of an IF with a protein 
content of 1.9 g/100 kcal compared with an IF with a protein content of 2.2 g/100 kcal which was 
consumed for four months. There were no statistically significant differences between the two formula 
groups with respect to weight gain, length gain and head circumference at the end of the study at four 
months of age. 
No studies which evaluated the safety and suitability of lower than currently permitted (i.e. 
2.25 g/100 kcal) protein contents in formulae containing ISP were published after the report by the 
SCF (2003b). Also, no evidence is available to suggest that this protein content would be inadequate to 
ensure adequate growth and development. 
The Panel considers that, based on the available evidence, a minimum protein intake of 1.8 g/100 kcal 
from IF and FOF based on intact milk protein and of 2.25 g/100 kcal from formula containing ISP is 
sufficient to ensure adequate growth and development. Adequate minimum protein intakes from IF 
and FOF containing protein hydrolysates need to be established for each specific IF or FOF containing 
hydrolysed proteins following clinical evaluation, as outlined in section 5.2.5.4. 
5.2.5.2. High protein intakes 
In infants, a very high protein intake (around 20 E %) can impair the water balance, particularly when 
no other liquids are consumed and/or extrarenal water losses are increased (EFSA NDA Panel, 2012c). 
It has been suggested that high protein intakes contribute to higher insulin secretion, and to a higher 
release of insulin-like growth factor (IGF)-1 and IGF-binding protein (IGFBP)-1 (Axelsson, 2006). It 
has also been suggested to be associated with increased growth (Koletzko et al., 2009b; EFSA NDA 
Panel, 2012c; Hörnell et al., 2013a) and a higher BMI in childhood (Hörnell et al., 2013a; Thorisdottir 
et al., 2013; Weber et al., 2014). Whether protein plays a role in the observed increased growth rate 
and higher BMI in childhood is still matter of debate and requires more research. 
5.2.5.3. Plant proteins as protein sources for IF and FOF 
Some plant proteins are deficient in certain indispensable amino acids and the digestibility of plant 
proteins can be less than that of milk proteins. Therefore, a higher minimum protein content is usually 
recommended for formulae with intact proteins other than milk proteins. Also, when setting minimum 
amounts for the contents of certain minerals in IF and FOF based on plant proteins, the increased 
content of phytic acid, which can reduce the availability of minerals, has to be taken into account 
(SCF, 2003b). 
Currently, for formulae containing intact proteins, the only permitted source of plant proteins is ISP. 
ISP is low in sulphur-containing amino acids. It contains around 1-2 % phytate and is rich in 
nucleotides and isoflavones (SCF, 2003b). Soy protein also contains trypsin inhibitors and lectins 
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(Bhatia et al., 2008). Reducing phytic acid content in formulae by about a half, from around 
600 mg/kg to around 270 mg/kg, or completely compared with around 250-400 mg/kg ready-to-feed 
formula, has been shown to improve zinc absorption and also, to a lesser extent, iron absorption 
(Lönnerdal et al., 1984; Davidsson et al., 1994; Davidsson et al., 2004). Concerns have been raised 
with respect to potential negative effects of soy isoflavones on sexual, reproductive and 
neurobehavioural development, immune function and thyroid function. The American Academy of 
Pediatrics (AAP) Committee on Nutrition concluded in its review that the evidence for adverse effects 
of dietary soy isoflavones on human development, reproduction or endocrine function is not 
conclusive (Bhatia et al., 2008). The European Society for Paediatric Gastroenterology Hepatology 
and Nutrition (ESPGHAN) Committee on Nutrition acknowledged the lack of evidence from human 
studies, but recommended the reduction of soy isoflavones in soy-based formulae as a precautionary 
approach (ESPGHAN Committee on Nutrition et al., 2006). Trypsin inhibitors and lectins may 
interfere with protein digestion and nutrient absorption. Enzyme inhibitors and lectins are inactivated 
under heat treatment, although some residual activity can be found when proper heating is not 
achieved (Lajolo and Genovese, 2002). It is technologically possible to remove isoflavones, trypsin 
inhibitors, lectins and phytic acid from formulae. 
The Panel considers that concentrations of isoflavones, trypsin inhibitors, lectins and phytic acid in IF 
and FOF should be kept as low as is feasible. 
The Panel notes that the main indications for the use of formulae exclusively based on ISP in place of 
milk-based formulae are congenital lactase deficiency and galactosaemia, provided the formula is 
lactose free according to the criteria laid down in Directive 2006/141/EC (i.e. 0.01 g/100 kcal) (EFSA 
NDA Panel, 2010a), and infants for whom caregivers chose a vegan diet. 
5.2.5.4. Protein hydrolysates as protein sources for IF and FOF 
According to Directive 2006/141/EC, formulae containing hydrolysed protein may be produced from 
any suitable protein source and by different enzymatic or chemical means provided that the 
compositional criteria laid down by the Directive are met. In its opinion, the SCF (2003b) concluded 
that there is a need for clinical evaluation of formulae containing protein hydrolysates with respect to 
their safety and suitability. 
The Panel emphasises that the safety and suitability of each specific formula containing protein 
hydrolysates has to be established by clinical studies. Information on protein sources and the 
technological processes applied should also be provided. In this context, the Panel notes that one 
particular formula containing partially hydrolysed whey protein has been evaluated for its safety and 
suitability by the Panel (EFSA, 2005f) and has been authorised for use by Directive 2006/141/EC. 
Directive 2006/141/EC specifies criteria that formulae containing protein hydrolysates must meet if 
they are to be allowed to be marketed as reducing the risk of developing allergy to milk proteins. 
Attempts have been made to classify formulae containing hydrolysed protein into partially and 
extensively hydrolysed protein formulae according to the degree of protein fragmentation, but there is 
no agreement on the criteria on which to base this classification (Greer et al., 2008), and no regulatory 
definition exists as to what would constitute a partially or extensively hydrolysed protein formula. 
Formulae containing hydrolysed protein have been studied with respect to their potential to reduce the 
risk of developing allergic manifestations in at-risk infants who are not exclusively breast fed (Osborn 
and Sinn, 2006; Szajewska and Horvath, 2010; von Berg et al., 2013; de Silva et al., 2014). These 
studies indicate that the characterisation of a formula by molecular weight of protein cannot predict 
their potential to reduce the risk of developing allergic manifestations in genetically predisposed 
infants in the general population. 
The Panel considers that the criteria given in Directive 2006/141/EC alone are not sufficient to predict 
the potential of a formula to reduce the risk of developing allergy to milk proteins. Clinical studies are 
necessary to demonstrate if and to what extent a particular formula reduces the risk of developing 
Essential composition of infant and follow-on formulae  
 
EFSA Journal 2014;12(7):3760 18 
short- and long-term clinical manifestations of allergy in at-risk infants who are not exclusively breast 
fed. 
5.2.5.5. Protein quality 
Amino acid reference patterns can be used in the assessment of protein quality by comparing the 
amino acid composition of a food with an amino acid reference pattern. Given that intakes of breast 
milk from a healthy, well-nourished mother are considered to satisfy the amino acid requirements for 
the first six months of life, the Panel considers the amino acid pattern of breast milk to be the best 
reference pattern for a product substituting for breast milk in infants. 
The SCF (2003b) determined the amount of indispensable and conditionally indispensable amino acids 
per energy value in IF and FOF based on six studies on the amino acid content of human milk (Bindels 
and Harzer, 1985; Lönnerdal and Forsum, 1985; Janas et al., 1987; Darragh and Moughan, 1998; 
Villalpando et al., 1998; Räihä et al., 2002). A recent meta-analysis of 26 studies (Zhang et al., 2013) 
which investigated the total amino acid profile in human milk closely corroborated the amounts of 
indispensable and conditionally indispensable amino acids in human milk determined by the SCF 
(2003b) and which are also in line with the values proposed by the Codex Alimentarius in Codex Stan 
72-1981 and by an ESPGHAN coordinated international expert group (Koletzko et al., 2005). The 
Panel, therefore, considers that the available evidence supports the amino acid pattern of human milk 
proposed by the SCF (2003b). 
Based upon results indicating a lower formation of cysteine from cystathionine in the 
transsulphuration pathway, it has been considered that L-cysteine is a conditionally indispensable 
amino acid for neonates and that methionine cannot substitute for cysteine completely (White et al., 
1994; Vina et al., 1995). These results were not confirmed in recent studies in parenterally fed infants 
(Courtney-Martin et al., 2008; Thomas et al., 2008; Courtney-Martin et al., 2010). However, as there 
is marked individual variability in the rate of transsulphuration, the Panel considers that it is 
appropriate to provide both cysteine and methionine in IF and FOF, and the ratio of methionine to 
cysteine in IF shall not exceed 2 unless the safety and suitability of the formula has been demonstrated 
by clinical evaluation. 
Tyrosine is synthesised by the hydroxylation of phenylalanine, via phenylalanine hydroxylase in the 
liver. Studies in human neonates have reported a substantial ability to hydroxylate phenylalanine (the 
first step in phenylalanine oxidation) (van Toledo-Eppinga et al., 1996; House et al., 1998). However, 
the extent to which neonates can accommodate high phenylalanine and low tyrosine intakes via 
phenylalanine hydroxylation remains unknown. Infants may require a pre-formed dietary source of 
tyrosine because the activity of phenylalanine hydroxylase in some neonates can be low, and 
hyperphenylalaninaemia tends to occur, whereas tyrosine tends to be deficient in these infants. 
Therefore, the Panel considers that it is appropriate to provide both tyrosine and phenylalanine in IF 
and FOF, but the ratio of tyrosine and phenylalanine in IF shall not exceed 2 unless the safety and 
suitability of the formula has been demonstrated by clinical evaluation. 
5.2.5.6. Effects of processing on nutritional value of protein 
The nutritional value of protein is influenced by its amino acid composition and by protein hydrolysis, 
but also by heat treatment, especially in the presence of iron, vitamin C and lactose in these products. 
Heat processing is essential for the preservation of IF and FOF but induces a number of degradation 
reactions in milk, including Maillard reactions between lactose and protein and advanced glycation 
end products, as well as other direct modification reactions, which reduce the nutritional value of 
protein and could produce potentially active derivatives (Pischetsrieder and Henle, 2012). Among the 
Maillard reaction products, the most important is lactulosyllysine, the reaction product of lactose and 
lysine side chains of the milk proteins (Fritsch and Klostermeyer, 1981; Langhendries et al., 1992; 
Henle et al., 1993). The presence of lactose is also an important prerequisite for extensive protein 
oxidation during the thermal treatment of milk (Meltretter et al., 2007) as the oxidation of other amino 
acid side chains can be promoted by reactive oxygen species, which are formed in the course of the 
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Maillard reaction (Mossine et al., 1999). As a consequence of their specific formulation and 
processing, IF and FOF can show higher content of glycation markers than regular milk products. 
Liquid formulae contain around twice as much advanced Maillard reaction products as formulae in 
powdered form (SCF, 2003b). 
The Panel considers that the contents of Maillard reaction products and protein degradation products 
in IF and FOF should be kept as low as technologically possible owing to their potentially untoward 
effects on the nutritional value of protein. 
5.2.6. Recommendations 
5.2.6.1. Calculation of protein content 
The SCF (2003b) proposed to use a default conversion factor of 6.25 to calculate the protein content 
from the total nitrogen content, irrespective of the protein source. The Panel is aware of the 
discussions with respect to the use of different conversion factors for different protein sources in order 
to reflect variations in the nitrogen content of different proteins (EFSA NDA Panel, 2012c). The 
Panel, however, proposes to retain the conversion factor of 6.25 mainly for practical considerations. 
5.2.6.2. Protein sources 
The Panel considers that cow’s milk protein, goat’s milk protein and ISP are safe and suitable protein 
sources for use in IF and FOF based on intact protein. The use of other protein sources in IF and FOF 
and/or the introduction of new technologies need clinical evaluation and their safety and suitability 
should be established in the target population prior to their general use in IF and FOF. 
With respect to formulae containing protein hydrolysates, the Panel reiterates the conclusions of the 
SCF (2003b) that those formulae are insufficiently characterised by the declared protein content even 
if they fulfil regulatory criteria concerning amino acid patterns and contents and that the safety and 
suitability of each specific IF or FOF containing protein hydrolysates has to be established by clinical 
evaluation. 
The Panel notes that the characterisation of protein hydrolysates by molecular weight of the protein 
cannot predict their potential to reduce the risk of developing allergic manifestations in genetically 
predisposed infants. Therefore, the Panel considers that the criteria given in Directive 2006/141/EC 
are not sufficient to predict the potential of a formula to reduce the risk of developing allergy to milk 
proteins. 
5.2.6.3. Minimum and maximum protein content of IF and FOF 
Human milk is a food of changing composition during the lactational period, during 24 hours and 
during one feed, whereas an IF is a product of constant composition and, therefore, must be a 
compromise on the safe side, both as to the amount and as to the quality of the protein. 
Based on the studies which investigated the adequacy of IF containing around 1.8 g protein per 
100 kcal, the Panel considers that a minimum protein content in IF and FOF of 1.8 g/100 kcal 
(0.43 g/100 kJ) for cow’s and goat’s milk-based formulae is suitable to satisfy the nutritional 
requirements of infants. For IF and FOF containing ISP, the Panel proposes a minimum protein 
content of 2.25 g/100 kcal (0.54 g/100 kJ). A minimum protein content for IF and FOF containing 
protein hydrolysates cannot be proposed and the adequacy of protein content of a specific IF or FOF 
containing hydrolysed proteins needs to be established based on clinical evaluation. 
There is no evidence of a physiological need for protein intakes at amounts of 3.0 g/100 kcal in 
infancy, which is the currently permitted maximum content of protein in IF. In addition, protein 
intakes of infants are generally well above the requirements, so the protein content of IF and FOF 
could be decreased. Therefore, the Panel proposes to reduce the currently permitted maximum protein 
content to 2.5 g/100 kcal (0.60 g/100 kJ) for IF and FOF based on cow’s milk and goat’s milk protein 
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and to 2.8 g/100 kcal (0.67 g/100 kJ) for IF and FOF containing ISP and IF and FOF containing 
protein hydrolysates. The Panel, however, acknowledges that there are no scientific data available 
which allow the establishment of precise cut-off values for the maximum protein content in IF and 
FOF and the proposed values are based on expert judgement of what would constitute an upper bound 
of the adequate range of intake. Table 4 gives an overview of the proposed minimum and maximum 
amounts of protein in IF and FOF. 
Table 4:  Proposed minimum and maximum content of protein in IF and FOF 
Formulae with Minimum content Maximum content 
g/100 kcal g/100 kJ g/100 kcal g/100 kJ 
Cow’s milk protein 1.80 0.43 2.50 0.60 
Goat’s milk protein 1.80 0.43 2.50 0.60 
ISP  2.25 0.54 2.80 0.67 
Protein hydrolysates 
(a)
 – – 2.80 0.67 
(a): The safety and suitability of formulae containing protein hydrolysates, including their minimum protein content, should 
be established based on clinical evaluation. 
5.2.6.4. Amino acid reference pattern 
As IF are considered breast milk substitutes and FOF can be used as the principal liquid element of a 
progressively diversified diet of infants in place of breast milk, the Panel considers that IF and FOF 
should provide indispensable and conditionally indispensable amino acids in amounts on an energy 
basis at least equal to the reference protein (i.e. breast milk), irrespective of the protein source. 
Given that a recent meta-analysis (Zhang et al., 2013) closely corroborated the findings of the SCF 
(2003b) with respect to the total amino acid content of human milk, the Panel proposes to base the 
amino acid reference pattern for IF and FOF on the analysis of indispensable and conditionally 
indispensable amino acids in human milk by the SCF (2003b). The proposed reference pattern is 
depicted in Table 5. 
Table 5:  Proposed amino acid reference pattern for human milk protein using a conversion factor 
of 6.25 
Amino acid g/100 g protein mg/100 kcal mg/100 kJ 
Cysteine 2.1 38 9 
Histidine 2.2 40 10 
Isoleucine 5.0 90 22 
Leucine 9.2 166 40 
Lysine 6.3 113 27 
Methionine 1.3 23 5 
Phenylalanine 4.6 83 20 
Threonine 4.3 77 18 
Tryptophan 1.8 32 8 
Tyrosine 4.2 76 18 
Valine 4.9 88 21 
 
The sum of methionine and cysteine and the sum of tyrosine and phenylalanine in IF may be used for 
calculation purposes. If the ratio of methionine to cysteine and/or the ratio of tyrosine and 
phenylalanine, exceeds 2, this must be justified by clinical evaluation. For FOF, the Panel considers 
that no restrictions with respect to amino acid ratios need to apply, because complementary foods will 
contribute to amino acid intakes and the metabolism of older infants is more mature with respect to the 
capacity to convert methionine to cysteine and phenylalanine to tyrosine. 
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5.3. Fat 
5.3.1. Current compositional requirements of IF and FOF 
Current compositional requirements of IF and FOF with respect to total fat, fatty acids and 
phospholipids as laid down by Directive 2006/141/EC are depicted in Table 6. These compositional 
requirements differ from the opinion of the SCF (2003b) with respect to the minimum content of 
alpha-linolenic acid (ALA, 18:3, n-3) and the maximum content of phospholipids (PLs) in IF and 
FOF. These differences are highlighted in Table 6 as footnotes. 
Table 6:  Current compositional requirements of IF and FOF with respect to total fat, fatty acids 
and PLs as laid down by Directive 2006/141/EC 
 IF FOF 
g per 100 kcal FA % g per 100 kcal FA % 
Min Max Min Max Min Max Min Max 
Compulsory composition 
Total fat 4.40 
(a)
 6.00 
(b) 
  4.00 
(c) 
6.00 
(b) 
  
Trans-fatty acids      3.0      3.0 
Lauric acid + myristic acid    20.0    20.0 
Erucic acid      1.0      1.0 
LA (18:2, n-6) 
(d) 
0.30 1.20   0.30 1.20   
ALA (18:3, n-3) 
(d) 
0.05 
(e) 
0.24 
(f)  
 0.05 
(e) 
0.24 
(f) 
  
Voluntary addition 
Total n-3 LCPUFAs      1.0      1.0 
Total n-6 LCPUFAs      2.0      2.0 
ARA (20:4, n-6)      1.0      1.0 
DHA (22:6, n-3)
 
Shall not exceed total n-6 LCPUFAs Shall not exceed total n-6 LCPUFAs 
EPA (20:5, n-3) Shall not exceed DHA Shall not exceed DHA 
Phospholipids  2 g/L 
(g) 
   2 g/L 
(g) 
  
(a): 40 E %. 
(b): 55 E %. 
(c): 35 E %. 
(d): With a ratio of LA to ALA of ≥ 5 and ≤ 15. 
(e): The SCF (2003b) proposed a minimum content of 0.05 mg/100 kcal for formulae supplemented with ARA and DHA 
and 0.10 mg/100 kcal for formulae not supplemented with ARA and DHA. 
(f): Calculated from the lowest permitted LA:ALA ratio of 5 and the highest permitted LA concentration. 
(g): The SCF (2003b) proposed a maximum content of 1 g/L. 
LA, linoleic acid; ALA, alpha-linolenic acid; ARA, arachidonic acid; DHA, docosahexaenoic acid; EPA, eicosapentaenoic 
acid; FA %, per cent of total fatty acids; LCPUFAs, long-chain polyunsaturated fatty acids. 
Conjugated-linoleic acid (CLA) is currently not permitted to be added to formulae in addition to the 
CLA naturally present in the fat ingredients, and it is considered to be a novel food ingredient in this 
context. Also, the use of sesame oil and cottonseed oil is not permitted in IF and FOF. 
5.3.2. Fat composition of human milk 
Breast milk has an average total fat content of 24-59 g/L (3.7-9.1 g/100 kcal, around 50 E %), but the 
fat content varies markedly with pregnancy weight gain and during the feed as the fat content 
increases as the breast is emptied (Michaelsen et al., 1994). Most of the fat in breast milk is 
triacylglycerol (TAG, > 98 %), but it also contains some cholesterol (around 0.25 g/L) and PLs 
(around 0.24 g/L), predominantly sphingomyelin, phosphatidylethanolamine and phosphatidylcholine 
(Abrahamse et al., 2012; Giuffrida et al., 2013). 
The main saturated fatty acid (SFA) in human milk is palmitic acid (16:0), which accounts for around 
26 % of total fatty acids (FA %), and the main monounsaturated fatty acid (MUFA) is oleic acid (18:1, 
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n-9), which typically accounts for approximately 35 FA % (Abrahamse et al., 2012). The composition 
of polyunsaturated fatty acids (PUFAs) in human milk varies depending on the dietary intake of the 
mother, with milk from vegans having the highest content of linoleic acid (LA, 18:2, n-6) and ALA 
(Sanders and Reddy, 1992; Davis and Kris-Etherton, 2003). Inuit and other populations with a high 
intake of marine animals have the highest breast milk content of docosahexaenoic acid (DHA, 22:6n-
3). The concentrations of DHA in breast milk, however, are also influenced by polymorphisms in the 
fatty acid desaturase (FADS) gene cluster (Moltó-Puigmarti et al., 2010). In general, DHA 
concentrations are the most variable of all fatty acid concentrations in human milk, while the content 
of arachidonic acid (ARA, 20:4, n-6) is much more stable (Brenna et al., 2007). Breast milk usually 
has a low content of trans-fatty acids (TFAs), around 2-5 FA % (Larqué et al., 2001), and CLA, 
0.2-0.6 FA % (Rist et al., 2007), but the content of these fatty acids varies depending on the maternal 
diet (Larqué et al., 2001; Rist et al., 2007). 
Human milk contains only small amounts of short-chain SFAs (SCFAs, with a carbon chain length 
< 6), but usually contains 8-10 FA % as medium-chain SFAs (MCFAs, usually defined as fatty acids 
with a carbon length of 6-10) (EFSA NDA Panel, 2010c)). TAGs containing SCFAs, MCFAs and to 
some extent also lauric acid, with 12 carbon atoms, are more rapidly hydrolysed by gastrointestinal 
lipases and the hydrolysis products are more easily absorbed and are taken to the liver directly via the 
portal vein (Novak and Innis, 2011). The ingestion of these fatty acids, therefore, could provide some 
benefit under conditions where fat absorption is a limiting factor. The MCFA content of human milk 
varies and is increased by a high carbohydrate and low fat intake of the mother (Koletzko et al., 1992; 
Sauerwald et al., 2001; Novak and Innis, 2011). 
About 70 % of the palmitic acid in human milk is esterified to the sn-2 position of the milk TAG 
(Innis, 2011) and, as the endogenous lipases hydrolyse dietary TAG mainly at the sn-1,3 position, 
palmitic acid may be absorbed in part as glycerol-palmitate. It has been proposed that the absorption 
of unesterified palmitic acid is limited. 
5.3.3. Requirement for total fat and essential fatty acids and Adequate Intakes (AIs) of long-
chain (LC) PUFAs 
In the Panel’s previous opinion on nutrient requirements and dietary intakes of infants and young 
children in the European Union (EFSA NDA Panel, 2013a), the Panel concluded on levels of intakes 
of fats, essential fatty acids and LCPUFAs (unsaturated fatty acids with 20 or more carbon atoms) 
considered adequate for the majority of infants. These are shown in Table 7. 
Table 7:  Intakes of fat, essential fatty acids and DHA considered adequate for the majority of 
infants (EFSA NDA Panel, 2013a) 
Age RI total fat AI LA AI ALA AI DHA 
E % E % E % mg/day 
0 to < 6 months 50–55 4 0.5 100 
6 to < 12 months 40 4 0.5 100 
RI, Reference Intake range for macronutrients. 
5.3.4. Total fat and fatty acid intakes of infants 
Mean total fat intakes in mostly formula-fed European infants below the age of six months were 
available from four studies (Hilbig, 2005; Noble and Emmett, 2006; Fantino and Gourmet, 2008; 
Lennox et al., 2013) and were between 42 and 46 E %. Intakes of SFAs, MUFAs and PUFAs were 
reported to be around 16-22 E %, 15-17 E % and 6.7-7.0 E %, respectively (Hilbig, 2005; Noble and 
Emmett, 2006; Lennox et al., 2013). Intakes of LA were 3.6-4.2 g/day (around 6-7 E %), of ALA 
0.41-0.48 g/day (around 0.7-0.8 E %) and of DHA 57 mg/day (Fantino and Gourmet, 2008; Schwartz 
et al., 2010). Total fat intake usually decreases once breast-feeding or formula-feeding ceases 
(Niinikoski et al., 2007). In infants aged between 6 and < 12 months, mean total fat intakes were 
reported to be between 26 and 40 E % (Lagström et al., 1997; Noble and Emmett, 2001; Hilbig, 2005; 
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de Boer et al., 2006; DGE, 2008; Fantino and Gourmet, 2008; Marriott et al., 2008; Thorsdottir et al., 
2008; Lennox et al., 2013). Intakes of SFAs, MUFAs and PUFAs were around 12-16 E %, 9-14 E % 
and 4.6-7.0 E %, respectively (Lagström et al., 1997; Noble and Emmett, 2001; Hilbig, 2005; de Boer 
et al., 2006; DGE, 2008). Intakes of LA were 3.4-6.8 g/day (around 3.4-4.4 E %), of ALA 
0.40-0.65 g/day (around 0.5-0.9 E %) and of DHA 28-47 mg/day (Lagström et al., 1997; de Boer et 
al., 2006; Fantino and Gourmet, 2008; Schwartz et al., 2010). The Panel, however, notes the skewed 
distribution of LA, ALA and DHA intakes and that in the absence of information on median intakes 
the given values cannot be interpreted. 
5.3.5. Fat sources for IF and FOF 
The obvious and previously used staple sources of fat for use in the production of IF and FOF are 
cow’s milk, to a certain extent goat’s milk and different types of vegetable oils. Like human milk, the 
lipids in bovine milk are mainly present in globules as an oil-in-water emulsion. Most of the fat is 
saturated, and around 11 % of the fatty acids are SCFAs, almost half of which is butyric acid (4:0) 
(Månsson, 2008). The SCFAs are esterified almost entirely at the sn-3 position of the TAG molecules, 
but, similar to human milk, cow’s milk usually has palmitic acid and MCFAs preferentially esterified 
at positions sn-2 and sn-1 and oleic acid in positions sn-1,3. Owing to the hydrogenation of PUFAs 
catalysed by rumen bacteria, cow’s milk has a relatively high content of TFAs, typically 
2.6-3.9 FA %, of which cis-9,11-trans-CLA and 11-trans-vaccenic acid (18:1t) are the major ones, 
accounting for 0.3-0.5 FA % and 2-3.3 FA %, respectively, and a low content of PUFAs (Slots et al., 
2009). 
The average total fat content in goat’s milk is similar to that found in other ruminant species and 
ranges from 3 to 6 % (Chilliard and Ferlay, 2004). The fatty acids are arranged in TAG in accordance 
with the milk pattern of other ruminants and the percentage of unsaturated fatty acids does not differ 
from that found in cow’s milk. The major difference between caprine and bovine milk fat is the 
distribution among specific SFAs, as goat’s milk has a lower content of SCFAs and more MCFAs, 
specifically a higher content of capric acid (10:0) and caprylic acid (8:0) (Strzałkowska et al., 2009). 
There are many different vegetable oils that could be used in the production of IF, but most of the 
vegetable oils that are used have a high content of PUFAs and a lower content of SFAs. Furthermore, 
the TAG positioning of SFAs in vegetable oils differs from that in breast milk, as vegetable oils will 
usually have more unsaturated fatty acids in the sn-2 position and the SFAs in position sn-1,3. An 
overview about the typical fatty acid composition of human milk and other potential fat sources for IF 
and FOF is given in Table 8. 
Table 8:  Typical fatty acid composition of breast milk and potential sources of fat other than 
sources of LCPUFAs for IF and FOF 
Fatty 
acid 
Human milk(a) Cow’s milk(b) Goat’s milk(c) Soybean oil(d) Canola oil(d) Sunflower oil(d) Palm oil(d) 
FA % FA % FA % FA % FA % FA % FA % 
SFA 45–46 53–84 62–79 16 7 10 49 
MUFA 35–40 13–42 17–29 23 63 20–45 37 
PUFA 14–19 2–4 3–6 58 28 40–66 9 
LA  10–15 1–2 1.5–4 50 18 40–66 9 
ARA 0.7–1.1 0.1      
ALA 0.1–2.0 0.2–1.3 0.25–1.3 7 9 0–0.2 0.2 
DHA 0.2–0.5       
(a): From Greek and Finnish mothers (Antonakou et al., 2013; Mäkelä et al., 2013). 
(b): Kliem et al. (2013); Ferrand-Calmels et al. (2014). 
(c): Ferrand-Calmels et al. (2014). 
(d): USDA (online). 
As neither cow’s milk nor vegetable oils contain LCPUFAs, oil sources other than those discussed 
above are needed to supply LCPUFAs. LCPUFA sources currently used in IF and FOF are fish oil, 
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DHA-rich algal oil from Crypthecodinium cohnii, ARA-rich fungal oil from Mortierella alpina and 
egg PL (lecithin/phosphatidylcholine from egg yolk). 
5.3.6. Health consequences 
5.3.6.1. Overall fat intake 
The content of fat in IF and FOF is determined by the need for energy for growth and for the supply of 
essential fatty acids. Moreover, fat facilitates the absorption of the fat-soluble vitamins. TAGs are the 
predominant source of energy for breast-fed and formula-fed infants. Major changes in body size and 
composition take place during early life, and the early growth pattern may have both beneficial and 
adverse long-term effects on health and obesity risk. The concern about excessive weight gain in 
infancy has increased as childhood obesity becomes increasingly more prevalent. The role of high or 
low fat intakes as determinants of adiposity in infancy and childhood has been poorly studied and 
results are inconclusive (Macé et al., 2006; Agostoni and Caroli, 2012; Rolland-Cachera et al., 2013). 
5.3.6.2. Fatty acid composition 
The background for the concern about the use of myristic and lauric acid in IF and FOF expressed by 
the SCF (2003b) is their cholesterol-increasing effects in adults. However, palmitic acid is by far the 
most dominant SFA in breast milk and also increases cholesterol. Furthermore, plasma cholesterol is 
higher in breast-fed than in formula-fed infants, and there is no evidence that this has any long-term 
adverse health effects (Owen et al., 2008; Owen et al., 2011). With respect to MCFAs, the SCF 
(2003b) concluded that there was no necessity to add MCFAs to IF or FOF. The main purpose of 
adding MCFAs would be to increase fat absorption (as would lauric acid), but healthy infants do not 
appear to have any limitations with respect to fat absorption. Furthermore, MCFAs may have potential 
negative health effects, as high MCFA intakes may lead to diarrhoea and dicarboxylic aciduria 
(Borum, 1992; Tserng et al., 1996; Odle, 1997). In infants, TFAs may interfere with PUFA 
metabolism (Larqué et al., 2001), but no studies have been able to link intake of TFAs with adverse 
effects on growth or developmental outcomes in infants. CLA, evaluated in the form of CLA-rich oils 
(cis-9,trans-11 and trans-10,cis-12 in a mixture 1:1), has been suggested to have negative health 
effects (EFSA NDA Panel, 2010e, 2010d). Both TFA and cis-9,trans-11-CLA are present in milk and 
therefore are contained in formula in which milk fat has been used as a fat source and are not of safety 
concern in the amounts which are naturally introduced to formula from milk fat. 
ALA is essential in human nutrition as a precursor for n-3 LCPUFAs. LA, when incorporated into skin 
ceramides, is essential for maintaining the water permeability barrier of the skin and thereby avoiding 
excessive transepidermal water loss and the accompanying energy loss from water evaporation. A 
meta-analysis of the effect of ALA on growth and development of pre-term and term infants (Udell et 
al., 2005) concluded that ALA supplementation had a statistically significant effect on plasma and 
erythrocyte PL DHA concentrations but that there was a lack of convincing evidence for the effects of 
ALA supplementation of formula on infant growth and development. The meta-analysis did not find 
any effects of ALA on growth of pre-term infants and the small differences in weight and length 
between term infants fed ALA-enriched formula and controls which were observed at 12 months of 
age were not sustained at 24 months of age. There was a transient improvement in retinal function in 
pre-term but not in term infants and no effect on any of the other developmental indices. 
Eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA) and, to a lesser degree, DHA are 
synthesised from ALA. DHA is a component of membrane structural lipids, especially of PL in 
nervous tissue and the retina. The developing brain accumulates large amounts of DHA both pre- and 
post-natally, particularly during the first two years of life. DHA is predominantly acquired from the 
mother via placental transfer and from breast milk or formula, although the capacity of the fetus and 
newborn to synthesise DHA increases with gestational age (EFSA NDA Panel, 2010c). Biochemical 
changes of n-3 PUFA deficiency include a decrease in plasma and tissue DHA concentrations. There 
is no accepted cut-off concentration of plasma or tissue DHA concentrations below which functions 
ascribed to n-3 PUFA such as visual or neurological functions are impaired (IoM, 2005a). 
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DHA is accreted in the brain during the first two years of life and data mainly from in vitro and animal 
studies have shown effects of DHA on neuronal cell growth, rhodopsin function and levels of 
neurotransmitters (Lauritzen and Carlson, 2011). Studies generally show that the most predictable way 
to increase tissue DHA is to supply DHA rather than ALA (Arterburn et al., 2006). 
DHA has mainly been studied for its potential effect on neurodevelopment in infants and children. 
Assessment of neurodevelopment in children is complex because of the broad range of developmental 
domains, which include neurological and brain function, cognition (memory, attention, learning, 
intelligence, language, problem solving), visual function, motor skills, temperament and mental health. 
Different assessments exist within each domain, and there is wide variation in performance measures 
and psychometric characteristics. For example, assessments of visual function include both 
behavioural and electrophysiological measures of acuity determined by discrimination of visual angle 
or stereoacuity, as well as recordings of electrical responses in the retina and visual cortex. 
Test characteristics vary considerably with children’s age. Standardised age-normed tests for assessing 
infant development (e.g. the Bayley Scales of Infant Development (BSID)) measure the timely 
achievement of developmental milestones, but provide only a crude and global assessment of 
development. Other infant tests measure specific abilities, such as speed of processing, attention, 
problem solving and working memory, but most are not standardised and age-normed, and for most 
there is no agreed procedure for administering the test. These factors make it difficult to interpret and 
compare the results from different studies, especially when assessments have been conducted at 
different ages. 
The effect of addition of DHA and ARA, or DHA alone, to IF on performance on the Mental 
Developmental Index (MDI) and the Psychomotor Development Index (PDI) of the BSID has been 
investigated in several studies on term infants at different ages. 
In these studies, no statistically significant differences between the intervention groups consuming IF 
with DHA and ARA and control groups in MDI scores were reported at three months of age (one 
study (Ben et al., 2004a)), six months of age (two studies (Auestad et al., 2001; Ben et al., 2004a)) and 
at one year of age (three studies (Scott et al., 1998; Makrides et al., 2000; Auestad et al., 2001)). At 18 
months of age, one study (Birch et al., 2000) reported significant differences in MDI scores while 
three other studies reported in four publications did not report such differences at 18 months of age 
(Lucas et al., 1999; Bouwstra et al., 2005; Drover et al., 2011; Colombo et al., 2013). In addition, the 
studies which investigated this outcome at two years of age (Makrides et al., 2000) and six years of 
age (Colombo et al., 2013) did not report any significant differences in this outcome. 
None of the studies investigating the effect of DHA alone on MDI scores reported any differences 
between intervention and control groups at one year of age (three studies (Scott et al., 1998; Makrides 
et al., 2000; Auestad et al., 2001)) and two years of age (one study (Makrides et al., 2000)), which 
were the only time points measured. 
The same studies which investigated the impact of DHA and ARA added to IF on MDI scores also 
tested the effect on PDI scores. None of the studies reported an effect on this outcome at any tested 
age (3, 6, 12, 18 and 24 and 72 months). Similarly, this was the case for the three studies which 
investigated the effect of DHA alone at one and two years of age. 
Two studies investigated the impact of DHA and ARA addition to IF on intelligence quotient (IQ) 
scores using the Wechsler Preschool and Primary Scale of Intelligence Revised (WPPSI-R) at four 
(Birch et al., 2007) and six (Willatts et al., 2013) years of age and one study the WPSSI, third edition 
(Colombo et al., 2013), also at six years of age. The study by Birch et al. (2007) also included a group 
who consumed formula with added DHA alone. None of the studies reported significant differences 
between the intervention and control groups for processing speed IQ (investigated only in the study by 
Colombo et al. (2013)), performance IQ, verbal IQ or full-scale IQ. In another study (de Jong et al., 
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2012), the Wechsler Abbreviated Scale of Intelligence was used to investigate the effect of addition of 
DHA and ARA to IF on IQ at nine years of age. DHA and ARA addition to IF was reported to have 
been associated with statistically significantly higher verbal IQ scores in children whose mothers had 
smoked during pregnancy and with statistically significantly lower scores in children whose mothers 
had not smoked. No statistically significant effects on full-scale IQ or performance IQ were reported. 
The Peabody Picture Vocabulary Test, 3rd edition (PPVT-III), was used in two studies to assess 
language comprehension at 2 years, 3.5 years (Drover et al., 2012) and 5 years (Colombo et al., 2013) 
of age and the PPVT, revised (PPVT-R), in one study (Auestad et al., 2003) at 39 months of age. The 
study by Colombo et al. (2013) comprised three intervention groups consuming DHA and ARA but 
with increasing amounts of DHA (i.e. 0.00 FA %, 0.32 FA %, 0.64 FA % and 0.96 FA %). 
Statistically significantly higher scores were reported in the intervention groups consuming the two 
intermediate doses of DHA but not in the group consuming the highest dose of DHA at five years of 
age. For the study by Drover et al. (2012), statistically significantly higher scores were reported at two 
years of age in the control group than in the intervention groups (consuming IF with added DHA and 
ARA) with no statistically significant differences at 3.5 years. In the study by Auestad et al. (2003), no 
statistically significant differences in this outcome were reported. 
Other studies have investigated the impact of addition of DHA and ARA, or DHA alone, to IF on 
other tests of neurodevelopment, including the Knobloch, Passamanik, and Sherrards Development 
Screening Inventory (Lucas et al., 1999), the Brunet–Lézine developmental test (Agostoni et al., 
1997), the Standford–Binet scales (Auestad et al., 2003), vocabulary and gesture communication 
scores from the MacArthur Communicative Development Inventories (Scott et al., 1998), the Fagan 
Infant Test of Development (Auestad et al., 2001), problem solving assessment (Willatts et al., 1998), 
the Behaviour Rating Scale (Drover et al., 2011), the Neurological Optimality Score (Bouwstra et al., 
2005), the pair subtask of the Children’s Memory Scale (de Jong et al., 2012), A Developmental 
NEuroPSYchological Assessment (NEPSY) (de Jong et al., 2012), the Test of Everyday Attention for 
Children (de Jong et al., 2012), the Delayed Response Task (Colombo et al., 2013), the Bear-Dragon 
Go/No-Go Task (Colombo et al., 2013), the Dimensional Change Card Sort (Colombo et al., 2013), 
the Stroop task (Colombo et al., 2013), the Tower of Hanoi task (Colombo et al., 2013), the Day–
Night test (Willatts et al., 2013), the matching family figures test (Willatts et al., 2013), the Bracken 
Basic Concept Scale Revised (Drover et al., 2012) and mean length of utterance (Auestad et al., 2003). 
Furthermore, the effects on brainstem auditory evoked potentials (Ünay et al., 2004), look duration 
and sustained attention (Colombo et al., 2011) were evaluated. However, all these studies were single 
studies only and, although a few studies reported statistically significant effects, these findings were 
not replicated in other studies. 
Consumption of IF with added DHA has been associated with greater visual acuity at 12 months of 
age compared with consumption of control formula (EFSA, 2009). Only a few studies have 
investigated the persistence of the effect beyond infancy. The study by Birch et al. (2007), which used 
HOTV testing to assess visual acuity, reported statistically significantly higher right eye acuity in the 
group who had consumed formula with DHA than in the control formula group, but not when the 
group consuming DHA and ARA was compared with the control group at four years of age. No 
differences in visual acuity of the left eye were observed. The study by Singhal et al. (2007), which 
used the Sonksen–Silver Acuity System, and the study by Auestad et al. (2003), which used Teller 
acuity cards, did not report an effect of DHA on visual acuity at 39 months, and between 4 and 6 years 
of age. However, it has to be acknowledged that studies using Teller acuity cards also did not report 
any significant findings on visual acuity at 12 months of age (Carlson et al., 1996; Auestad et al., 
1997; Auestad et al., 2001). 
The effect of addition of DHA and ARA to IF on blood pressure at four, six and nine years of age was 
investigated in two studies (Forsyth et al., 2003; de Jong et al., 2011). None of the studies reported a 
significant effect on systolic blood pressure. In the study by Forsyth et al. (2003), a statistically 
significantly lower diastolic blood pressure was reported in the intervention group compared with the 
control formula group, while the study by de Jong et al. (2011) did not report such an effect. 
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The principal PUFA components of membrane PLs are DHA, ARA and LA. In the presence of 
adequate dietary intakes, DHA is preferentially incorporated into brain membranes and is favoured 
over ARA and LA (Makrides et al., 1994). Low dietary intakes of n-3 PUFA led to the replacement of 
DHA in brain membranes with the nearest n-6 PUFA equivalents in animal studies, but few changes 
were seen when n-6 PUFA intakes were low (Neuringer et al., 1986; Carrie et al., 2000). This is 
consistent with findings that brain DHA concentrations can be influenced by diet, whereas ARA levels 
are not (Hsieh and Brenna, 2009). The current requirement, established by Directive 2006/141/EC, to 
add n-6 LCPUFAs to IF and FOF in the presence of DHA in amounts which exceed those of DHA 
stems from a concern which was raised in one small randomised controlled trial (RCT) in pre-term 
infants (Carlson et al., 1993) in relation to potential adverse effects on growth of formulae containing 
DHA but no ARA. In this study, plasma phosphatidylcholine ARA concentrations were found to 
correlate with measures of normalised growth, which led the authors to hypothesise that ARA 
deficiency may contribute to decreased growth in pre-term infants over the first year of life. Earlier 
observational data have also shown a positive correlation between body weight and post-natal plasma 
triglyceride ARA (and total n-6 PUFAs) content and an inverse correlation with ALA (Koletzko and 
Braun, 1991). Since then, three RCTs investigated the effect on growth in term infants, comparing an 
IF containing added ARA and DHA with an IF containing DHA alone and with a control formula 
(Auestad et al., 1997; Birch et al., 1998; Makrides et al., 1999), and three studies (Makrides et al., 
1995; Innis et al., 1996; Lapillonne et al., 2000) compared an IF containing added DHA with a control 
formula. None of these studies found any statistically significant differences in growth, although 
erythrocyte ARA concentrations were observed to be lower in the groups consuming IF with DHA 
alone than in the groups consuming the control formula. Only two RCTs (Scott et al., 1998; Makrides 
et al., 2000)  allow the assessment of whether ARA would have an independent effect on cognitive 
function by comparing infants having been fed formula containing DHA and ARA and infants who 
have received formula containing DHA; however, there were no statistically significant differences 
between the two groups in BSID-MDI or PDI scores. In a previous opinion (EFSA, 2009), the Panel 
has already investigated the potential role of ARA in visual development and concluded that, on the 
basis of available data, a role of ARA in visual development cannot be established. 
One meta-analysis concluded that post-natal n-3 LCPUFA intake (from fish, fish oil and breast milk) 
decreases childhood asthma (Yang et al., 2013), whereas a systematic review of RCTs found an effect 
on asthma and the response to skin prick test only after supplementation during pregnancy, and no 
significant effect was seen after post-natal intake (Klemens et al., 2011). 
Studies have suggested that polymorphisms in the FADS gene cluster that determine the endogenous 
conversion of LA and ALA to LCPUFAs alter the effect of breast-feeding on cognitive outcomes 
(Caspi et al., 2007; Steer et al., 2010; Martin et al., 2011; Morales et al., 2011; Steer et al., 2013) and 
risk of atopy (Rzehak et al., 2010; Standl et al., 2011; Standl et al., 2012). Different FADS single-
nucleotide polymorphisms (SNPs) may have different effects on LCPUFA synthesis, and these may 
vary with age (Harsløf et al., 2013). The presence of these polymorphisms could influence the effect 
of LCPUFA addition and thus further complicate the evaluation of the effects of addition of LCPUFAs 
to IF and FOF. 
The Panel considers that DHA should be added to IF and FOF, even though there is currently no 
conclusive evidence for any effects beyond infancy of addition of DHA to IF or FOF on any of the 
health outcomes studied. The reasons for proposing this addition are that (1) DHA is an essential 
structural component of the nervous tissue and the retina, and is involved in normal brain and visual 
development (EFSA, 2009); (2) the developing brain has to accumulate large amounts of DHA in the 
first two years of life; (3) although DHA can be synthesised in the body from ALA, the intake of pre-
formed DHA generally results in an erythrocyte DHA status more closely resembling that of a breast-
fed infant than is achieved with ALA alone (Brenna et al., 2009); and (4) although, to date, there is no 
convincing evidence that the addition of DHA to IF and FOF has benefits beyond infancy on any 
functional outcomes, there is also a lack of long-term follow-up data on specific aspects of cognitive 
and behavioural function from adequately powered RCTs of DHA addition to IF and FOF to 
demonstrate any purported biologically plausible effect of DHA on these aspects. Considering all of 
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these factors, it seems prudent to provide pre-formed DHA to formula-fed infants in similar amounts 
as breast-fed infants, even though benefits beyond infancy of this practice cannot be established based 
on the currently available data. 
The Panel notes that even though studies have shown that feeding an IF containing DHA alone, 
(without addition of ARA) leads to lower concentrations of ARA in erythrocytes compared with the 
consumption of control formula without DHA, no direct functional consequences have been observed 
in relation to growth and neurodevelopment and this lower concentration of ARA in erythrocytes 
seems not to be associated with a decrease in concentrations of ARA in the brain. The adverse effects 
on growth which had been reported in one RCT in pre-term infants have not been replicated in several 
more recent trials. Therefore, the Panel considers that there is no necessity to add ARA to IF even in 
the presence of DHA. 
With respect to the EPA:DHA ratio, the SCF (2003b) recommended that the ratio should be kept 
below 1. However, there are no studies which investigated any potential health risk of high intakes of 
EPA in infants, but the content of EPA in breast milk is usually low, typically in the range 
0.05-0.4 FA % (Lauritzen and Carlson, 2011). 
5.3.6.3. Molecular speciation of fatty acids 
In breast milk, PLs that constitute the fat globule membrane have a high content of LCPUFAs 
compared with the TAG molecules in the core of the milk globules (Abrahamse et al., 2012). The PLs 
supplied by breast milk are expected to play a role, together with bile PLs, in the emulsification of the 
fat in the infant gut and thus promote digestion, absorption and transport (Ramirez et al., 2001). It has 
been proposed that, specifically, LCPUFAs may be better utilised if supplied in PLs owing to 
increased absorption and tissue incorporation (Abrahamse et al., 2012). Furthermore, as constituents of 
the membranes of all cells in the infant, PLs are involved in a variety of physiological processes, but 
these are usually not expected to be influenced by dietary intake of PLs (German, 2011; Küllenberg et 
al., 2012; Oosting et al., 2012; Tanaka et al., 2013). Few studies have looked at functional 
consequences of inclusion of PLs in IF. A meta-analysis that specifically evaluated the effect of 
formula LCPUFAs on infant growth did not find any differences depending on whether these were 
added as PLs or TAG (Makrides et al., 2005). The Panel considers that there is no convincing 
evidence for a beneficial effect of LCPUFAs supplied as PLs instead of TAG in IF or FOF. There are 
no adverse effects reported of the use of PLs to supply LCPUFAs in IF and/or FOF instead of TAG. 
Lecithins are authorised by Regulation (EC) No 1333/2008
15
 to be added to IF and FOF as emulsifier 
in an amount of 1 g/L. 
5.3.6.4. TAG with palmitic acid predominantly in the sn-2 position 
Structured triglycerides in which palmitic acid has been predominantly esterified in the sn-2 position 
in order to imitate breast milk have been studied for a number of health outcomes in healthy term 
infants, including mineral absorption and retention, bone mineral density (BMD), growth, stool 
consistency, blood lipid profiles and infant crying time. 
In these studies, no effects on infant growth (Kennedy et al., 1999; Nelson and Innis, 1999; 
Litmanovitz et al., 2013) or on phosphorus and magnesium absorption (Carnielli et al., 1996) were 
observed. In addition, no cause and effect relationship could be established by the Panel previously 
between the feeding of formula high in sn-2 palmitate and stool consistency (EFSA NDA Panel, 
2014d). The study by Yao et al. (2014), which was published after the opinion of the Panel, reported a 
significantly higher percentage of mushy soft stools and a significantly lower percentage of formed 
stools in the group consuming formula high in sn-2 palmitate than in controls. However, results from 
the pre-planned analyses on the average stool consistency scores between groups and on the 
percentage of stools in the other stool consistency categories (in total five) were not reported. The 
                                                     
15 Regulation (EC) No 1333/2008 of the European Parliament and of the Council of 16 December 2008 on food additives. OJ 
L 354, 31.12.2008, p. 16–33. 
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studies investigating calcium absorption (EFSA NDA Panel, 2011) and infant crying time (Kennedy et 
al., 1999; Litmanovitz et al., unpublished; Zhong et al., unpublished) reported inconsistent results. The 
only study which used dual-energy X-ray absorptiometry (DXA) to measure BMD showed that infants 
fed a formula with high sn-2 palmitate had higher BMD than those fed a control formula. However, 
DXA measurements were available only for a sub-group of subjects, and bone mineral content of the 
radius obtained using single photon absorptiometry in all infants did not differ between groups 
(Kennedy et al., 1999). A small study (Yaron et al., 2013) evaluated the effect of formula with high 
sn-2 palmitate compared with a formula with low sn-2 palmitate on infant gut microbiota composition, 
reporting increases in Clostridium, Escherichia coli, Pseudomonas and Staphylococcus numbers, but 
only by plate counting and without providing further characterisation of the bacterial groups analysed 
to infer possible physiological/clinical consequences of the changes reported. One study which 
investigated the effect of sn-2 palmitate on blood lipids found lower high-density lipoprotein (HDL)-
cholesterol and apolipoprotein A1 concentrations and higher apolipoprotein B concentrations in the 
group being fed high sn-2 palmitate formula (Nelson and Innis, 1999), but the relevance of this finding 
in infants is unknown. The Panel considers that there is no convincing evidence for a beneficial effect 
of the use of TAG with palmitic acid predominantly esterified in the sn-2 position in IF and/or FOF 
instead of other TAGs. There are no adverse effects reported of the use of TAG with palmitic acid 
predominantly esterified in the sn-2 position in IF and/or FOF instead of other TAGs. 
5.3.7. Recommendations 
5.3.7.1. Total fat 
According to Directive 2006/141/EC and in line with the SCF (2003b), IF have to provide fat in the 
range of 40-55 E % and FOF in the range of 35-55 E %. The Panel had concluded in its previous 
opinion (EFSA NDA Panel, 2013a) that intakes of fat of 50-55 E % and 40 E % were adequate for the 
majority of infants for the first and second half year of life, respectively. The Panel considers that 
there is no scientific reason to differentiate the fat content of IF and FOF and that complementary 
foods that contribute to the dietary intake in the later half of infancy have a low fat content. 
Therefore, the Panel proposes a minimum fat content of IF and FOF of 40 E % (i.e. 4.4 g/100 kcal 
(1.1 g/100 kJ)) and a maximum fat content of 55 E % (i.e. 6.0 g/100 kcal (1.4 g/100 kJ)). 
5.3.7.2. Linoleic acid (LA) 
The range of LA concentrations in IF and FOF can be derived based on the level of LA intakes 
(4 E %) which the Panel had considered to be adequate for the majority of infants (EFSA NDA Panel, 
2013a) and the highest concentrations of LA observed in human milk (24 FA %) (Sanders and Reddy, 
1992). These derivations translate into a lower bound of the range of 500 mg/100 kcal (120 mg/100 kJ, 
equivalent to 4.5 E %) and an upper bound of the range of 1 200 mg/100 kcal (300 mg/100 kJ, 
equivalent to 10.8 E %), in line with what has been recommended previously by the SCF (2003b). 
5.3.7.3. Alpha-linolenic acid (ALA) 
In line with the approach for LA, a lower bound for ALA in IF and FOF can be derived based on the 
level of ALA intakes (0.5 E %) which the Panel had considered to be adequate for the majority of 
infants (EFSA NDA Panel, 2013a) and an upper bound can be derived based on the highest ALA 
concentrations observed in human milk (2 FA %) (Mäkelä et al., 2013). These derivations translate 
into a lower bound of the range of 50 mg/100 kcal (12 mg/100 kJ, equivalent to 0.5 E %) and an upper 
bound of the range of 100 mg/100 kcal (24 mg/100 kJ, equivalent to 0.9 E %). 
The Panel considers that there is no necessity to set a specific ratio for LA:ALA in the presence of 
LCPUFAs in IF and FOF. 
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5.3.7.4. Long-chain polyunsaturated fatty acid (LCPUFAs) 
In line with the approach for LA and ALA, a lower bound for DHA in IF and FOF can be derived 
based on the level of DHA intakes (100 mg/day) which the Panel had considered to be adequate for 
the majority of infants (EFSA NDA Panel, 2013a) and an upper bound can be derived based on the 
highest observed DHA concentrations in human milk (around 1 FA %) (Brenna et al., 2009). These 
derivations translate into a lower bound of the range of 20 mg/100 kcal (4.8 mg/100 kJ, approx. 
0.36-0.49 FA %) and an upper bound of the range of 50 mg/100 kcal (12 mg/100 kJ, approx. 
0.90-1.23 FA %). 
The Panel considers that there is no necessity to set a specific minimum content of ARA or EPA in IF 
or FOF or a specific ratio for DHA:ARA. Considering that the DHA content in breast milk always 
exceeds the content of EPA, the Panel proposes that, for IF and FOF also, the amount of EPA should 
not be higher than that of DHA. 
The Panel notes that there is no convincing evidence that the addition of DHA to IF and FOF has 
benefits beyond infancy on any functional outcomes. However, the proposal of the Panel to add DHA 
to IF and FOF is based on its structural role in the nervous tissue and the retina and its involvement in 
normal brain and visual development, the need of the developing brain to accumulate large amounts of 
DHA in the first two years of life and the consideration that the intake of pre-formed DHA generally 
results in an erythrocyte DHA status more closely resembling that of a breast-fed infant than is 
achieved with ALA alone. 
5.3.7.5. Saturated fatty acids (SFAs) and trans-fatty acids (TFAs) 
The Panel considers that there is no evidence which allows for the proposal of lower or upper bounds 
of a range for specific types of SFA (MCFAs or lauric, myristic or palmitic acid) in IF or FOF. For 
TFAs, the Panel considers the current specifications for TFA content in IF and FOF (< 3 FA %) to be 
adequate. These specifications allow for the use of milk as a source of fat for formulae. 
5.3.7.6. Vegetable oils 
The Panel considers that the vegetable oils used in the production of IF and FOF should be safe from a 
toxicological point of view (regarding the content of eruric acid, cyclopentene fatty acids, etc.). The 
use of partially hydrogenated vegetable oils in IF and FOF should be avoided because of their TFA 
content. 
5.3.7.7. Phospholipids (PLs) 
Taking into account the lack of convincing evidence for a beneficial effect of LCPUFAs supplied as 
PLs instead of TAG in IF or FOF, the Panel considers that there is no necessity to use PLs as a source 
of LCPUFAs instead of TAG in IF and FOF. PLs are naturally present in milk and ISP, and may be 
added to IF and FOF for technological purposes, for example as an emulsifier or as a source of 
LCPUFAs. 
5.3.7.8. TAG with palmitic acid predominantly in the sn-2 position 
Taking into account the lack of convincing evidence for a benefit of using TAG with palmitic acid 
predominantly esterified in the sn-2 position in IF and/or FOF, the Panel considers that there is no 
necessity to use TAG with palmitic acid predominantly esterified in the sn-2 position in IF and FOF 
instead of TAG from other fat sources. 
Table 9 provides an overview of the proposed minimum and maximum content of total fat and an 
adequate range of fatty acids in IF and FOF. 
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Table 9:  Proposed minimum and maximum content of fat and adequate range of fatty acids in IF 
and FOF 
 Minimum content Maximum content 
mg/100 kcal mg/100 kJ mg/100 kcal mg/100 kJ 
Total fat 4 400 1 052 6 000 1 434 
 Lower bound Upper bound 
LA 500 120 1 200 300 
ALA 50 12 100 24 
DHA 
(a) 
20 4.8 50 12 
TFA – – 3 FA % 3 FA % 
(a): The amount of EPA should not be higher than the amount of DHA. 
5.4. Carbohydrates 
Nutritionally, two broad categories of carbohydrates can be differentiated: “glycaemic carbohydrates”, 
i.e. carbohydrates digested and absorbed in the human small intestine with a substantial subsequent 
rise in blood glucose, and “dietary fibre‟, i.e. non-glycaemic carbohydrates passing undigested to the 
large intestine and with no rise in blood glucose. The absolute dietary requirement for glycaemic 
carbohydrates is not known because there is no indispensable carbohydrate. For practical purposes, 
recommendations for glycaemic carbohydrates will depend on the amount of fat and protein ingested. 
The main glycaemic carbohydrates are monosaccharides, disaccharides, malto-oligosaccharides and 
starch. Dietary fibre is defined to include all non-digestible carbohydrates (plus lignin) (EFSA NDA 
Panel, 2010b), but for IF and FOF only resistant oligosaccharides (fructo-oligosaccharides (FOS), 
galacto-oligosaccharides (GOS), other resistant oligosaccharides) and resistant starch and chemically 
and/or physically modified starches are of relevance. 
5.4.1. Current compositional requirements of IF and FOF 
Permitted carbohydrates in IF are lactose, maltose, sucrose, glucose, maltodextrins, glucose syrup (or 
dried glucose syrup), pre-cooked starch and gelatinised starch free from gluten. These carbohydrates 
can be used under the conditions outlined in Table 10. For FOF, there are no restrictions with respect 
to the type of carbohydrates that can be used as long as they are free from gluten. If honey is used (for 
FOF only), it has to be treated in order to destroy spores of Clostridium botulinum. 
Table 10:  Current compositional requirements for IF and FOF with respect to glycaemic 
carbohydrates and FOS plus GOS according to Directive 2006/141/EC 
g/100 kcal IF with FOF with 
Milk 
protein 
ISP Protein 
hydrolysates 
Milk 
protein 
ISP Protein 
hydrolysates 
Carbohydrates 9-14 9-14 
of which   
Lactose ≥ 4.5 NR (a) ≥ 4.5 ≥ 4.5 NR (a) ≥ 4.5 
Sucrose Not to be added ≤ 20 % of total 
carbohydrates 
(b) (c) 
Sum of sucrose, fructose, sugar from honey 
≤ 20 % of total carbohydrates (b) 
Fructose Not to be added 
Glucose Not to be added
 ≤ 2 (b) (c) Not to be added ≤ 2 (b) (c) 
Maltose, 
maltodextrins 
(b) 
Unrestricted within specifications for total 
carbohydrates
 
Unrestricted within specifications for total 
carbohydrates
 
Starches 
(b) ≤ 2 g/100 mL and ≤ 30 % of total 
carbohydrates 
(d) 
Unrestricted within specifications for total 
carbohydrates as long as free of gluten 
FOS + GOS 
(b) (e) ≤ 0.8 g/100 mL ≤ 0.8 g/100 mL 
(a): Not required (NR) if more than 50 % of the protein content is from ISP. 
(b): Voluntary addition. 
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(c): To mask the bitter taste. 
(d): Pre-cooked or gelatinised starch only. 
(e): A combination of 90 % oligogalactosyl-lactose and 10 % high-molecular-weight oligofructosyl-saccharose only. 
5.4.2. Carbohydrate content of human milk 
5.4.2.1. Digestible (glycaemic) carbohydrates 
The Panel proposes to differentiate between glycaemic and non-glycaemic carbohydrates to underline 
the difference in their physiological function. The first source of glycaemic carbohydrates in infants is 
human milk, in which lactose, a disaccharide of glucose and galactose, is the primary sugar. Lactose 
occurs exclusively in milk and milk products. Human milk has the highest lactose content of all milks, 
about 55-70 g/L or 8.2-10.4 g/100 kcal (corresponding to 33-42 E %), whereas the content of 
monosaccharides is only about 1 % of total carbohydrates (Coppa et al., 1994). Human milk does not 
contain sucrose or fructose but does contain small amounts of sugar alcohols, including inositol 
(Cavalli et al., 2006). 
5.4.2.2. Non-digestible (non-glycaemic) carbohydrates in human milk 
The third main component in human milk after lactose and fat are neutral and acid oligosaccharides in 
concentrations between around 5-15 g/L (Aggett et al., 2003; Coppa et al., 2011). The structure of 
about 200 human milk oligosaccharides has been identified (Kunz et al., 2000). These 
oligosaccharides are typically composed of 3–23 monosaccharide units, including glucose, galactose, 
N-acetylglucoamine, fucose and sialic acid. Approximately 20 oligosaccharides make up more than 
90 % of the total amount of oligosaccharides in human milk, with the principal oligosaccharides being 
fucosyllactoses, lacto-N-tetraose, lacto-N-neotetraose, sialyllactoses, lacto-N-fucopentaoses (I–V) and 
lacto-N-difucohexaoses (I–III). The neutral linear and branched-chain oligosaccharides are fucosylated 
to a varying degree and make up 80-85 % of the total amount of oligosaccharides in human milk, 
whereas the acidic oligosaccharides contain sialic acid and make up 15-20 % of the total amount. The 
production of oligosaccharides is genetically determined and the individual pattern of oligosaccharides 
differs between women (Ninonuevo et al., 2006). 
The oligosaccharides of human milk are considered to be one of the principal growth factors, for 
example, for bifidobacteria in the infant gut and are responsible for the composition of the gut 
microbiota found in breast-fed infants. The fermentation of non-digestible oligosaccharides leads to 
the generation of organic acids (lactic acid) and SCFAs such as acetic, propionic and butyric acids. 
Butyrate is a main source of energy for the colonocytes and has effects on cell differentiation. Acetate 
and propionate are absorbed from the colon and thus provide energy to the host (Aggett et al., 2003). 
Fermentation products, i.e. SCFAs, contribute to the energy content of the diet, but to a lesser extent 
than glycaemic carbohydrates. Human milk oligosaccharides are not considered in the estimation of 
the energy content of the milk. 
5.4.3. Carbohydrate requirements of infants 
In the Panel’s previous Opinion on nutrient requirements and dietary intakes of infants and young 
children in the European Union (EFSA NDA Panel, 2013a), the Panel concluded on a Reference 
Intake range (RI) for total carbohydrates of 40-45 E % for infants below six months of age and of 
45-55 E % for infants from 6 to < 12 months. Fibre intakes are usually not considered in 
recommendations up to one year of life. 
5.4.4. Carbohydrate intake of infants 
5.4.4.1. Digestible (glycaemic) carbohydrates 
Assuming a human milk intake of 0.8 L/day and a lactose content of 70 g/L, a breast-fed infant would 
consume 56 g of lactose per day (around 50 E %) during the first six months of life. Mean total 
carbohydrate intakes in mostly formula-fed infants have been reported in the range of around 
63-93 g/day or 46-50 E % (Hilbig, 2005; Noble and Emmett, 2006; Fantino and Gourmet, 2008; 
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Lennox et al., 2013). In infants older than six months, mean total carbohydrate intakes reportedly 
amount to around 80-140 g/day or 49-58 E % (Lagström et al., 1997; Noble and Emmett, 2001; 
Hilbig, 2005; de Boer et al., 2006; DGE, 2008; Fantino and Gourmet, 2008; Marriott et al., 2008; 
Thorsdottir et al., 2008; Lennox et al., 2013). 
5.4.4.2. Non-digestible (non-glycaemic) carbohydrates 
Assuming an intake of 0.8 L/day of human milk and an oligosaccharide content of 5-15 g/L, a breast-
fed infant would consume between 4 and 12 g per day of non-digestible oligosaccharides during the 
first half of the first year of life. There are no data on the oligosaccharide intakes in infants. In some 
European countries (Germany, France, Finland and the Netherlands) the dietary fibre intake of infants 
older than six months has been reported to be around 4-10 g/day (Lagström et al., 1997; Noble and 
Emmett, 2001; Hilbig, 2005; de Boer et al., 2006; DGE, 2008; Fantino and Gourmet, 2008). 
5.4.5. Health consequences 
5.4.5.1. Type of carbohydrates 
Currently, only carbohydrates which are free of gluten can be used in IF and FOF. The risk of 
developing coeliac disease (CD) and type 1 diabetes mellitus (T1DM) has been related to the timing of 
gluten introduction into the infant’s diet. In 2009, the Panel concluded, based on available data, that 
the early (less than four months of age) introduction of gluten might increase the risk of CD and 
T1DM, whilst the introduction of gluten between four and six months of age, preferably while the 
infant is still being breast fed, might decrease the risk of CD and T1DM (EFSA NDA Panel, 2009). 
CD is a multi-organ disease, triggered by gluten and related prolamins in genetically predisposed 
subjects. The prevalence in Europe is in the range of 0.5-1 % (Fasano, 2001; Virta et al., 2009; Catassi 
et al., 2012). 
A current European intervention study on 1 000 infants positive for human leucocyte antigen (HLA) 
DQ2/DQ8 and randomised to receive about 100 mg of gluten per day or placebo is expected to 
provide further evidence regarding the role of gluten introduction into the infant’s diet. However, 
detailed results of this study have not yet been published. 
The Panel considers that the available data suggest that gluten-containing complementary foods could 
be introduced between four and six months of age in small amounts, preferably while the infant is still 
being breast fed. However, in the case of FOF feeding together with complementary foods, the use of 
gluten-containing starches in such formulae could result in amounts of gluten that are too high to be 
tolerated in genetically predisposed infants. Therefore, gluten-containing starches should not be added 
to IF and FOF. 
5.4.5.2. Glycaemic carbohydrates 
Glycaemic carbohydrates provide carbohydrates to body cells, mainly in the form of glucose. Only 
cells in the central nervous system, red blood cells and some other cells dependent on anaerobic 
glycolysis have an absolute requirement for glucose. The body can in principle synthesise glucose 
from protein and glycerol, but this is not efficient and may lead to ketosis. Therefore, the DRV for 
carbohydrates is based on the energy gap between the energy provided by the sum of recommended 
protein and fat intakes and the total energy requirement. 
Lactose 
Lactose should be the preferred carbohydrate in IF and FOF although no absolute requirement for 
dietary galactose intake exists. This preference for lactose in formulae is justified by the predominance 
of lactose in human milk, the newborn’s capacity to hydrolyse lactose from human milk and the 
absence of advantages that other glycaemic carbohydrates might have compared with lactose. 
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The capacity of the newborn to metabolise lactose was demonstrated in a study of 24 infants of 
> 36 weeks’ gestation, post-natal age 2-16 days, and taking full enteral feeding (n = 6 breast milk, 
n = 5 formula, n = 11 mixed) and which showed that, although lactose from formula or human milk 
provides glucose and galactose in equimolar amounts to the portal vein, galactose is cleared almost 
completely by the liver within 60 minutes after a meal and reaches only 1-2 % of the glucose 
concentration in plasma, whilst glucose increased in both the hepatic and systemic circulation without 
net hepatic uptake. There was a positive influence of post-natal age on hepatic galactose clearance that 
could be attributed to either maturation of enzymes or closure of a patent ductus venosus (shunting 
blood from the left portal vein to the vena cava) (Brown et al., 2008). 
Evidence that lactose is not a requirement for healthy growth is provided by two RCTs, of 12 weeks’ 
duration, with lactose-free formulae with maltodextrin and sucrose (Heubi et al., 2000; Lasekan et al., 
2011) performed on healthy term infants in comparison with a standard lactose-containing formula in 
which growth parameters did not differ. As soy does not contain digestible lactose or galactose 
naturally and formulae containing ISP may be used in infants with galactosaemia, these formulae 
should not contain any lactose. 
Sucrose, glucose and fructose 
The ingestion of sucrose and fructose by infants with fructose intolerance, a hereditary disease 
affecting approximately 1 in 26 000 infants in Central Europe (Santer et al., 2005), can lead to severe 
symptoms, including poor feeding, vomiting and overall failure to thrive (Coffee and Tolan, 2010). 
The consumption of sucrose and fructose by healthy infants does not have any advantages over the 
consumption of lactose and may, because of their greater sweetness, increase the preference for sweet 
tastes in infants. Sucrose may be added to IF containing hydrolysed protein to camouflage the taste of 
the hydrolysate. Because complementary food will provide other glycaemic carbohydrates than 
lactose, there is no reason to restrict their use in FOF as long as certain maximum levels are not 
exceeded. 
Glucose is rapidly absorbed with a rapid rise in blood glucose and has, moreover, a higher osmotic 
activity than di-, oligo- and polysaccharides. Hyperosmolar feeds may lead to an increased incidence 
of diarrhoea. Small amounts of glucose may, however, help mitigate the disagreeable taste of IF and 
FOF containing protein hydrolysates. 
Maltodextrins and starches 
Maltodextrins and starches have the advantage of producing lower osmolality in products than mono- 
and disaccharides. The SCF (2003b) recommended that maltodextrins with 5-9 glucose units should be 
preferred because this corresponds to the chain-length specificity of the intestinal glucoamylase. 
Pancreatic α-amylase concentrations in the infant’s duodenum are lower than in adults (Christian et 
al., 1999). Shulman et al. (1983) compared the effects of feeding glucose, glucose polymers and 
precooked corn starch, which were substituted for saccharose in the basal diet for one meal at a dose 
of 1 g/kg body weight in 16 healthy infants aged between three and four weeks, on breath 
13
CO2, 
breath hydrogen and stool 
13
C abundance taking into account the natural 
13
C abundance in the different 
formulae. The calculated oxidation rate was comparable for the different carbohydrates studied, but 
hydrogen production increased with carbohydrate complexity, indicating that more undigested 
carbohydrates reached the colon with increasing complexity of the carbohydrates. This finding is 
similar to the findings of another study (Shulman et al., 1986) in which it was found that long-chain 
glucose polymers are absorbed less, and with greater individual variation, than glucose or short-chain 
glucose polymers. Carbohydrates that are not digested and absorbed in the small intestine may be 
fermented by colonic bacteria. This fermentation increases the net utilisation of complex 
carbohydrates, but the capacity for bacterial fermentation can be exceeded by high intakes of complex 
carbohydrates (Shulman et al., 1983). Earlier studies reviewed by Fomon (1993) suggested that starch 
is tolerated up to daily intakes of 5.5-6 g/kg body weight per day and that most infants from one to 
five months of age are able to digest 10-25 g of starch per day. 
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5.4.5.3. Non-digestible (non-glycaemic) carbohydrates 
Because of the variety, variability, complexity and polymorphism of human milk oligosaccharides, the 
addition to IF and FOF of a mixture of oligosaccharides mimicking those found in breast milk is not 
feasible and oligosaccharides which are currently added to IF and FOF are not comparable to human 
milk oligosaccharides. Instead, oligofructosyl-saccharose (oligofructose; FOS) and oligogalactosyl-
lactose (oligogalactose; GOS) have been used in IF and FOF. FOS is not found in human milk and 
GOS is found only in trace amounts. 
Cow’s milk contains only trace amounts of oligosaccharides (0.03-0.06 g/L), mostly sialylated 
derivatives, whilst the content of neutral and acidic oligosaccharides (AOS) in goat milk is four to five 
times higher than in cow’s milk (Martinez-Ferez et al., 2006). 
The SCF (2001d) has previously assessed the safety of a formula with the addition of 0.8 g/100 mL of 
a mixture of 90 % GOS and 10 % high-molecular-weight FOS and found no reason for concern or 
conclusive proof of potential beneficial effects for infants in the second half of the first year of life. It 
found the evidence insufficient to establish the safety for infants below six months of age. It 
recommended that additional information on the suitability and safety of resistant short-chain 
oligosaccharides should be submitted, with particular attention to possible effects on water balance. 
When reviewing the available evidence in 2003, the SCF (2003b) concluded that the particular 
mixture of GOS and FOS which had been evaluated previously did not give rise to any safety concerns 
at concentrations used in both IF and FOF up to a maximum of 0.8 g/100 mL. The SCF also 
reaffirmed its conclusions that further information on the safety and benefits of this combination as 
well as of other forms of oligosaccharides in IF and FOF should be gathered. 
Since the report by the SCF (2003b), other oligosaccharides or combinations of oligosaccharides (e.g. 
GOS, inulin-type fructans or their combination or with mixtures of polydextrose and AOS) have been 
studied for a number of health outcomes, such as bowel function, gastrointestinal and respiratory tract 
infections, atopic dermatitis, eczema, urticaria and asthma. They have also been studied in relation to 
any potential untoward effects, such as delayed growth, diarrhoea and an increased risk of inadequate 
water balance. 
Two recent systematic reviews on the effects of the addition of oligosaccharides to IF and FOF 
comprised 12 RCTs (Mugambi et al., 2012) and 23 RCTs (Braegger et al., 2011). 
The systematic review by the ESPGHAN Committee on Nutrition (Braegger et al., 2011) builds upon 
and updates two earlier systematic reviews on “prebiotic” supplementation of full-term infants (Rao et 
al., 2009) and on “prebiotics” in the prevention of allergic disease and food hypersensitivity (Osborn 
and Sinn, 2007) and included 23 publications of RCTs performed in healthy term infants with 
durations between two weeks and six months. The “prebiotics” were added to IF, and in two studies to 
FOF. In most studies, a 9:1 mixture of short-chain GOS and long-chain FOS was used (Moro et al., 
2002; Moro et al., 2003; Bakker-Zierikzee et al., 2005; Decsi et al., 2005; Haarman and Knol, 2005; 
Knol et al., 2005; Bakker-Zierikzee et al., 2006; Moro et al., 2006; Alliet et al., 2007; Costalos et al., 
2008; Magne et al., 2008; Scholtens et al., 2008), four studies used GOS alone (Ben et al., 2004b; 
Bakker-Zierikzee et al., 2005; Bettler and Euler, 2006; Ben et al., 2008), and one each AOS (Fanaro et 
al., 2005), GOS/FOS/AOS together (Fanaro et al., 2005), FOS plus inulin (Brunser et al., 2006) and 
polydextrose plus GOS (with or without lactulose) (Ziegler et al., 2007; Nakamura et al., 2009). The 
concentration in the formula ranged from 0.15 to 0.8 g/100 mL. 
The review by Braegger et al. (2011) considered all studies included in the review by Mugambi et al. 
(2012) except for the studies by Bruzzese et al. (2009) and Moro et al. (2005). Therefore, the Panel has 
taken the review by Braegger et al. (2011) as a basis for the evaluation of data but has also considered 
the studies by Bruzzese et al. (2009) and Moro et al. (2005), both of which used GOS/FOS. The Panel 
is aware of a recent study which investigated the effect of the addition of a 50:50 mixture of FOS and 
long-chain inulin to an IF (Closa-Monasterolo et al., 2013). Three additional studies conducted in term 
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infants were identified during the public consultation of the draft opinion. In the studies by Ashley et 
al. (2012) and Scalabrin et al. (2012), the addition of a 50:50 mixture of polydextrose and GOS to IF 
was investigated, and in the study by Veereman-Wauters et al. (2011) a GOS/FOS mixture was 
evaluated. The studies by Ashley et al. (2012) and by Veereman-Wauters et al. (2011) also assessed 
the addition of GOS alone to IF. 
Some of the studies reviewed assessed the effect of different oligosaccharides on the reduction of stool 
pH, SCFA production or the number of bifidobacteria or lactobacilli in stools. Although some of the 
studies reported significant effects on these outcomes for some of the oligosaccharides used, the 
relevance of these effects for infant health is unclear. None of the studies which investigated the 
effects on numbers of potentially pathogenic microorganisms in stools reported significant effects on 
this outcome (GOS/FOS: five studies (Moro et al., 2002; Moro et al., 2003; Ben et al., 2004b; Decsi et 
al., 2005; Alliet et al., 2007; Costalos et al., 2008); GOS/FOS/AOS: one study (Fanaro et al., 2005)). 
The studies which examined the impact of supplementing formula with GOS/FOS (three studies) 
(Moro et al., 2002; Moro et al., 2003; Moro et al., 2006; Costalos et al., 2008) or with a mixture of 
FOS and long-chain inulin (Closa-Monasterolo et al., 2013) on stool frequency reported statistically 
significant effects on stool frequency in infants, whereas the study by Veereman-Wauters et al. (2011), 
which used GOS/FOS and GOS alone, the study by Brunser et al. (2006), which used a combination of 
FOS and inulin, and the studies by Ashley et al. (2012) and Scalabrin et al. (2012), which used a 
polydextrose-GOS mixture and GOS alone, did not. The Panel notes that all these studies had 
considerable methodological limitations which severely hamper the conclusions which can be drawn 
from them. 
The effect of GOS/FOS on stool consistency was examined in five studies. Four of these studies 
reported statistically significant effects on this outcome (Moro et al., 2002; Moro et al., 2003; Moro et 
al., 2006; Costalos et al., 2008; Veereman-Wauters et al., 2011), while one did not (Knol et al., 2005). 
The studies which used a combination of GOS/FOS/AOS (Fanaro et al., 2005), polydextrose plus 
GOS (Ziegler et al., 2007; Ashley et al., 2012; Scalabrin et al., 2012) or a mixture of FOS and long-
chain inulin (Closa-Monasterolo et al., 2013) and a study in which GOS alone was used (Veereman-
Wauters et al., 2011) reported effects on stool consistency, but not the study by Brunser et al. (2006), 
which also used a combination of FOS and inulin, and also not a study which used GOS alone (Ashley 
et al., 2012). The Panel notes that all these studies had considerable methodological limitations which 
severely hamper the conclusions which can be drawn from them. 
The effect of oligosaccharides on the incidence of infections has been studied for GOS/FOS in two 
studies (one reported in three publications) (Moro et al., 2006; Arslanoglu et al., 2007; Arslanoglu et 
al., 2008; Bruzzese et al., 2009) and for a combination of FOS and inulin in one study (Brunser et al., 
2006). For the administration of GOS/FOS, a statistically significantly reduced cumulative incidence 
of fever and of infectious episodes of the upper respiratory tract requiring antibiotic treatment was 
reported in one study (Arslanoglu et al., 2007; Arslanoglu et al., 2008), whilst there was no difference 
in the incidence of lower respiratory tract, gastrointestinal and urinary tract infections. In contrast, 
Bruzzese et al. (2009) did not report any effect of GOS/FOS on upper respiratory tract infections, but 
on gastrointestinal infections. For the administration of a combination of FOS and inulin (Brunser et 
al., 2006) there was no effect reported on the incidence of gastrointestinal infections. The Panel notes 
that the findings of these studies are inconsistent and that they had considerable methodological 
limitations which severely hamper the conclusions which can be drawn from them. 
GOS/FOS have also been studied with respect to the occurrence of allergic manifestations. A reduced 
cumulative incidence of atopic dermatitis, of recurrent wheezing and of allergic urticaria was reported 
in one study (Arslanoglu et al., 2007; Arslanoglu et al., 2008). The Panel notes that this study had 
considerable methodological limitations which severely hamper the conclusions which can be drawn 
from it. 
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The Panel notes that most of the studies which investigated the effect of non-digestible 
oligosaccharide addition to formula had considerable limitations, including a high drop-out rate, lack 
of consideration of missing values, unclear sequence generation and unclear achievement of allocation 
concealment and/or blinding. All these limitations and the resulting uncertainties greatly limit the 
conclusions which can be drawn from these studies. None of the studies gave rise to concerns on any 
of the studied non-digestible oligosaccharides with respect to growth and adverse effects. 
On the basis of the data available and in consideration of the modest quality of the available studies, 
the Panel considers that there is insufficient evidence for beneficial effects on infant health of the non-
digestible oligosaccharides that have been tested to date in RCTs when added to IF or FOF. 
5.4.6. Recommendations 
5.4.6.1. Total carbohydrates 
The minimum and maximum content of carbohydrates in IF and FOF can be calculated based on the 
residual energy in formulae that contain the permitted minimum and maximum amounts of protein and 
fat, and converting this energy into grams of carbohydrates (4 kcal/g). The corresponding calculations 
are given in Table 11. 
Table 11:  Calculation of total minimum and maximum carbohydrate content in IF and FOF 
Proposed amounts IF and FOF with 
Milk protein ISP and hydrolysed protein 
Min Max Min Max 
Protein (g/100 kcal) 1.8 2.5 2.25 2.8 
Protein (E %) 7.2 10 9.0 11.2 
Fat (g/100 kcal) 4.4 6.0 4.4 6.0 
Fat (E %) 39.6 54 39.6 54 
Corresponding calculated amounts  Max Min Max Min 
Carbohydrates (E %) 
(a) 
53.2 36 51.4 34.8 
Carbohydrates (g/100 kcal) 13.3 9 12.85 8.7 
(a): Calculated as: 100 – E % protein – E % fat. 
Rounding up, the Panel proposes a minimum carbohydrate content in IF and FOF of 9 g/100 kcal 
(2.2 g/100 kJ) and a maximum content of 14 g/100 kcal (3.3 g/100 kJ) for all types of formulae. 
The Panel considers that only carbohydrates free of gluten should be used in IF and FOF. 
5.4.6.2. Glycaemic carbohydrates 
Lactose 
The Panel considers that lactose should be the preferred carbohydrate in IF and FOF. In line with the 
opinion of the SCF (2003b), the Panel proposes a minimum content of lactose in IF and FOF based on 
milk protein and in IF and FOF containing hydrolysed protein of 4.5 g/100 kcal (1.1 g/100 kJ), unless 
the formulae are intended to be labelled as “lactose free”. In this case, IF and FOF should comply with 
the existing criterion of a “lactose-free” formula and provide at most 0.01 g/100 kcal (0.0024 g/100 kJ) 
lactose. 
The Panel notes that the minimum lactose content has its origin in the traditional practice of diluting 
cow’s milk to make it more suitable for infant feeding with respect to protein. IF and FOF containing 
ISP were traditionally manufactured without lactose, which made such formulae suitable for feeding 
infants who could not metabolise lactose. 
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Sucrose, glucose and fructose 
The Panel considers that sucrose, glucose and fructose, irrespective of their sources, should not be 
added to IF, as sucrose and fructose do not have any advantage over lactose for healthy infants, but 
may pose a risk to infants with fructose intolerance and saccharase deficiency and as the addition of 
glucose may increase the osmolality of the formula. For FOF, the use of sucrose and fructose can be 
tolerated since an infant will receive both from complementary foods. The sum of sucrose, fructose 
and sugars from honey in FOF should not constitute more than 20 % of total carbohydrates. Honey 
should be treated in order to destroy spores of C. botulinum. 
However, for gustatory reasons, sucrose and glucose are currently permitted to be added to IF 
containing protein hydrolysates and glucose is currently permitted to be added to FOF containing 
protein hydrolysates in order to mask the bitter taste of these formulae. The maximum concentrations 
which may currently be added are ≤ 20 % of total carbohydrates for sucrose and ≤ 2 g/100 kcal 
(≤ 0.5 g/100 kJ) for glucose. The Panel proposes to retain these values. 
Maltose and maltodextrins 
In line with the opinion of the SCF (2003b), the Panel does not consider it necessary to propose any 
minimum and maximum amounts for maltose and maltodextrins in IF and FOF, as long as the 
maximum content of carbohydrates in IF and FOF is not exceeded. 
Starches 
Based on the evidence described in section 5.4.5.2.3 and assuming that infants can tolerate starch in 
amounts of around 5.5 g/kg body weight per day and that average body weight at birth is 3.25 kg 
(WHO Multicentre Growth Reference Study Group, 2006), this would translate into a daily starch 
intake of 18 g/day which could theoretically be tolerated by newborns. However, lower tolerances 
have also been reported. Assuming an average formula consumption of 500 kcal/day, a daily starch 
intake of 18 g/day would be equivalent to a starch content in formula of 2.2-2.5 g/100 mL. The Panel 
notes that this calculated theoretical value is not much higher than the maximum content of starch 
which was proposed by the SCF (2003b) (i.e. 2 g/100 mL). The Panel also notes that there are 
considerable uncertainties about the amount of starch which can be tolerated by newborns and that no 
adverse effects from current amounts of starch in IF have been reported. 
Therefore, the Panel proposes, in line with the SCF (2003b), that starches should not be added in 
concentrations higher than 2 g/100 mL (2.9-3.3 g/100 kcal (0.7-0.8 g/100 kJ)) and that they should not 
constitute more than 30 % of total carbohydrates. For FOF, no restrictions need to apply. The Panel 
agrees with the SCF (2003b) that only pre-cooked and gelatinised starches free of gluten are suitable 
for use in IF and FOF. 
5.4.6.3. Non-digestible (non-glycaemic) carbohydrates 
In the absence of convincing evidence of any beneficial effects of non-digestible oligosaccharides on 
infant health, the Panel considers that there is no necessity to add non-digestible oligosaccharides to IF 
or FOF. The Panel considers that there is no evidence to change the previous conclusions of the SCF 
(2001d) that a mixture of 90 % GOS and 10 % of high-molecular-weight FOS is safe under the current 
conditions of use (i.e. ≤ 0.8 g/100 mL) in IF and FOF. The safety of any other non-digestible 
oligosaccharides or any new mixture of non-digestible oligosaccharides in IF and FOF should be 
established by clinical evaluation. 
Table 12 summarises the conclusions of the Panel regarding the composition of IF and FOF with 
respect to glycaemic carbohydrates. 
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Table 12:  Proposed composition of IF and FOF with respect to glycaemic carbohydrates 
g/100 kcal IF with FOF with 
Milk 
protein 
ISP Protein 
hydrolysates 
Milk 
protein 
ISP Protein 
hydrolysates 
Carbohydrates 9-14 
(a)
 9-14
(a)
 
of which   
Lactose ≥ 4.5 (b) (c) NR(d) ≥ 4.5(b) (c) ≥ 4.5 (b) (c) NR (d) ≥ 4.5(b) (c) 
Sucrose Not to be added ≤ 20 % of total 
carbohydrates 
(e) (f) 
Sum of sucrose, fructose, sugar from 
honey ≤ 20 % of total carbohydrates(e) 
Fructose Not to be added 
Glucose Not to be added
 ≤ 2 (e) (d) (g) Not to be added ≤ 2 (e) (f) (g) 
Maltose, 
maltodextrins 
(e) 
Unrestricted within specifications for total 
carbohydrates
 
Unrestricted within specifications for 
total carbohydrates
 
Starches 
(e) ≤ 2 g/100 mL and ≤ 30 % of total 
carbohydrates 
(h) 
Unrestricted within specifications for 
total carbohydrates as long as free of 
gluten 
(a): 2.2-3.3 g/100 kJ. 
(b): Not applicable to formulae declared as “lactose-free”; in such case the lactose content should not exceed 0.01 g/100 kcal 
(0.0024 g/100 kJ). 
(c): 1.1 g/100 kJ. 
(d): Not required (NR) if more than 50 % of the protein content is from ISP. 
(e): Voluntary addition. 
(f): To mask the bitter taste. 
(g): 0.5 g/100 kJ. 
(h): Pre-cooked or gelatinised starch only, free of gluten. 
6. Minimum content of micronutrients in IF and FOF 
From a nutritional point of view, the minimum contents proposed by the Panel cover the nutritional 
needs of virtually all healthy infants born at term and there is no need to exceed these amounts in 
formulae, as nutrients which are not used or stored have to be excreted and this may put a burden on 
the infant’s metabolism and/or other physiological functions. Therefore, the Panel emphasises that the 
proposed minimum contents should be understood as target values for micronutrient contents of IF and 
FOF. 
6.1. Calcium 
6.1.1. Current compositional requirements of IF and FOF 
Based on the opinion of the SCF (2003b), Directive 2006/141/EC provides for minimum and 
maximum calcium contents in IF and FOF of 50 mg/100 kcal and 140 mg/100 kcal, respectively, with 
a calcium-to- available phosphorus ratio of between 1 and 2. 
6.1.2. Calcium content of human milk 
Calcium in breast milk was found to be in the range of 200-300 mg/L (31-46/100 kcal) (Rodriguez 
Rodriguez et al., 2002; Hicks et al., 2012; Olausson et al., 2012). The ratio of calcium to phosphorus 
in human milk is about 2:1 on a weight basis or about 1.6:1 on a molar basis (Specker et al., 1991; 
Steichen and Koo, 1992). 
6.1.3. Calcium requirements of infants 
In the Panel’s previous opinion on nutrient requirements and dietary intakes of infants and young 
children in the European Union (EFSA NDA Panel, 2013a), the Panel concluded that a calcium intake 
of 200 mg/day and 400 mg/day was adequate for the majority of infants in the first half and in the 
second half of the first year of life, respectively. 
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6.1.4. Calcium intakes of infants 
Assuming a human milk intake of 0.8 L/day and a calcium content of 250 mg/L, an exclusively breast-
fed infant would consume 200 mg calcium per day during the first six months of life. Mean/median 
calcium intakes of mostly formula-fed infants below six months of age are reported to be around 
370-560 mg/day (Hilbig, 2005; Noble and Emmett, 2006; Fantino and Gourmet, 2008; Lennox et al., 
2013). Mean/median calcium intakes in infants aged 6 to < 12 months are in the range of 
450-730 mg/day (Noble and Emmett, 2001; Hilbig, 2005; de Boer et al., 2006; DGE, 2008; Fantino 
and Gourmet, 2008; Marriott et al., 2008; Thorsdottir et al., 2008; Lennox et al., 2013). 
6.1.5. Health consequences 
Calcium is an integral component of the skeleton, in which it has a structural role, and is needed for 
bone rigidity, strength and elasticity. Calcium deficiency in children leads to inadequate growth and 
bone deformity. No UL for calcium was set for infants owing to insufficient data. The UL for adults of 
2 500 mg per day is based on the absence of adverse effects in long-term human intervention studies in 
which 2 500 mg calcium per day was administered (EFSA NDA Panel, 2012b). 
The concept of maintaining a certain calcium-to-phosphorus ratio in the diet has little relevance in 
adults but may have some utility under conditions of rapid growth. An absorbed calcium-to-
phosphorus molar ratio of around 1.3:1 is assumed to be sufficient to support the sum of bony and soft 
tissue growth in infants (IoM, 1997). In order to derive an intake ratio, this value has to be corrected 
for the fractional absorption of calcium and phosphorus. Assuming an absorption efficiency of 60 % 
for calcium and of 80 % for phosphorus, the US Institute of Medicine has suggested a calcium-to-
phosphorus molar intake ratio of 2:1 for infants. However, fractional absorption may vary with age 
and type of formula consumed and the ratio by itself is of limited value if the consumption of absolute 
quantities of both nutrients is insufficient to support adequate growth (IoM, 1997). The currently 
permitted lower calcium-to-phosphorus ratio of 1:1 reflects the calcium-to-phosphorus molar ratio of 
cow’s milk, which does not change if cow’s milk is diluted for the manufacturing of formula. There 
are no reports which indicate that the currently permitted calcium-to-phosphorus ratio together with 
the current minimum content of calcium and phosphorus in IF and FOF is insufficient to ensure 
adequate growth of infants. 
6.1.6. Recommendations 
Assuming an average energy intake of an infant below six months of age of 500 kcal/day and taking as 
a basis the intake levels of calcium considered adequate by the Panel for this age group of 200 mg/day 
based on calcium intakes from breast milk, this would convert into a required minimum calcium intake 
of 40 mg/100 kcal. 
The SCF (2003b) considered mean calcium absorption from cow’s milk to be around 20 percentage 
points lower than from human milk and therefore corrected the theoretical minimum level derived 
based on breast milk content by this factor, yielding a minimum calcium content of 50 mg/100 kcal. 
Calcium absorption efficiency was assumed to be about 58 % from human milk and about 38 % from 
milk-based IF during the first four months of life. More recent studies have reported calcium 
absorption efficiencies from IF based on milk protein and IF containing hydrolysed protein of around 
60 % (Abrams, 2010; Hicks et al., 2012; Leite et al., 2013). One of these studies (Hicks et al., 2012) 
also assessed fractional calcium absorption from human milk and reported an absorption efficiency 
from breast milk of 76 %. No information on calcium absorption from formula containing ISP is 
available. However, there is no evidence that current amounts of calcium in formulae containing ISP 
would be insufficient for infants. 
Considering the potential difference in absorption efficiency of calcium between human milk and 
formula, the Panel considers it prudent to maintain the recommendations of the SCF (2003b) with 
respect to the minimum calcium content in IF and FOF of 50 mg/100 kcal. 
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Therefore, the Panel proposes a minimum calcium content in IF and FOF of 50 mg/100 kcal 
(12 mg/100 kJ). 
With respect to the molar ratio of calcium-to-available phosphorus (based on measured bioavailability, 
or calculated as 80 % of total phosphorus in milk protein-based formulae or formulae containing 
protein hydrolysates and as 70 % of total phosphorus in formulae containing ISP), the Panel proposes 
a calcium-to-available phosphorus molar ratio of not less than 1.0 and not greater than 2.0. 
6.2. Phosphorus 
6.2.1. Current compositional requirements of IF and FOF 
Based on the opinion of the SCF (2003b), Directive 2006/141/EC provides for minimum and 
maximum phosphorus contents in IF and FOF based on milk protein and IF and FOF containing 
hydrolysed protein of 25 mg/100 kcal and 90 mg/100 kcal, respectively. For IF and FOF containing 
ISP, the minimum content should be 30 mg/100 kcal and the maximum 100 mg/100 kcal. The 
calcium-to-available phosphorus ratio should be between 1 and 2. 
With respect to the determination of the amount of available phosphorus, the SCF (2003b) concluded 
that the amount of available phosphorus should be either measured or calculated as 80 % of total 
phosphorus for milk protein or as 70 % for ISP and that at least 20 mg/100 kcal and at most 
70 mg/100 kcal of available phosphorus should be contained in the formula. 
6.2.2. Phosphorus content of human milk 
The reported phosphorus content of human milk has been reported to be in the range 107-164 mg/L 
(17-25 mg/100 kcal) (Fomon, 1993), peaking in early lactation and decreasing as lactation progresses 
(Fomon, 1993; Atkinson et al., 1995) with an average concentration of around 120 mg/L 
(19 mg/100 kcal) (Atkinson et al., 1995). Motil et al. (1997) reported average ± SD concentrations 
falling from 184 ± 16 mg/L (28 ± 2.4 mg/100 kcal) at six weeks of lactation to 155 ± 17 mg/L 
(24 ± 2.6 mg/100 kcal) at 24 weeks. 
6.2.3. Phosphorus requirements of infants 
In the Panel’s previous opinion on nutrient requirements and dietary intakes of infants and young 
children in the European Union (EFSA NDA Panel, 2013a), the Panel concluded that a phosphorus 
intake of 100 mg/day and 300 mg/day was adequate for the majority of infants in the first half and in 
the second half of the first year of life, respectively. 
6.2.4. Phosphorus intakes of infants 
Assuming a human milk intake of 0.8 L/day and a phosphorus content of 120 mg/L, an exclusively 
breast-fed infant would consume around 100 mg phosphorus per day during the first six months of 
life. Mean/median phosphorus intakes of mostly formula-fed infants below six months of age are 
reported to be between around 210 mg/day and 330 mg/day (Hilbig, 2005; Fantino and Gourmet, 
2008). Mean/median phosphorus intakes in infants aged 6 to < 12 months are in the range of around 
360-700 mg/day (Hilbig, 2005; de Boer et al., 2006; Fantino and Gourmet, 2008; Thorsdottir et al., 
2008). 
6.2.5. Health consequences 
Although phosphorus in the form of phosphate ions is essential for numerous body functions, its 
metabolism is intricately linked to that of calcium because of the actions of calcium-regulating 
hormones. Adequate phosphorus and calcium intakes are needed not only for skeletal growth and 
maintenance, but also for many cellular roles, such as energy production (i.e. adenosine triphosphate 
(ATP)). Too much phosphorus, in relation to too little dietary calcium, may contribute to bone loss, 
and too little phosphorus along with too little dietary calcium may not adequately maintain bone mass 
(Anderson, 2005). Data were insufficient to establish a UL for phosphorus (EFSA, 2005d). 
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6.2.6. Recommendations 
Assuming an average energy intake of an infant below six months of age of 500 kcal/day and taking as 
a basis the intake levels of phosphorus considered adequate by the Panel for this age group of 
100 mg/day based on phosphorus intakes from breast milk, this converts into a required minimum 
intake of available phosphorus of 20 mg/100 kcal. Assuming that 80 % of total phosphorus from milk 
protein and 70 % from ISP is available, this translates into a minimum phosphorus content in IF and 
FOF based on milk protein of 25 mg/100 kcal and for IF and FOF containing ISP of 28.6 mg/100 kcal 
(rounded up to 30 mg/100 kcal). 
Therefore, the Panel proposes a minimum phosphorus content in IF and FOF based on milk protein 
and IF and FOF containing protein hydrolysates of 25 mg/100 kcal (6.0 mg/100 kJ) and in IF and FOF 
containing ISP of 30 mg/100 kcal (7.2 mg/100 kJ). 
The molar ratio of calcium-to-available phosphorus (based on measured bioavailability, or calculated 
as 80 % of total phosphorus in milk protein-based formulae or formulae containing protein 
hydrolysates and as 70 % of total phosphorus in formulae containing ISP) should be not less than 1.0 
and not greater than 2.0. 
6.3. Magnesium 
6.3.1. Current compositional requirements of IF and FOF 
Based on the opinion of the SCF (2003b), Directive 2006/141/EC provides for minimum and 
maximum magnesium contents in IF and FOF of 5 mg/100 kcal and 15 mg/100 kcal, respectively. 
6.3.2. Magnesium content of human milk 
Reported concentrations of magnesium in breast milk vary over a wide range (15-64 mg/L 
(2.3-9.8 mg/100 kcal)), with a median value of 31 mg/L (4.8 mg/100 kcal) and 75 % of reported mean 
concentrations below 35 mg/L (5.4 mg/100 kcal) (Dorea, 2000). 
6.3.3. Magnesium requirements of infants 
In the Panel’s previous opinion on nutrient requirements and dietary intakes of infants and young 
children in the European Union (EFSA NDA Panel, 2013a), the Panel concluded that a magnesium 
intake of 25 mg/day and 80 mg/day was adequate for the majority of infants in the first half and in the 
second half of the first year of life, respectively. 
6.3.4. Magnesium intakes of infants 
Assuming a human milk intake of 0.8 L/day and a magnesium content of 31 mg/L, an exclusively 
breast-fed infant would consume 25 mg magnesium per day during the first six months of life. 
Mean/median magnesium intakes of mostly formula-fed infants below six months of age are reported 
to be between 43 and 70 mg/day (Hilbig, 2005; Fantino and Gourmet, 2008; Lennox et al., 2013). 
Mean/median magnesium intakes in infants aged 6 to < 12 months are in the range of around 
75-140 mg/day (Hilbig, 2005; de Boer et al., 2006; DGE, 2008; Fantino and Gourmet, 2008; Marriott 
et al., 2008; Lennox et al., 2013). 
6.3.5. Health consequences 
Magnesium is the second most abundant intracellular cation after sodium and is a critical cofactor in 
several enzymatic reactions. Severe magnesium deficiency is rare and causes neuromuscular 
manifestations (Feillet-Coudray and Rayssiguier, 2005). No UL for magnesium normally present in 
foods could be established by the SCF. A UL related to readily dissociable forms of magnesium was 
set at 250 mg/day for children aged from four years upwards and adults (SCF, 2001a). 
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6.3.6. Recommendations 
Assuming an average energy intake of an infant below six months of age of 500 kcal/day and taking as 
a basis the intake levels of magnesium considered adequate by the Panel for this age group of 
25 mg/day based on magnesium intakes from breast milk, this converts into a required minimum 
magnesium content in formula of 5 mg/100 kcal. 
Therefore, the Panel proposes a minimum magnesium content in IF and FOF of 5 mg/100 kcal 
(1.2 mg/100 kJ). 
6.4. Sodium 
6.4.1. Current compositional requirements of IF and FOF 
Based on the opinion of the SCF (2003b), Directive 2006/141/EC provides for minimum and 
maximum sodium contents in IF and FOF of 20 mg/100 kcal and 60 mg/100 kcal, respectively. 
6.4.2. Sodium content of human milk 
The average sodium concentration in human milk has been reported to be in the range of 
140-160 mg/L (22-25 mg/100 kcal) (IoM, 2005b). 
6.4.3. Sodium requirements of infants 
In the Panel’s previous opinion on nutrient requirements and dietary intakes of infants and young 
children in the European Union (EFSA NDA Panel, 2013a), the Panel concluded that a sodium intake 
of 120 mg/day was adequate for the majority of infants in the first half-year of life. The Panel also 
concluded that a sodium intake of 170-370 mg/day was adequate for the majority of infants from 6 to 
< 12 months of age. 
6.4.4. Sodium intakes of infants 
Assuming a human milk intake of 0.8 L/day and a sodium content of 150 mg/L, an exclusively breast-
fed infant would consume 120 mg sodium per day during the first six months of life. Mean/median 
sodium intakes in mostly formula-fed infants from 0 to < 6 months of age have been reported to be in 
the range of around 180-240 mg/day (Fantino and Gourmet, 2008; Lennox et al., 2013) and in the 
second half of the first year of life are in the range 270-730 mg/day (DGE, 2008; Fantino and 
Gourmet, 2008; Marriott et al., 2008; Lennox et al., 2013). 
6.4.5. Health consequences 
Cell membrane potentials in cells throughout the body are controlled by the concentrations of sodium 
and potassium. The concentration gradients of sodium and potassium are tightly regulated as they 
provide the potential for neural transmission, muscle contraction and vascular tone as well as the drive 
for active transport of nutrients (e.g. glucose). Sodium deficiency arising from inadequate dietary 
intakes is unlikely because of the ubiquity of this element (SCF, 1993b). The major adverse effect of 
increased sodium chloride intake is elevated blood pressure. It has also been suggested that taste 
preferences later in life are influenced by salt intakes in early life (Stein et al., 2012). No UL for 
sodium could derived by the Panel owing to insufficient data (EFSA, 2005b). 
6.4.6. Recommendations 
Assuming an average energy intake of an infant below six months of age of 500 kcal/day and taking as 
a basis the intake level of sodium considered adequate by the Panel for this age group of 120 mg/day 
based on sodium intakes from breast milk, this converts into a required minimum sodium content of 
formula of 24 mg/100 kcal (after rounding 25 mg/100 kcal). 
Therefore, the Panel proposes a minimum sodium content in IF and FOF of 25 mg/100 kcal 
(6.0 mg/100 kJ). 
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6.5. Chloride 
6.5.1. Current compositional requirements of IF and FOF 
Based on the opinion of the SCF (2003b), Directive 2006/141/EC provides for minimum and 
maximum chloride contents in IF and FOF of 50 mg/100 kcal and 160 mg/100 kcal, respectively. 
6.5.2. Chloride content of human milk 
The average chloride content in human milk has been reported to be around 400 mg/L (IoM, 2005b). 
6.5.3. Chloride requirements of infants 
In the Panel’s previous opinion on nutrient requirements and dietary intakes of infants and young 
children in the European Union (EFSA NDA Panel, 2013a), the Panel concluded that a chloride intake 
of 300 mg/day was adequate for the majority of infants in the first half-year of life. The Panel also 
concluded that a chloride intake of 270-570 mg/day was adequate for the majority of infants from 6 to 
< 12 months of age. 
6.5.4. Chloride intakes of infants 
Assuming a human milk intake of 0.8 L/day and a chloride content of 400 mg/L, an exclusively 
breast-fed infant would consume 320 mg chloride per day during the first six months of life. No 
information on chloride intakes in infants living in Europe is available. 
6.5.5. Health consequences 
Chloride is the most abundant anion in the extracellular fluid and counterbalances the intracellular 
negative charges provided by proteins. Chloride also plays a major role as a constituent of 
hydrochloric acid excreted in the gastric juice. Chloride deficiency arising from inadequate dietary 
intakes is unlikely because of the ubiquity of this element (SCF, 1993b). The major adverse effect of 
increased intake of chloride, as sodium chloride, is elevated blood pressure. No UL for chloride was 
derived by the Panel owing to insufficient data (EFSA, 2005a). 
6.5.6. Recommendations 
Assuming an average energy intake of an infant below six months of age of 500 kcal/day and taking as 
a basis the intake level of chloride considered adequate by the Panel for this age group of 300 mg/day 
based on chloride intakes from breast milk, this converts into a minimum chloride content of formula 
of 60 mg/100 kcal. 
Therefore, the Panel proposes a minimum chloride content in IF and FOF of 60 mg/100 kcal 
(14.3 mg/100 kJ). 
6.6. Potassium 
6.6.1. Current compositional requirements of IF and FOF 
Based on the opinion of the SCF (2003b), Directive 2006/141/EC provides for minimum and 
maximum potassium contents in IF and FOF of 60 mg/100 kcal and 160 mg/100 kcal, respectively. 
6.6.2. Potassium content of human milk 
The average content of potassium in human milk has been reported to be around 500 mg/L 
(80 mg/100 kcal) (IoM, 2005b). 
6.6.3. Potassium requirements of infants 
In the Panel’s previous opinion on nutrient requirements and dietary intakes of infants and young 
children in the European Union (EFSA NDA Panel, 2013a), the Panel concluded that a potassium 
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intake of 400 mg/day was adequate for the majority of infants in the first half-year of life. The Panel 
also concluded that a potassium intake of 800 mg/day was adequate for the majority of infants from 6 
to < 12 months of age. 
6.6.4. Potassium intakes of infants 
Assuming a human milk intake of 0.8 L/day and a potassium content of 500 mg/L, an exclusively 
breast-fed infant would consume 400 mg potassium per day during the first six months of life. 
Mean/median potassium intakes of mostly formula-fed infants in the first half-year of life ranged from 
around 490 to 900 mg/day (Hilbig, 2005; Noble and Emmett, 2006; Lennox et al., 2013) and in the 
second half-year of life they ranged from around 1 000 to 1 400 mg/day (Noble and Emmett, 2001; 
Hilbig, 2005; DGE, 2008; Marriott et al., 2008; Lennox et al., 2013). 
6.6.5. Health consequences 
Cell membrane potentials in cells throughout the body are controlled by the concentrations of sodium 
and potassium. The concentration gradients of sodium and potassium are tightly regulated as they 
provide the potential for neural transmission, muscle contraction and vascular tone as well as the drive 
for active transport of nutrients (e.g. glucose). Potassium deficiency arising from inadequate dietary 
intakes is unlikely because of the ubiquity of the element (SCF, 1993b). No UL for potassium was 
derived by the Panel owing to insufficient data (EFSA, 2005e). Prolonged high potassium intake can 
lead to high concentrations of blood potassium that may affect cardiac function, especially in infants 
with impaired kidney function. 
6.6.6. Recommendations 
Assuming an average energy intake of an infant below six months of age of 500 kcal/day and taking as 
a basis the intake level of potassium considered adequate by the Panel for this age group of 
400 mg/day, based on potassium intakes from breast milk, this converts into a required minimum 
potassium content in formula of 80 mg/100 kcal. 
Therefore, the Panel proposes a minimum potassium content in IF and FOF of 80 mg/100 kcal 
(19.1 mg/100 kJ). 
6.7. Iron 
6.7.1. Current compositional requirements of IF and FOF 
Currently permitted minimum and maximum content of iron in IF and FOF compared with the 
recommendations by the SCF (2003b) are shown in Table 13. 
Table 13:  Currently permitted minimum and maximum content of iron in IF and FOF as laid down 
in Directive 2006/141/EC in comparison with the recommendations by the SCF (2003b) 
Formula IF FOF 
 Directive 2006/141/EC SCF (2003b) Directive 2006/141/EC SCF (2003b) 
mg per 100 kcal min max min max min max min max 
Cow’s milk 0.30 1.30 0.30 1.30 0.60 2.00 0.60 1.70 
Goat’s milk 0.30 1.30 0.30 1.30 0.60 2.00 0.60 1.70 
Protein hydrolysates 0.30 1.30 0.30 1.30 0.60 2.00 0.60 1.70 
ISP 0.45 2.00 0.45 1.90 0.90 2.50 0.90 2.50 
 
6.7.2. Iron content of human milk 
The iron concentration in human milk is around 0.2-0.4 mg/L (0.03-0.06 mg/100 kcal). The average 
concentration given by the US Institute of Medicine is 0.35 mg/L (0.05 mg/100 kcal) (IoM, 2001). In 
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line with previous published values is a new analysis showing concentrations of iron in breast milk to 
be 0.28 mg/L (0.054 mg/100 kcal) (Concha et al., 2013). The absorption of iron from human milk is 
high. Absorption efficiencies up to 50 % have been reported but have been observed to vary down to 
25 % with infant age and total dietary iron intake (Domellöf et al., 2002; Domellöf, 2007; Quinn, 
2014). 
6.7.3. Iron requirements of infants 
Full-term infants have iron stores sufficient to cover their needs for a couple of months and, when 
exclusively breast fed, most healthy term infants need no extra iron up to six months of age (Domellöf 
et al., 2002; Domellöf, 2007, 2011; Jonsdottir et al., 2012). 
Most of the body iron in healthy, term newborns is in haemoglobin and about one-quarter is in iron 
stores. Haemoglobin falls from an average of 170 g/L to about 120 g/L during the first six weeks of 
life and, as iron from erythrocytes is recycled, the size of the body’s iron stores grows. In the coming 
months iron is moved back from stores to red blood cells (Domellöf, 2007). Together with the intake 
of iron from breast milk or other foods, these iron stores serve as back-up for the growing infant for 
increasing blood volume and for meeting other needs. Exclusive breast-feeding during this period can 
meet the infant’s additional iron requirements despite the low concentration of iron in breast milk as 
iron absorption from breast milk is high, and the newborn’s iron needs are also supported through the 
iron stores at birth and the recycling. 
The Panel considered in its opinion on nutrient requirements and dietary intakes of infants and young 
children in the European Union that observed mean iron intakes from breast milk of 0.3 mg/day are 
generally sufficient to ensure that iron status in the first half-year of life remains within the normal 
range for most healthy term infants in industrialised countries (Jonsdottir et al., 2012; EFSA NDA 
Panel, 2013a). This advice was based on an assumed iron content in breast milk of 0.35 mg/L 
assuming an average consumption of breast milk of 0.8 L/day, equal to around 500 kcal/day, leading 
to iron intakes of 0.28 mg/day (rounded up to 0.3 mg/day). With the absorption efficiency of iron in 
human milk taken as 50 %, around 0.15 mg of iron per day is thus supplied to the body. This value 
would be lower if a lower absorption efficiency and a lower iron content of breast milk is assumed. 
Therefore, the estimate of 0.15 mg/day of absorbed iron could be considered a high estimate. 
When iron is provided through formula, in which it is assumed to be less available than in breast milk, 
a daily iron intake of 0.3 mg can no longer be considered to be adequate for the majority of infants, 
and additional dietary iron needs to be provided in these formulae in order to ensure a sufficient iron 
supply to formula-fed infants. Assuming that, on average, 0.15 mg/day of iron has to be absorbed from 
formula in the first four to six months of life and that under a conservative assumption the absorption 
efficiency is around 10 % (range 7-14 %) (Quinn, 2014), an iron intake from formula of 1.5 mg/day in 
the first four to six months of life would ensure a sufficient iron supply to the infant. 
For the second half-year of life, the Panel considered an iron intake of 8 mg/day adequate for the 
majority of infants (EFSA NDA Panel, 2013a). 
6.7.4. Iron intakes of infants 
Mean/median iron intakes of infants below six months of age are reported to be between 0.3 and 
8 mg/day in mostly formula-fed infants (Hilbig, 2005; Noble and Emmett, 2006; Fantino and 
Gourmet, 2008; Lennox et al., 2013). Mean/median iron intakes in infants aged 6 to < 12 months are 
in the range of around 4-10 mg/day (Noble and Emmett, 2001; Hilbig, 2005; de Boer et al., 2006; 
DGE, 2008; Fantino and Gourmet, 2008; Marriott et al., 2008; Thorsdottir et al., 2008; Lennox et al., 
2013). 
6.7.5. Health consequences 
Iron has the biological ability to donate and accept an electron and change between two oxidation 
states, ferrous (Fe
2+
) and ferric (Fe
3+
) iron. Iron has many functions in the body, such as in the oxygen-
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transporting haemoglobin and myoglobin and in the enzymes of many metabolic pathways in the liver, 
brain and endocrine organs. The growth and development of the central nervous system is rapid during 
early childhood, and iron is critical for this process. Iron deficiency and iron deficiency anaemia can 
have a serious impact on the health and later development of infants and children, i.e. alteration of the 
immune status, adverse effects on morbidity, delayed behavioural and mental development, below 
average school achievements and growth retardation, as well as adverse effects on cognition that may 
or may not be reversible with iron supplementation (Moffatt et al., 1994; Iannotti et al., 2006; 
Hermoso et al., 2011). Even severe iron deficiency anaemia in infancy may pass unnoticed, as 
symptoms such as pallor, fatigue and developmental or behavioural disturbances are quite subtle. 
Active excretion of iron in humans is minimal. An overload of iron in the body is a risk for those with 
hereditary haemochromatosis, a relatively common disorder, especially in Northern Europe, with a 
reported frequency of homozygosity for the C282Y mutation of around 0.7 % (Thorstensen et al., 
2010), but overload may also occur in infants without this hereditary disease. Studies suggest that the 
absorption of iron cannot be down-regulated before the age of nine months (Domellöf and Hernell, 
2002), with a risk of overload in those infants with sufficient iron stores but high iron intakes. Iron-
replete infants might therefore be at risk of negative health consequences if given extra iron. 
The evidence for risk and benefit of iron supplementation in infancy and young childhood in 
developing countries was reviewed by Iannotti et al. (2006). Iron doses were 10-50 mg/day. It was 
reported that 3 out of 10 studies showed a lower weight gain in the iron-fortified groups, and 4 out of 
16 studies showed an increased incidence of infections. The authors concluded that supplementation 
may need to be targeted to iron-deficient children. A study on infants in Sweden and Honduras 
observed negative growth consequences associated with higher iron intakes (supplementation at 
1 mg/kg body weight per day vs. no supplementation), although the effects were small, i.e. 0.2-0.6 cm 
difference in length gain in both Honduras and Sweden between the ages of four and nine months and, 
in Swedish infants, there was a difference in weight gain of 100-200 g and in head circumference of 
0.2-0.3 cm over the five-month period (Dewey et al., 2002). In this study, there was an increased 
likelihood of diarrhoea in a sub-group of infants with adequate iron status. In a follow-up of the study 
by Walter et al. (1998) at 10 years of age (Lozoff et al., 2012), scores on tests for spatial memory and 
visual motor integration, but not on tests for IQ, visual perception, motor coordination and arithmetic 
achievement, were statistically significantly lower in the group who had received high-iron formula 
(1.95 mg/100 kcal). Effects were generally small. Among a sub-group of children with the highest 
haemoglobin concentrations at six months of age, scores on all tests (i.e. IQ, spatial memory, visual 
motor integration, visual perception, motor coordination and arithmetic achievement) were statistically 
significantly lower in the children who had been fed the high-iron formula. The drop-out rate between 
infancy and the age of 10 years was over 40 %. Other studies which investigated FOF with the 
currently permitted maximum concentrations of iron (i.e. 2 mg/100 kcal (12-14 mg/L)) (Fuchs et al., 
1993; Stevens and Nelson, 1995; Daly et al., 1996; Gill et al., 1997; Morley et al., 1999; Williams et 
al., 1999) did not find any adverse effects at the levels of iron intake provided by these formulae. 
The Panel notes that even though some data suggest that iron supplementation in iron-replete infants 
may lead to impaired growth and development and an increased risk of infections, the evidence is 
limited and does not allow conclusions to be drawn for the establishment of maximum iron content in 
IF and FOF. 
In a recent review of the evidence, the ESPGHAN Committee on Nutrition (Domellöf et al., 2014) 
considered that formula-fed infants should receive a formula with a minimum iron content of 4 mg/L 
(around 0.6 mg/100 kcal) based on current fortification practices, but acknowledged that based on 
theoretical considerations a minimum level of iron of 2 mg/L (around 0.3 mg/100 kcal) would be 
sufficient. Some RCTs have investigated the impact of feeding formulae of varying iron 
concentrations to infants before the age of six months. Three trials performed in the United Kingdom, 
Sweden and Canada (Moffatt et al., 1994; Hernell and Lönnerdal, 2002; Tuthill et al., 2002) 
investigated the impact of feeding IF with iron concentrations at or below currently required minimum 
iron concentrations in IF (i.e. 1.8-2.1 mg/L (around 0.3 mg/100 kcal)) on iron status in infants below 
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six months of age. The studies by Tuthill et al. (2002) and by Hernell and Lönnerdal (2002), which 
investigated the effect on iron status of IF with iron concentrations of < 1 vs. 5 mg/L (around < 0.2 vs. 
0.8 mg/100 kcal) (Tuthill et al. (2002) and 2 vs. 4 mg/L (around 0.3 vs. 0.6 mg/100 kcal) (Hernell and 
Lönnerdal, 2002) did not find any differences in iron status at either three and six months of age. 
However, study formulae in the study by Tuthill et al. (2002) were consumed only in the first three 
months of life, which does not allow any conclusions to be drawn with respect to the effect of a 
formula with a similar iron content consumed for the entire period of six months. The study by Moffatt 
et al. (1994), which investigated the impact of a formula with an iron concentration of 1.1 vs. 
12.8 mg/L (around 0.2 vs. 2 mg/100 kcal), found a statistically significant difference in iron status 
between the two formula groups. However, this study was conducted in a poor population with a high 
prevalence of anaemia which could not necessarily be considered representative of the current 
European infant population. 
These data show that an IF providing iron at an amount of 0.3 mg/100 kcal (2 mg/L) is adequate to 
maintain iron status within the normal range within the first six months of life, and this conclusion is 
also supported by the theoretically calculated value of 1.5 mg/day based on iron concentrations in 
breast milk and differences in absorption efficiency. 
One RCT (Walter et al., 1998) investigated the effect on iron status of FOF containing 2.3 mg/L 
(0.35 mg/100 kcal) iron (n = 405) compared with a formula providing 12.7 mg/L (1.95 mg/100 kcal) 
iron (n = 430), which were fed for six months to six-month-old infants who had been partially or 
exclusively breast fed. Iron status was assessed in infants at 12 months, and at 18 months of age in 
those infants who were not classified as anaemic at the 12-months’ follow-up. Iron deficiency was 
defined as two out of three measures of iron status in the abnormal range (serum ferritin < 12 µg/L, 
erythrocyte protoporphyrin > 100 µg/L red blood cells, or mean cell volume < 70 fL). At 12 months of 
age, 39 % of infants were classified as iron deficient in the low-iron formula group, compared with 
20 % in the high-iron formula group (p < 0.001). At 18 months of age, this was 35 % vs. 17 % 
(p < 0.01). There was no significant difference in the prevalence of iron deficiency anaemia between 
groups at either time point. 
The Panel notes that consumption of FOF containing 0.35 mg/100 kcal iron led to a significantly 
lower iron status in infants older than six months of age than formula with higher iron content. 
However, the prevalence of iron deficiency was also high in the group consuming high-iron formula 
and there were no indications of long-term adverse effects on cognitive outcomes of consumption of a 
formula containing 0.35 mg/100 kcal iron during the second half of infancy. The Panel considers that 
in the absence of data investigating the impact of varying concentrations of iron, especially in the 
lower range of iron concentrations in FOF, no conclusions can be drawn from this study with respect 
to the nutritional adequacy of a FOF containing 0.35 mg/100 kcal iron and consumed throughout the 
second half of the first year of life. 
FOF containing the lowest currently permitted concentrations of iron (0.6 mg/100 kcal) would provide 
around 2.3 mg iron per day, if an average formula consumption of 600 mL/day is assumed at this age 
(Fantino and Gourmet, 2008). Such concentrations require that complementary foods provide around 
70 % of the daily iron intake. In the survey by Lennox et al. (2013), conducted in the framework of the 
UK Rolling Programme, complementary foods contributed around 52 % of the total daily iron intakes 
of infants between seven and nine months of age and 58 % at 10-11 months of age, with median total 
iron intakes of 7.4 mg/day and 7.6 mg/day, respectively. In a study in US breast-fed infants, iron 
intakes from complementary foods at seven and nine months were reported to be 1.5 mg/day and 
7.2 mg/day, respectively, in the group consuming meat and 7.2 mg/day and 8.5 mg/day, respectively, 
in the group consuming iron fortified cereal (Krebs et al., 2006). Therefore, the Panel considers that, if 
a FOF with a minimum content of iron of 0.6 mg/100 kcal is consumed, it is reasonable to assume that 
complementary foods could provide the remaining iron, around 5.7 mg per day, necessary to reach 
daily iron intakes of 8 mg/day. 
Essential composition of infant and follow-on formulae  
 
EFSA Journal 2014;12(7):3760 49 
6.7.6. Recommendations 
The physiological changes in iron metabolism during the first year of life are considerable. Until the 
age of six months, most infants need little dietary iron and endogenous iron compensates for low 
intakes. 
Based on clinical data indicating that an IF providing iron at a level of 0.3 mg/100 kcal is adequate to 
maintain iron status within the normal range within the first four to six months of life, the Panel 
proposes a minimum iron content in IF of 0.3 mg/100 kcal (0.07 mg/100 kJ). This is supported by the 
theoretically calculated value based on iron concentrations in breast milk and assumed differences in 
absorption efficiency. 
Based on the consideration that around 70 % of daily iron (equivalent to 5.7 mg iron per day) could be 
supplied by complementary foods, a minimum content of iron in FOF of 0.6 mg/100 kcal is proposed, 
in line with the SCF (2003b). 
There is no new evidence regarding the impact of different iron contents in IF and FOF containing 
ISP. Therefore, the Panel proposes to maintain the recommendations of the SCF (2003b) with respect 
to the minimum iron content in such formulae (i.e. 0.45 mg/100 kcal), taking into account a potentially 
lower absorption efficiency of iron from formulae containing ISP. 
Therefore, the Panel proposes the minimum iron contents in IF and FOF given in Table 14. 
Table 14:  Proposed minimum content of iron in IF and FOF 
 Minimum IF Minimum FOF 
mg/100 kcal mg/100 kJ mg/100 kcal mg/100 kJ 
Cow’s milk 0.30 0.07 0.60 0.14 
Goat’s milk 0.30 0.07 0.60 0.14 
Protein hydrolysates 0.30 0.07 0.60 0.14 
ISP 0.45 0.11 0.90 0.22 
 
If the same formula is to be used from the first months of infancy and be suitable for the whole first 
year of life, the minimum iron content should be 0.6 mg/100 kcal (0.14 mg/100 kJ) for milk-based 
formulae and formulae containing protein hydrolysates and 0.9 mg/100 kcal (0.22 mg/100 kJ) for 
formulae containing ISP. 
6.8. Zinc 
6.8.1. Current compositional requirements of IF and FOF 
Directive 2006/141/EC provides for minimum and maximum zinc contents in IF and FOF, irrespective 
of the protein source, of 0.5 mg/100 kcal and 1.5 mg/100 kcal, respectively. Contrary to the Directive, 
the SCF (2003b) recommended a higher zinc content in IF and FOF containing ISP, namely 
0.75 mg/100 kcal and 2.4 mg/100 kcal for the minimum and maximum content, respectively. 
6.8.2. Zinc content of human milk 
A comprehensive review of breast milk zinc concentrations which covered 63 studies globally, 
including 12 from European countries (Brown KH et al., 2009), reported zinc concentrations 
(mean ± SD) of 4.11 ± 1.50 mg/L below 1 month (n = 74), 1.91 ± 0.53 mg/L at 1-2 months (n = 42), 
0.98 ± 0.35 mg/L at 3-5 months (n = 24) and 0.77 ± 0.22 mg/L at 6–11 months (n = 24) post partum. 
For the first four to six months of life, breast milk provides sufficient zinc for infants (Prasad, 2003). 
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6.8.3. Zinc requirements of infants 
In the Panel’s previous opinion on nutrient requirements and dietary intakes of infants and young 
children in the European Union (EFSA NDA Panel, 2013a), the Panel concluded on levels of zinc 
intakes which can be considered adequate. For the majority of breast-fed infants in the first half-year 
of life, an adequate zinc intake would be 2 mg/day, and for the majority of infants in the second half of 
the first year of life a zinc intake of 4 mg/day is considered adequate. In a more recent draft opinion on 
DRVs for zinc (EFSA NDA Panel, 2014a) released for public consultation, the Panel proposes a PRI 
for infants in the second half of the first year of life of 2.9 mg/day. 
6.8.4. Zinc intakes of infants 
Assuming a human milk intake of 0.8 L/day, with a zinc content of 4 mg/L at two weeks of life and of 
1.5 mg/L at three months of life, an exclusively breast-fed infant would consume 3.2 mg zinc per day 
during the first month of life and 1.2 mg/day at around three months of life. Mean/median zinc intakes 
of mostly formula-fed infants below six months of age are reported to range from 2.1 to 4.7 mg/day 
(Hilbig, 2005; Noble and Emmett, 2006; Fantino and Gourmet, 2008; Lennox et al., 2013), with the 
two studies which investigated zinc intakes from only formula-fed infants reporting intakes of around 
4 mg/day. For infants aged 6 to < 12 months, zinc intakes were observed to be in the range 
3.1-6.7 mg/day (Noble and Emmett, 2001; Hilbig, 2005; de Boer et al., 2006; DGE, 2008; Fantino and 
Gourmet, 2008; Marriott et al., 2008; Thorsdottir et al., 2008; Lennox et al., 2013). 
6.8.5. Health consequences 
Zinc is involved in many aspects of cell metabolism, with several enzymes depending on zinc for 
catalytic activity. It plays a role in immune function, protein synthesis, wound healing, 
deoxyribonucleic acid (DNA) synthesis and cell division. The current understanding of zinc deficiency 
in humans, much of which is marginal zinc deficiency, is based on responses to zinc supplementation. 
Studies have shown that physical growth and cognitive performance improved following zinc 
supplementation in zinc-deficient children (Fischer Walker and Black, 2004). While signs of acute 
zinc intoxication are gastrointestinal disturbances, chronic zinc toxicity is associated with symptoms 
of copper deficiency. A UL for zinc of 7 mg/day for one- to three-year-old children was derived by the 
SCF (2002a). 
6.8.6. Recommendations 
The Panel’s previous opinion (EFSA NDA Panel, 2013a) provided advice only on the levels of zinc 
intake considered adequate for the majority of breast-fed infants (approx. 0.4 mg/100 kcal) but did not 
include formula-fed infants. Therefore, the conclusions on the minimum amount of zinc in IF cannot 
be based on the Panel’s previous considerations. Evidence supports the concept that zinc in formula 
can be less available than from human milk, which needs to be considered in the establishment of the 
minimum content of zinc in IF and FOF. 
As there are no reports that zinc deficiency occurs in formula-fed infants at current levels of zinc 
intakes from formulae, the Panel proposes to maintain the minimum content of zinc in IF and FOF 
based on milk protein or IF and FOF containing protein hydrolysates proposed by the SCF (2003b). 
As phytic acid has been shown to reduce zinc absorption efficiency (Lönnerdal et al., 1984; Davidsson 
et al., 1994; Davidsson et al., 2004), the Panel proposes to also retain the minimum content of zinc in 
IF and FOF containing ISP established by the SCF (2003b). 
Therefore, the Panel proposes a minimum zinc content in IF and FOF based on milk protein or IF and 
FOF containing protein hydrolysates of 0.5 mg/100 kcal (0.12 mg/100 kJ). For IF and FOF containing 
ISP a minimum content of 0.75 mg/100 kcal (0.18 mg/100 kJ) is proposed. 
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6.9. Copper 
6.9.1. Current compositional requirements of IF and FOF 
Based on the opinion of SCF (2003b), Directive 2006/141/EC lays down a minimum content of copper 
in IF and FOF of 35 μg/100 kcal and maximum content of 100 μg/100 kcal. 
6.9.2. Copper in human milk 
Mean concentrations of copper in breast milk observed in Europe range from 329 to 390 µg/L 
(51-60 µg/100 kcal), with medians between 368 and 400 µg/L (57-62 µg/100 kcal) (Krachler et al., 
1998; Rodriguez Rodriguez et al., 2002; Leotsinidis et al., 2005). 
6.9.3. Copper requirements of infants 
In the Panel’s previous opinion on nutrient requirements and dietary intakes of infants and young 
children in the European Union (EFSA NDA Panel, 2013a), the Panel concluded on levels of copper 
intakes which were considered adequate for the majority of infants of 300 µg/day. 
6.9.4. Copper intakes of infants 
Assuming a human milk intake of 0.8 L/day and a copper content of 350 µg/L, an exclusively breast-
fed infant would consume 280 µg copper per day during the first six months of life. Mean/median 
copper intakes of breast-fed and formula-fed infants below six months of age are 200-400 µg/day 
(Hilbig, 2005; Lennox et al., 2013). Median copper intakes of infants from 6 to < 12 months are 
400-900 µg/day (Hilbig, 2005; Marriott et al., 2008; Lennox et al., 2013). 
6.9.5. Health consequences 
Copper is an essential nutrient and an indispensable cofactor of many proteins including enzymes 
involved in oxidative reactions, in the production of collagen and of pigment, in iron metabolism and 
in the function of the heart, brain and the immune system. Copper deficiency is rare in humans and 
occurs predominantly in premature and small-for-gestational-age infants fed cow’s milk formulae, 
patients with malnutrition and patients receiving total parenteral nutrition (TPN) devoid of copper or 
subjects consuming high-dose zinc supplements. Signs of severe copper deficiency include anaemia, 
leucopenia and neutropenia. Osteoporosis has also been observed (Turnlund, 2006). Copper excess is 
rare and results acutely in gastrointestinal symptoms and chronically in liver and kidney dysfunction. 
A UL for copper of 1 000 µg/day was derived by the SCF (2003a) for children aged one to three years. 
6.9.6. Recommendations 
Assuming an average energy intake of an infant below six months of age of 500 kcal/day and taking as 
a basis the intake levels of copper considered adequate by the Panel for this age group of 300 µg/day 
based on copper intakes from breast milk, this converts into a required minimum copper content of 
formulae of 60 µg/100 kcal. 
Therefore, the Panel proposes a minimum copper content in IF and FOF of 60 µg/100 kcal 
(14.3 µg/100 kJ). 
6.10. Selenium 
6.10.1. Current compositional requirements of IF and FOF 
Directive 2006/141/EC provides for minimum and maximum selenium contents in IF and FOF of 
1 µg/100 kcal and 9 µg/100 kcal, respectively, while the SCF (2003b) had recommended minimum 
and maximum contents of 3 µg/100 kcal and 9 µg/100 kcal, respectively. 
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6.10.2. Selenium content of human milk 
A wide range of selenium concentrations in human milk have been observed, depending on the 
amount of selenium consumed by the mother from natural foods. Breast milk concentrations of 
selenium in Europe range from 3 to 84 µg/L (0.46-12.9 µg/100 kcal), with a mean (SD) value of 
16.3 ± 4.7 µg/L (2.51 ± 0.72 µg/100 kcal) (Krachler et al., 1998; Zachara and Pilecki, 2000; Navarro-
Blasco and Alvarez-Galindo, 2003; Özdemir et al., 2008). 
6.10.3. Selenium requirements of infants 
In the Panel’s previous opinion on nutrient requirements and dietary intakes of infants and young 
children in the European Union (EFSA NDA Panel, 2013a), the Panel concluded that a selenium 
intake of 12.5 µg/day and 15 µg/day is adequate for the majority of infants in the first half and in the 
second half of the first year of life, respectively. This is in line with a more recent draft opinion of the 
Panel on DRVs for selenium (EFSA NDA Panel, 2014g) released for public consultation. 
6.10.4. Selenium intakes of infants 
Assuming a human milk intake of 0.8 L/day and a selenium content of 16 µg/L, an exclusively breast-
fed infant would consume 12.8 µg selenium per day during the first six months of life. Mean selenium 
intakes in breast-fed and formula-fed infants in the first half-year of life were reported to be 15 µg/day 
in one study in the United Kingdom (Lennox et al., 2013). For infants in the second half-year of the 
first year of life, selenium intakes in the range 18-22 µg/day were reported in the Netherlands and the 
United Kingdom (de Boer et al., 2006; Lennox et al., 2013). 
6.10.5. Health consequences 
Selenocysteine is an indispensable constituent of 25 different selenoproteins. Most selenoproteins are 
involved in redox reactions, and three deiodinases convert thyroxine to triiodothyronine. Selenium 
deficiency, for example following long-term TPN, malabsorption syndromes or use of special diets 
containing insufficient selenium, leads to impaired muscle function and loss of pigment in hair and 
skin. Chronic selenium excess is characterised by hair loss and nail dystrophy, breath smelling of 
garlic, dermatitis and neurological and endocrinological symptoms (selenosis). The SCF (2000b) has 
set a UL for selenium of 60 µg per day for children aged one to three years. 
6.10.6. Recommendations 
Assuming an average energy intake of an infant below six months of age of 500 kcal/day and taking as 
a basis the intake levels of selenium considered adequate by the Panel for this age group of 
12.5 µg/day based on selenium intakes from breast milk, this converts into a required minimum 
selenium content in formula of 2.5 µg/100 kcal (rounding up to 3 µg/100 kcal) 
Therefore, the Panel proposes a minimum selenium content in IF and FOF of 3 µg/100 kcal 
(0.72 µg/100 kcal). 
6.11. Iodine 
6.11.1. Current compositional requirements of IF and FOF 
Based on the opinion of the SCF (2003b), Directive 2006/141/EC provides for minimum and 
maximum iodine contents in IF and FOF of 10 µg/100 kcal and 50 µg/100 kcal, respectively. 
6.11.2. Iodine content of human milk 
Average iodine concentrations of breast milk in Europe have been observed to be around 50-100 µg/L 
(8-15 µg/100 kcal) (Costeira et al., 2009; EFSA NDA Panel, 2014e). 
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6.11.3. Iodine requirements of infants 
In its scientific opinion on the DRVs for iodine (EFSA NDA Panel, 2014e), the Panel proposed an AI 
of iodine of 70 µg/day for infants from 7-11 months of age. No AI was set for infants from birth to six 
months of age, during which period exclusive breast-feeding is assumed to provide an adequate iodine 
supply. In the Panel’s previous opinion on nutrient requirements and dietary intakes of infants and 
young children in the European Union (EFSA NDA Panel, 2013a), the Panel concluded that an iodine 
intake of 90 µg/day is adequate for the majority of infants. Since there is no reason to assume that 
infants from birth to six months of age need more iodine than infants in the second half of the first 
year of life, the Panel considers, in line with its most recent evaluation (EFSA NDA Panel, 2014e), 
that an intake of iodine of 70 µg/day is adequate for the majority of infants from birth to 12 months of 
age. 
6.11.4. Iodine intakes of infants 
Assuming a human milk intake of 0.8 L/day and an iodine content of 50-100 µg/L, an exclusively 
breast-fed infant would consume 40-80 µg iodine per day during the first six months of life. 
Mean/median iodine intakes in breast-fed and formula-fed infants below six months of age were 
reported to range from around 35 to 94 µg/day in Germany and the United Kingdom (Hilbig, 2005; 
Noble and Emmett, 2006; Lennox et al., 2013). In infants from 6 to < 12 months, mean/median iodine 
intakes were between 42 and 118 µg/day in Germany and the UK (Noble and Emmett, 2001; Hilbig, 
2005; DGE, 2008; Lennox et al., 2013). 
6.11.5. Health consequences 
The most critical physiological role for iodine is the normal functioning of the thyroid gland. Iodine 
deficiency disorders (IDDs) are caused by insufficient iodine intake leading to hypothyroidism. IDDs 
are particularly of concern in pregnancy and infancy because of the risk of developmental brain 
damage. Chronic iodine deficiency may also lead to compensatory thyroid hyperplasia with goitre. 
Chronic excessive iodine intake can also lead to goitre. A UL for iodine was set at 200 µg/day for 
children aged one to three years based on biochemical changes in thyroid-stimulating hormone levels 
(SCF, 2002d). 
6.11.6. Recommendations 
Assuming an average energy intake of an infant below six months of age of 500 kcal/day and taking as 
the basis the intake levels of iodine considered adequate by the Panel for this age group of 70 µg/day 
based on iodine intakes from breast milk, this converts into a required minimum iodine content of 
formula of 14 µg/100 kcal (rounded up to 15 µg/100 kcal). 
Therefore, the Panel proposes a minimum iodine content in IF and FOF of 15 µg/100 kcal 
(3.6 µg/100 kJ). 
6.12. Chromium 
6.12.1. Current compositional requirement of IF and FOF 
The SCF (2003b) concluded that there were no biological or nutritional data to use to define minimum 
and maximum contents of chromium in IF and FOF. No minimum and maximum chromium contents 
in IF and FOF are specified by Directive 2006/141/EC. 
6.12.2. Chromium content of human milk 
In Europe, mean concentrations of chromium in mature breast milk are highly variable, ranging from 
0.19 to 10.8 µg/L (0.03-1.7 µg/100 kcal) (Kumpulainen and Vuori, 1980; Kumpulainen et al., 1980; 
Clemente et al., 1982; Deelstra et al., 1988; Bougle et al., 1992; Cocho et al., 1992; Aquilio et al., 
1996; Wappelhorst et al., 2002). 
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6.12.3. Chromium requirements of infants 
No AR and no PRI for chromium for the performance of physiological functions can be defined. 
6.12.4. Health consequences 
The case for the essentiality of dietary Cr
3+
 for humans was uncertain when the SCF considered the 
element 20 years ago (SCF, 1993b); then, as now, the postulation of its essentiality was almost entirely 
based on case reports of patients on long-term TPN who developed metabolic and neurological defects 
which responded to Cr
3+
. The Panel considers that there is as yet no convincing evidence that 
chromium is an essential nutrient, because no specific physiological changes due to experimental 
chromium deficiency have been identified. No AR for the performance of essential physiological 
functions can be defined. Owing to limited data, the SCF (2003d) was unable to set a UL. It was stated 
that in a number of limited studies there was no evidence of adverse effects in adults associated with 
supplementary intake of chromium up to a dose of 1 mg/day. A Tolerable Daily Intake (TDI) for Cr
3+
 
of 0.3 mg/kg body weight per day was derived by the EFSA CONTAM Panel (2014). 
6.12.5. Recommendations 
Because of the unproven essentiality of chromium together with the fact that no specific physiological 
function can be ascribed to chromium, the Panel considers that there is no necessity to add chromium 
to IF and FOF. 
6.13. Molybdenum 
6.13.1. Current compositional requirements of IF and FOF 
The SCF (2003b) concluded that there were no biological or nutritional data to use to define  
minimum and maximum contents of molybdenum in IF and FOF. No minimum and maximum 
molybdenum contents in IF and FOF are specified by Directive 2006/141/EC. 
6.13.2. Molybdenum content of human milk 
Mean molybdenum concentrations in human milk were reported to range between 0.72 µg/L and 
4 µg/L (0.11-0.62 µg/100 kcal), with a mean of around 2.5 µg/L (0.38 µg/100 kcal) (EFSA NDA 
Panel, 2013c). 
6.13.3. Molybdenum requirements of infants 
In the Panel’s previous opinion on nutrient requirements and dietary intakes of infants and young 
children in the European Union (EFSA NDA Panel, 2013a), the Panel concluded that a molybdenum 
intake of 2 µg/day and 10 µg/day was adequate for the majority of infants in the first half and in the 
second half of the first year of life, respectively. 
6.13.4. Molybdenum intakes of infants 
Assuming a human milk intake of 0.8 L/day and a molybdenum content of 2.5 µg/L, an exclusively 
breast-fed infant would consume 2 µg molybdenum per day during the first six months of life. No data 
on molybdenum intakes in infants in the first year of life living in Europe are available. 
6.13.5. Health consequences 
In humans, sulphite oxidase, xanthine oxidoreductase, aldehyde oxidase and mitochondrial amidoxime 
reducing component require molybdenum linked with a pterin (molybdopterin) as cofactor. Only one 
human case of likely dietary molybdenum deficiency has been reported in an adult patient on TPN 
because of short-bowel syndrome (Abumrad et al., 1981). A UL for molybdenum for children one to 
three years old was set at 100 µg/day (SCF, 2000c). This UL was extrapolated from the UL for adults 
(600 µg/day), which was based on reproductive toxicity and adverse effects on growth in rats. 
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6.13.6. Recommendations 
Assuming an average energy intake of an infant below six months of age of 500 kcal/day and taking as 
the basis the intake levels of molybdenum considered adequate by the Panel for this age group of 
2 µg/day based on molybdenum intakes from breast milk, this converts into a required minimum 
molybdenum content of formulae of 0.4 µg/100 kcal. 
Therefore, the Panel proposes a minimum molybdenum content in IF and FOF of 0.4 µg/100 kcal 
(0.1 µg/100 kJ). 
6.14. Manganese 
6.14.1. Current compositional requirements of IF and FOF 
Based on the opinion of the SCF (2003b), Directive 2006/141/EC provides for minimum and 
maximum manganese contents of 1 µg/100 kcal and 100 µg/100 kcal, respectively, in IF and FOF. 
6.14.2. Manganese content of human milk 
The mean manganese concentrations of human milk of European mothers vary from 3 to 30 µg/L 
(0.46-4.6 µg/100 kcal), but most values are around 4 µg/L (0.62 µg/100 kcal) (Mullee et al., 2012). 
6.14.3. Manganese requirements of infants 
In the Panel’s previous opinion on nutrient requirements and dietary intakes of infants and young 
children in the European Union (EFSA NDA Panel, 2013a), the Panel concluded that a manganese 
intake of 3 µg/day and 20-500 µg/day was adequate for the majority of infants in the first half and in 
the second half of the first year of life, respectively. 
6.14.4. Manganese intakes of infants 
Assuming an average milk intake of 0.8 L/day and a manganese content of 3-30 µg/L, an exclusively 
breast-fed infant would consume 2.4-24 μg manganese per day in the first six months of life. Median 
manganese intakes of infants have been reported only for German infants (Hilbig, 2005) and were 
30 µg/day for breast-fed and formula-fed infants between birth and six months of age and 500 µg/day 
for infants from 6 to < 12 months of age. 
6.14.5. Health consequences 
Manganese is an essential dietary mineral for mammals; it is a component of metalloenzymes such as 
superoxide dismutase, arginase and pyruvate carboxylase, and is involved in amino acid, lipid and 
carbohydrate metabolism. In animals, glycosyltransferases and xylosyltransferases, which are involved 
in proteoglycan synthesis (e.g. for bone formation), are sensitive to manganese status (Nielsen, 1999). 
No specific manganese deficiency syndrome has been described in humans. The symptoms of 
manganese toxicity can result in a permanent neurological disorder known as manganism (ATSDR, 
2012). Professional exposure by inhalation is the main cause of manganism but oral exposure to 
manganese, especially from contaminated water sources, can also cause adverse health effects, which 
are similar to those observed from inhalation exposure. No UL for manganese has been set (SCF, 
2000a). 
6.14.6. Recommendations 
Assuming an average energy intake of an infant below six months of age of 500 kcal/day and taking as 
the basis the intake levels of manganese considered adequate by the Panel for this age group of 
3 µg/day based on manganese intakes from breast milk, this would convert into a required minimum 
manganese content in IF and FOF of 0.6 µg/day. Taking into account that manganese from formula 
may be absorbed less than manganese from human milk, the Panel proposes to retain the minimum 
manganese content in IF and FOF of 1 µg/100 kcal as proposed by the SCF (2003b). 
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Therefore, the Panel proposes a minimum manganese content in IF and FOF of 1 µg/100 kcal 
(0.24 µg/100 kJ). 
6.15. Fluoride 
6.15.1. Current compositional requirements of IF and FOF 
Based on the opinion of the SCF (2003b), Directive 2006/141/EC provides for a maximum fluoride 
content in IF and FOF of 100 µg/100 kcal. 
6.15.2. Fluoride content of human milk 
Fluoride concentrations in human milk vary from non-detectable to 100 µg/L (15.4 µg/100 kcal), with 
a trend for lower concentrations in regions with low fluoride concentrations in drinking water 
(≤ 0.3 mg/L) (EFSA NDA Panel, 2013b). 
6.15.3. AI of fluoride in infants 
Fluoride is not an essential nutrient. Nevertheless, the Panel considered in its opinion on DRVs for 
fluoride (EFSA NDA Panel, 2013b) that the setting of an AI was appropriate because of the beneficial 
effects of dietary fluoride on prevention of dental caries. For infants below six months of age, the 
Panel concluded in its previous opinion on nutrient requirements and dietary intakes of infants and 
young children in the European Union (EFSA NDA Panel, 2013a) that a fluoride intake of 
0.08 mg/day is adequate for the majority of infants below six months of age. For infants between 6 and 
< 12 months, this AI was set at 0.4 mg/day (0.05 mg/kg body weight per day). The AI covers fluoride 
intake from all sources, including non-dietary sources. 
6.15.4. Fluoride intakes of infants 
Major fluoride food sources are water and water-based beverages or foods reconstituted with water, 
for example IF. The fluoride content of food is generally low. Breast-fed infants have a low fluoride 
intake. An intake of 0.8 L of human milk by an infant corresponds to a fluoride intake of 1.6-8 μg/day. 
No data on fluoride intakes in infants living in Europe are available. 
6.15.5. Health consequences 
Fluoride has a beneficial effect on tooth health by decreasing the risk of caries development. Dental 
fluorosis is an undesirable side-effect of excessive fluoride intake during critical periods of 
amelogenesis of both primary and secondary teeth. Chronic high intake of fluoride increases the risk 
of bone fractures and of the development of skeletal fluorosis in adults. Based on its effects on dental 
fluorosis, the UL for fluoride for children up to the age of eight years was set by the Panel (EFSA, 
2005c) at 100 µg/kg body weight per day or at 1.5 mg/day for children aged one to three years. 
6.15.6. Recommendations 
Taking into account that fluoride is not an essential nutrient, the Panel considers that there is no 
necessity to add fluoride to IF and FOF. The fluoride content of ready-to-feed formulae will depend on 
the fluoride content of the water used for preparation. In this context, the Panel notes the importance 
of the quality of water, in relation to its fluoride content, used to reconstitute powdered formulae. 
6.16. Vitamin A 
6.16.1. Current compositional requirements of IF and FOF 
Based on the opinion of the SCF (2003b), Directive 2006/141/EC provides for minimum and 
maximum vitamin A contents in IF and FOF of 60 µg retinol equivalents (RE)/100 kcal and 180 µg 
RE/100 kcal, respectively. Retinol sources authorised for use in IF and FOF are retinol and two forms 
of retinyl esters, i.e. retinyl palmitate and retinyl acetate. Carotenoids are not considered as a source of 
vitamin A in infants owing to a lack of knowledge on the bioconversion of carotenoids in infants. 
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6.16.2. Vitamin A content of human milk 
Pre-formed vitamin A concentrations in human milk in Western countries were traditionally 
considered to be between 450 and 600 µg RE/L (69-92 µg RE/100 kcal), whereas considerably lower 
values were reported in two recent studies in Europe: 80 µg RE/L (12 µg RE/100 kcal) (Tijerina-Saenz 
et al., 2009) and 85 µg RE/L (13 µg RE/100 kcal) (Szlagatys-Sidorkiewicz et al., 2012). 
6.16.3. Vitamin A requirements of infants 
In the Panel’s previous opinion on nutrient requirements and dietary intakes of infants and young 
children in the European Union (EFSA NDA Panel, 2013a), the Panel concluded that a vitamin A 
intake of 350 µg RE/day is adequate for the majority of infants. This was based on an assumed mean 
vitamin A content in breast milk of 450 µg/L and a daily intake of 0.8 L and rounding down. 
6.16.4. Vitamin A intakes of infants 
Assuming a human milk intake of 0.8 L/day and a pre-formed vitamin A content of 450 µg/L, an 
exclusively breast-fed infant would consume 360 µg of pre-formed vitamin A per day during the first 
six months of life. Mean/median vitamin A intakes of mostly formula-fed infants below six months of 
age are reported to range from around 510 to 980 µg RE/day (Hilbig, 2005; Noble and Emmett, 2006; 
Fantino and Gourmet, 2008; Lennox et al., 2013). For infants aged 6 to < 12 months, mean/median 
total vitamin A intakes were observed to be in the range 530-1 090 µg RE/day (Noble and Emmett, 
2001; Hilbig, 2005; de Boer et al., 2006; DGE, 2008; Fantino and Gourmet, 2008; Marriott et al., 
2008; Thorsdottir et al., 2008; Lennox et al., 2013). 
6.16.5. Health consequences 
Vitamin A has several important functions, including a role in vision, maintenance of epithelial 
surfaces, immune competence, growth, development and reproduction (Nordic Council of Ministers, 
2014). Deficiency of vitamin A leads to neonatal growth retardation and affects several functions such 
as vision, immunity and reproduction. The most specific clinical consequence of severe vitamin A 
deficiency is xerophthalmia and deficient dark adaptation (night blindness). The deficient dark 
adaptation due to inadequate vitamin A intake disappears after retinol or β-carotene supplementation 
(Chase et al., 1971; Sauberlich et al., 1974). In a systematic review and meta-analysis of studies on 
children living in Asia, Africa and Latin America aged six months to five years, vitamin A 
supplementation was associated with reductions in mortality, morbidity and vision problems (Mayo-
Wilson et al., 2011). Vitamin A deficiency in healthy, exclusively breast-fed and formula-fed infants 
has not been observed in Europe. Children are particularly sensitive to vitamin A, with daily intakes of 
about 450 µg RE/kg body weight per day leading to toxicity (Bendich and Langseth, 1989; Hathcock 
et al., 1990; Coghlan and Cranswick, 2001; Allen and Haskell, 2002). Signs of chronic 
hypervitaminosis A in infants are reported as loss of appetite, dermal dryness, loss of hair, fissuring of 
the corners of the mouth, bone pain, hepatomegaly, increased intracranial pressure and failure to thrive 
(Fomon, 1993). A UL for pre-formed vitamin A (retinol and retinyl esters) for children one to three 
years of age of 800 μg RE/day has been set based on the risk of hepatotoxicity and teratogenicity and 
subsequent extrapolation to children (SCF, 2002b). 
There is an interaction between iron and vitamin A. Vitamin A deficiency impairs iron mobilisation 
and vitamin A supplementation improves haemoglobin concentrations. Iron supplementation 
combined with vitamin A seems to be more effective than iron alone in increasing haemoglobin 
concentrations (Michelazzo et al., 2013). No consistent relationship between zinc and vitamin A status 
has been established in humans (Christian and West, 1998), although zinc supplementation improves 
dark adaptation in zinc-deficient patients (Morrison et al., 1978). 
6.16.6. Recommendations 
Assuming an average energy intake of an infant below six months of age of 500 kcal/day and taking as 
a basis the intake levels of vitamin A considered adequate by the Panel for this age group of 350 µg 
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RE/day based on pre-formed vitamin A intakes from breast milk, this converts into a required 
minimum vitamin A content of formula of 70 µg RE/100 kcal. 
Therefore, the Panel proposes a minimum vitamin A content in IF and FOF of 70 µg RE/100 kcal 
(16.7 µg RE/100 kJ). 
The vitamin A activity in IF and FOF should be provided by retinol or retinyl esters. In view of the 
existing uncertainties as to the relative equivalence of β-carotene and retinol in infants, any content of 
carotenes should not be included in the calculation and declaration of vitamin A activity. 
6.17. Vitamin D 
6.17.1. Current compositional requirements of IF and FOF 
Based on the opinion of the SCF (2003b), Directive 2006/141/EC lays down 1 μg/100 kcal as the 
minimum and 2.5 μg/100 kcal as the maximum vitamin D content in IF and 1 μg/100 kcal as the 
minimum and 3 μg/100 kcal as the maximum vitamin D content in FOF. 
6.17.2. Vitamin D content of human milk 
The mean vitamin D content of breast milk in healthy women has been reported to be in the range 
0.25-2.0 µg/L (0.04-0.31 µg/100 kcal) (Dawodu and Tsang, 2012). There is general agreement that 
human milk does not contain sufficient vitamin D to prevent rickets (Olafsdottir et al., 2001). 
6.17.3. Vitamin D requirements of infants 
In the Panel’s previous opinion on nutrient requirements and dietary intakes of infants and young 
children in the European Union (EFSA NDA Panel, 2013a), the Panel concluded that a vitamin D 
intake of 10 μg/day is adequate for the majority of infants having minimal sun exposure. Vitamin D 
can also be synthesised in the skin under the influence of ultraviolet B light. Consequently, 
requirements of dietary vitamin D depend also on geographical area and lifestyle factors determining 
the exposure of skin to sunlight. 
6.17.4. Vitamin D intakes of infants 
Mean/median vitamin D intakes of formula-fed infants below six months of age are reported to be 
around 9-10 µg/day in formula-fed infants (Noble and Emmett, 2006; Fantino and Gourmet, 2008; 
Lennox et al., 2013) and 3.5 µg/day in breast-fed infants (Lennox et al., 2013). For infants aged 6 to 
< 12 months, mean/median vitamin D intakes were observed to be in the range 3.6-10.4 µg/day (Noble 
and Emmett, 2001; de Boer et al., 2006; DGE, 2008; Fantino and Gourmet, 2008; Marriott et al., 2008; 
Thorsdottir et al., 2008; Lennox et al., 2013). The Panel notes that, given that vitamin D can be 
synthesised endogenously, low vitamin D intakes do not necessarily lead to an inadequate vitamin D 
status. 
6.17.5. Health consequences 
Vitamin D plays a key role in calcium and phosphate metabolism and is essential for bone health. 
There is no evidence from interventional studies to support vitamin D supplementation for other health 
benefits (muscle strength, prevention of infectious or allergic diseases or T1DM) in infants and young 
children (Braegger et al., 2013). Early signs of vitamin D deficiency are subclinical and include 
decreased serum concentrations of calcium and phosphorus, while later signs comprise inadequate 
skeletal mineralisation (rickets and osteomalacia), bone deformities, bone pain, and alterations in 
muscle metabolism and respiratory function (SCF, 1993b). Reports of clinical manifestations of 
rickets in healthy infants have become few in Europe. In its recent consensus statement, the 
ESPGHAN Committee on Nutrition noted that reports on vitamin D intoxication are scarce and that 
there is no agreement on a vitamin D toxicity threshold (Braegger et al., 2013). However, a UL might 
be defined despite the lack of toxicity threshold data. Recent intervention studies using doses up to 
25 µg vitamin D per day (plus the amount ingested via fortified IF) for up to five months after birth 
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did not indicate that these intakes were associated with hypercalcaemia in infants and a UL of 25 µg 
vitamin D per day has been established by the Panel (EFSA NDA Panel, 2012d). 
6.17.6. Recommendations 
Assuming an average energy intake of an infant below six months of age of 500 kcal/day and taking as 
a basis the intake levels of vitamin D considered adequate by the Panel for this age group of 10 µg/day 
based on 25(OH)D vitamin serum concentrations, this converts into a minimum vitamin D content in 
formulae of 2 µg/100 kcal. 
Therefore, the Panel proposes a minimum vitamin D content in IF and FOF of 2 µg/100 kcal 
(0.48 µg/100 kJ). 
6.18. Vitamin E 
6.18.1. Current compositional requirements of IF and FOF 
Based on the opinion of the SCF (2003b), Directive 2006/141/EC lays down 0.5 mg α-tocopherol 
equivalents (TE)/g PUFA but not less than 0.5 mg TE/100 kcal as the minimum and 5 mg 
α-TE/100 kcal as the maximum vitamin E concentration in IF and FOF. 
6.18.2. Vitamin E content of human milk 
The α-tocopherol content in mature human milk has traditionally been taken as 3.5 mg α-tocopherol 
per litre (0.54 mg/100 kcal) (e.g. Jansson et al., 1981). A very similar value in three-month-old infants 
was reported in one recent study (3.5 mg α-tocopherol per litre (0.54 mg/100 kcal) (Antonakou et al., 
2011), whereas different values have been reported in other studies, .e.g. 2.3 mg α-tocopherol per litre 
(0.36 mg/100 kcal) (Tijerina-Saenz et al., 2009). 
6.18.3. Vitamin E requirements of infants 
In the Panel’s previous opinion on nutrient requirements and dietary intakes of infants and young 
children in the European Union (EFSA NDA Panel, 2013a), the Panel concluded that a vitamin E 
intake of 3 mg α-tocopherol per day and 5 mg α-tocopherol per day was adequate for the majority of 
infants in the first and second half-year of life, respectively. 
6.18.4. Vitamin E intakes of infants 
Assuming a human milk intake of 0.8 L/day and a vitamin E content of 3.5 mg α-tocopherol/L, an 
exclusively breast-fed infant would consume 2.8 mg vitamin E per day during the first six months of 
life. Studies which have assessed nutrient intakes in infants have reported vitamin E intakes as TE 
only (including also tocopherols other than α-tocopherol as well as tocotrienols) and no information is 
available on intakes of α-tocopherol as such in this population group. 
6.18.5. Health consequences 
The major biological role of α-tocopherol is its antioxidant activity, contributing to the prevention of 
propagation of free radicals in various lipid structures within the organism. RRR-α-tocopherol is the 
principal isomer in animal tissues and, as this form is relatively unstable, more stable tocopherol esters 
are commonly used in the production of IF and FOF. These forms have a biological activity lower than 
that of RRR-α-tocopherol. Muscle and neurological problems can be a direct consequence of human 
vitamin E deficiency; however, they usually develop only in sick infants and young children (e.g. in 
those with fat malabsorption). Vitamin E appears to have very low toxicity, and amounts of 
100-200 mg/day of synthetic α-tocopherols are consumed widely as supplements in adults without 
reported untoward effects. No adverse effects have been described from intakes provided by food 
sources (Nordic Council of Ministers, 2014). The SCF (2003c) did not set a UL for infants and 
children. For adults, a UL of 300 mg/day was derived. 
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6.18.6. Recommendations 
Assuming an average energy intake of an infant below six months of age of 500 kcal/day and taking as 
a basis the intake levels of vitamin E considered adequate by the Panel for this age group of 3 mg α-
tocopherol per day based on vitamin E intakes from breast milk, this converts into a required 
minimum vitamin E content of formulae of 0.6 mg α-tocopherol/100 kcal as RRR-α-tocopherol. 
Therefore, the Panel proposes a minimum vitamin E content in IF and FOF of 0.6 mg 
α-tocopherol/100 kcal (0.14 mg/100 kJ). This figure is based on vitamin E activity of RRR-α-
tocopherol. 
6.19. Vitamin K 
6.19.1. Current compositional requirements of IF and FOF 
Directive 2006/141/EC lays down 4 μg/100 kcal as the minimum and 25 μg/100 kcal as the maximum 
vitamin K content in IF and FOF, while the SCF (2003b) had proposed 4 μg/100 kcal as the minimum 
and 20 μg/100 kcal as the maximum content. 
6.19.2. Vitamin K content of human milk 
Mean vitamin K concentrations in human milk are around 2.5 μg/L (0.38 µg/100 kcal), but they vary 
considerably, from 0.85 to 9.2 µg/L (0.13-1.4 µg/100 kcal) (IoM, 2001). 
6.19.3. Vitamin K requirements of infants 
In the Panel’s previous opinion on nutrient requirements and dietary intakes of infants and young 
children in the European Union (EFSA NDA Panel, 2013a), the Panel concluded that a vitamin K 
intake of 5 µg/day and 8.5 µg/day was adequate for the majority of infants in the first and second half-
year of life respectively. These values were based on the guidance value proposed by the SCF (1993b) 
of 1 µg/kg body weight per day. 
6.19.4. Vitamin K intakes of infants 
Assuming a human milk intake of 0.8 L/day and a vitamin K content of 2.5 µg/L, an exclusively 
breast-fed infant would consume 2 µg vitamin K per day during the first six months of life. No 
information on vitamin K intakes in infants living in Europe is available. 
6.19.5. Health consequences 
Vitamin K is needed primarily for the synthesis of various factors and proteins involved in blood 
coagulation. No studies have been conducted following the post-natal period to assess any functional 
marker of vitamin K sufficiency or deficiency in infants and young children. The suggested 
associations between phylloquinone intakes and bone health or prevention of atherosclerosis are 
inconsistent (Nordic Council of Ministers, 2014). While low vitamin K stores at birth may predispose 
to haemorrhages in healthy neonates and young infants, later in life clinical consequences of vitamin K 
deficiency are seen almost exclusively in sick children. Natural vitamin K seems to be free of toxic 
side-effects. The SCF concluded in its opinion that there was no evidence of adverse effects associated 
with supplementary intakes of vitamin K in the form of phylloquinone of up to 10 mg/day for limited 
periods of time (SCF, 2003b). 
6.19.6. Recommendations 
Assuming an average energy intake of an infant below six months of age of 500 kcal/day and taking as 
a basis the intake levels of vitamin K considered adequate by the Panel for this age group of 5 µg/day, 
this converts into a required minimum vitamin K content of formulae of 1 µg/100 kcal. 
Therefore, the Panel proposes a minimum vitamin K content in IF and FOF of 1 µg/100 kcal 
(0.24 µg/100 kJ). 
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6.20. Thiamin (vitamin B1) 
6.20.1. Current compositional requirements of IF and FOF 
Based on the opinion of the SCF (2003b), Directive 2006/141/EC provides for minimum and 
maximum thiamin contents in IF and FOF of 60 µg/100 kcal and 300 µg/100 kcal, respectively. 
6.20.2. Thiamin content of human milk 
The average content of thiamin in human milk is 200 µg/L (31 µg/100 kcal) (IoM, 1998) with a range 
of 150-330 µg/L (23-51 µg/100 kcal) (SCF, 2003b). 
6.20.3. Thiamin requirements of infants 
The SCF (1993b) defined the AR and PRI for thiamin for all age groups to be 72 µg/MJ 
(30 µg/100 kcal) and 100 µg/MJ (42 µg/100 kcal), respectively. In the Panel’s previous opinion on 
nutrient requirements and dietary intakes of infants and young children in the European Union (EFSA 
NDA Panel, 2013a), the Panel concluded that a thiamin intake of 200 µg/day and 300 µg/day was 
adequate for the majority of infants in the first half and in the second half of the first year of life, 
respectively. 
6.20.4. Thiamin intakes of infants 
Assuming a human milk intake of 0.8 L/day and a thiamin content of 200 µg/L, an exclusively breast-
fed infant would consume 160 µg thiamin per day during the first six months of life. Mean/median 
thiamin intakes in mostly formula-fed infants from birth to six months are reported to range from 
around 150 to 700 µg/day (Hilbig, 2005; Noble and Emmett, 2006; Fantino and Gourmet, 2008; 
Lennox et al., 2013) and in infants from 6 to < 12 months from around 300 to 1 000 µg/day (Noble 
and Emmett, 2001; Hilbig, 2005; de Boer et al., 2006; DGE, 2008; Fantino and Gourmet, 2008; 
Marriott et al., 2008; Thorsdottir et al., 2008; Lennox et al., 2013). 
6.20.5. Health consequences 
Thiamin in its phosphorylated forms is a coenzyme in the oxidative decarboxylation of 2-oxoacids, for 
example pyruvate, 2-oxoglutarate and branched-chain 2-oxoacids, and in the transketolase reaction 
among hexose and pentose phosphates. The rate of thiamin utilisation depends on carbohydrate intake 
and is related to energy intake. Thiamin deficiency as a consequence of dietary insufficiency has been 
shown to lead to growth restriction, recurrent infections and sudden infant death. Thiamin deficiency 
is rare in higher income countries but an outbreak of lactic acidosis and encephalopathy was reported 
in young infants who had received a formula unintentionally devoid of thiamin as the sole source of 
nutrition (Fattal-Valevski et al., 2005). There are no adverse effects known to be associated with 
excessive thiamin consumption. No UL for thiamin was set by the SCF (2001c). 
6.20.6. Recommendations 
Assuming an average energy intake of an infant below six months of age of 500 kcal/day and taking as 
a basis the intake levels of thiamin considered adequate by the Panel for this age group of 200 µg/day 
based on thiamin intakes from breast milk, this converts into a required minimum thiamin content in 
formula of 40 µg/100 kcal. 
Therefore, the Panel proposes a minimum thiamin content in IF and FOF of 40 µg/100 kcal 
(9.6 µg/100 kJ). 
6.21. Riboflavin (vitamin B2) 
6.21.1. Current compositional requirements of IF and FOF 
Based on the opinion of the SCF (2003b), Directive 2006/141/EC provides for minimum and 
maximum riboflavin contents in IF and FOF of 80 µg/100 kcal and 400 µg/100 kcal, respectively. 
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6.21.2. Riboflavin content of human milk 
The average content of riboflavin in human milk is around 350-600 µg/L (54-92 µg/100 kcal) 
(Picciano, 1995; IoM, 1998). 
6.21.3. Riboflavin requirements of infants 
In the Panel’s previous opinion on nutrient requirements and dietary intakes of infants and young 
children in the European Union (EFSA NDA Panel, 2013a), the Panel concluded that a riboflavin 
intake of 300 µg/day and 400 µg/day was adequate for the majority of infants in the first half and in 
the second half of the first year of life, respectively. 
6.21.4. Riboflavin intakes of infants 
Assuming a human milk intake of 0.8 L/day and a riboflavin content of 450 µg/L, an exclusively 
breast-fed infant would consume 360 µg riboflavin per day during the first six months of life. 
Mean/median riboflavin intakes in mostly formula-fed infants from birth to six months are reported to 
range from around 300 to 700 µg/day (Hilbig, 2005; Noble and Emmett, 2006; Fantino and Gourmet, 
2008; Lennox et al., 2013) and in infants aged 6 to < 12 months from around 500 to 1 400 µg/day 
(Noble and Emmett, 2001; Hilbig, 2005; de Boer et al., 2006; DGE, 2008; Fantino and Gourmet, 
2008; Marriott et al., 2008; Thorsdottir et al., 2008; Lennox et al., 2013). 
6.21.5. Health consequences 
Riboflavin is a precursor of two flavin coenzymes, flavin mononucleotide (FMN) and flavin adenine 
dinucleotide (FAD). FMN and FAD have a role in many biochemical reactions, as components of 
enzymes that catalyse oxidation/reduction reactions in numerous metabolic pathways. They are 
required for lipid degradation, synthesis of steroids and glycogen and amino acid metabolism. Flavo-
enzymes are also involved in niacin synthesis from tryptophan, in the conversion of vitamin B6 into 
pyridoxal phosphate and in the production of methyl-tetrahydrofolate. There is an interaction with iron 
metabolism. Dietary riboflavin deficiency is rare. It leads to non-specific symptoms, particularly of 
mucosal tissues (cheilosis, glossitis, keratitis, gastrointestinal disturbances), and in a late stage to 
hypochromic anaemia. Excess riboflavin consumption has not been associated with adverse effects in 
humans. Therefore, no UL could be established by the SCF (2000e). 
6.21.6. Recommendations 
Assuming an average energy intake of an infant below six months of age of 500 kcal/day and taking as 
a basis the intake levels of riboflavin considered adequate by the Panel for this age group of 
300 µg/day based on riboflavin intakes from breast milk, this converts into a required minimum 
riboflavin content in formulae of 60 µg/100 kcal. 
Therefore, the Panel proposes a minimum riboflavin content in IF and FOF of 60 µg/100 kcal 
(14.3 µg/100 kJ). 
6.22. Niacin 
6.22.1. Current compositional requirements of IF and FOF 
Directive 2006/141/EC provides for minimum and maximum niacin contents in IF and FOF of 
0.3 mg/100 kcal and 1.5 mg/100 kcal, respectively. The SCF (2003b) concluded in its opinion on 
minimum and maximum contents in IF and FOF of 0.3 mg/100 kcal and 1.2 mg/100 kcal, respectively. 
6.22.2. Niacin content of human milk 
The average content of niacin in mature human milk from European mothers has been reported to be 
in the range 1.8-2.2 mg/L (0.28-0.34 mg/100 kcal) (DHSS, 1977; Ford et al., 1983). 
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6.22.3. Niacin requirements of infants 
Niacin requirements are given as niacin equivalents (NE), the sum of pre-formed niacin plus niacin 
produced from tryptophan (assuming that 60 mg tryptophan is equivalent to 1 mg NE); this definition 
is valid only when the diet contains both niacin and sufficient tryptophan. The niacin requirement is, 
moreover, dependent on the energy intake, with an AR and PRI for all age groups of 1.3 mg NE/MJ 
(0.55 mg NE/100 kcal) and 1.6 mg NE/MJ (0.67 mg NE/100 kcal), respectively. 
In the Panel’s previous opinion on nutrient requirements and dietary intakes of infants and young 
children in the European Union (EFSA NDA Panel, 2013a), the Panel concluded that a niacin intake 
of 2 mg NE/day and 5 mg NE/day was adequate for the majority of infants in the first half and in the 
second half of the first year of life, respectively. These values are in line with a more recent opinion on 
DRVs for niacin (EFSA NDA Panel, 2014f). 
6.22.4. Niacin intakes of infants 
Assuming a human milk intake of 0.8 L/day and a niacin content of 2 mg/L, an exclusively breast-fed 
infant would consume 1.6 mg niacin per day during the first six months of life. Mean/median niacin 
intakes in mostly formula-fed infants from birth to six months are reported to range from 4 to 10 mg 
NE/day (Hilbig, 2005; Noble and Emmett, 2006; Fantino and Gourmet, 2008; Lennox et al., 2013) and 
in infants aged 6 to < 12 months from 4.5 to 14 mg NE/day (Noble and Emmett, 2001; Hilbig, 2005; 
DGE, 2008; Fantino and Gourmet, 2008; Marriott et al., 2008; Thorsdottir et al., 2008; Lennox et al., 
2013). 
6.22.5. Health consequences 
Niacin, that is both nicotinic acid and nicotinamide, is the precursor of the nicotinamide nucleotide 
coenzymes nicotine adenine dinucleotide (NAD) and nicotine adenine dinucleotide phosphate 
(NADP), which are crucial for many oxidation/reduction reactions and are associated with both 
catabolic and anabolic processes. Niacin can be provided in the diet and can be formed in the human 
body from its precursor amino acid, tryptophan. Long-term inadequate intake of niacin and tryptophan 
can lead to the development of pellagra. The profile of adverse effects after excessive intake of 
nicotinic acid and nicotinamide is different. For nicotinic acid, the main adverse effects are flushing 
and hepatotoxicity. For nicotinamide, no such adverse effects have been reported at intakes of several 
grams per day, except for hepatotoxicity in rare cases following consumption of slow-release 
preparations of nicotinamide. The ULs for children aged one to three years of nicotinic acid 
(2 mg/day) and nicotinamide (150 mg/day) have been derived from adult values on the basis of 
reference body weights (SCF, 2002c). 
6.22.6. Recommendations 
Assuming an average energy intake of an infant below six months of age of 500 kcal/day and taking as 
a basis the intake levels of niacin considered adequate by the Panel for this age group of 2 mg/day 
based on niacin intakes from breast milk, this converts into a required minimum niacin content in 
formula of 0.4 mg/100 kcal. 
Therefore, the Panel proposes a minimum niacin content in IF and FOF of 0.4 mg/100 kcal 
(0.10 mg/100 kJ). This is pre-formed niacin. 
6.23. Pantothenic acid 
6.23.1. Current compositional requirements of IF and FOF 
Based on the opinion of the SCF (2003b), Directive 2006/141/EC provides for minimum and 
maximum pantothenic acid contents in IF and FOF of 0.4 mg/100 kcal and 2 mg/100 kcal, 
respectively. 
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6.23.2. Pantothenic acid content of human milk 
The average content of pantothenic acid in human milk is reported to be around 2.5 mg/L 
(0.38 mg/100 kcal) (EFSA NDA Panel, 2014h). 
6.23.3. Pantothenic acid requirements of infants 
In the Panel’s previous opinion on nutrient requirements and dietary intakes of infants and young 
children in the European Union (EFSA NDA Panel, 2013a), the Panel concluded that a pantothenic 
acid intake of 2 mg/day and 3 mg/day was adequate for the majority of infants in the first half and in 
the second half of the first year of life, respectively. These values are in line with the more recent 
opinion of the Panel on DRVs for pantothenic acid (EFSA NDA Panel, 2014h). 
6.23.4. Pantothenic acid intakes of infants 
Assuming a human milk intake of 0.8 L/day and a pantothenic acid content of 2.5 mg/L, an 
exclusively breast-fed infant would consume 2 mg pantothenic acid per day during the first six months 
of life. No information on pantothenic acid intakes in infants living in Europe is available. 
6.23.5. Health consequences 
Pantothenic acid is required in the synthesis of coenzyme A (CoA) and acyl carrier proteins and thus 
has a central role in a wide variety of metabolic pathways. Pantothenic acid deficiency is rare because 
of the widespread nature of this nutrient. Deficiency occurs only in individuals on a diet free of 
pantothenic acid or given pantothenic acid antagonists (EFSA NDA Panel, 2013a). Pantothenic acid 
has a very low toxicity, and minor adverse gastrointestinal effects occur only at very high intake levels 
(10-20 g/day). The SCF estimated that no UL could be established for pantothenic acid (SCF, 2002e). 
6.23.6. Recommendations 
Assuming an average energy intake of an infant below six months of age of 500 kcal/day and taking as 
the basis the intake levels of pantothenic acid considered adequate by the Panel for this age group of 
2 mg/day based on pantothenic acid intakes from breast milk, this converts into a required minimum 
pantothenic acid content in formulae of 0.4 mg/100 kcal. 
Therefore, the Panel proposes a minimum pantothenic acid content in IF and FOF of 0.4 mg/100 kcal 
(0.10 mg/100 kJ). 
6.24. Vitamin B6 
6.24.1. Current compositional requirements of IF and FOF 
Directive 2006/141/EC provides for minimum and maximum vitamin B6 contents in IF and FOF of 
35 µg/100 kcal and 175 µg/100 kcal. The SCF (2003b) concluded in its opinion on minimum and 
maximum contents in IF and FOF of 35 µg/100 kcal and 165 µg/100 kcal. 
6.24.2. Vitamin B6 content of human milk 
The content of vitamin B6 in breast milk varies greatly and is dependent on maternal intakes. The 
average concentration of vitamin B6 in milk of unsupplemented well-nourished mothers is 130 µg/L 
(20 µg/100 kcal), reflecting a maternal vitamin B6 intake of less than 2.5 mg/day (IoM, 1998). The 
pyridoxine content of human milk may be marginal for infants whose mothers’ vitamin B6 intake is 
low. 
6.24.3. Vitamin B6 requirements of infants 
In the Panel’s previous opinion on nutrient requirements and dietary intakes of infants and young 
children in the European Union (EFSA NDA Panel, 2013a), the Panel concluded that a vitamin B6 
intake of 100 µg/day and 400 µg/day was adequate for the majority of infants in the first half and in 
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the second half of the first year of life, respectively. The dietary requirement for vitamin B6 varies in 
relation to the dietary consumption of protein (Hansen et al., 1996). 
6.24.4. Vitamin B6 intakes of infants 
Assuming a human milk intake of 0.8 L/day and a vitamin B6 content of 130 µg/L, an exclusively 
breast-fed infant would consume 104 µg vitamin B6 per day during the first six months of life. 
Mean/median vitamin B6 intakes in mostly formula-fed infants from birth to six months were reported 
to range from around 200-500 µg/day (Hilbig, 2005; Noble and Emmett, 2006; Fantino and Gourmet, 
2008; Lennox et al., 2013) and in infants from 6 to < 12 months from around 400-1 150 µg/day (Noble 
and Emmett, 2001; Hilbig, 2005; de Boer et al., 2006; DGE, 2008; Fantino and Gourmet, 2008; 
Marriott et al., 2008; Thorsdottir et al., 2008; Lennox et al., 2013). 
6.24.5. Health consequences 
Pyridoxine and pyridoxal, found in plants and animal products, respectively, are converted to 
pyridoxal phosphate in tissues. Pyridoxal phosphate acts as a coenzyme in the metabolic 
transformation of amino acids, decarboxylation, transamination and racemisation, the metabolism of 
lipids and nucleic acids and in glycogen metabolism. Symptomatic dietary vitamin B6 deficiency was 
described in infants with pyridoxine-responsive convulsive seizures in the early 1950s, and was 
associated with hypochromic microcytic anaemia, vomiting, diarrhoea, failure to thrive, lethargy or 
hyper-irritability (Borschel, 1995). It was concluded that an intake below 50 μg/day can cause vitamin 
B6 deficiency whilst an intake of about 70 μg/day does not. Reversible acute neuropathy and 
encephalopathy were observed in an infant with infantile type I hyperoxaluria at age 10 weeks under 
treatment with megadoses of pyridoxine (1 000 mg/day); symptoms disappeared when the dose was 
reduced to 400 mg/day (de Zegher et al., 1985). The UL for vitamin B6 is based on neurotoxicity, 
which may occur in a mild form at doses of 100 mg/day in adults. By applying an uncertainty factor of 
4, the UL of 25 mg for adults was derived. A UL for children aged one to three years of 5 mg/day has 
been set by extrapolation from adults (SCF, 2000g). 
6.24.6. Recommendations 
Assuming an average energy intake of an infant below six months of age of 500 kcal/day and taking as 
a basis the intake levels of vitamin B6 considered adequate by the Panel for this age group of 
100 μg/day based on vitamin B6 intakes from breast milk, this converts into a required minimum 
vitamin B6 content in formulae of 20 μg/100 kcal. 
Therefore, the Panel proposes a minimum vitamin B6 content in IF and FOF of 20 μg/100 kcal 
(4.8 µg/100 kJ). 
6.25. Biotin 
6.25.1. Current compositional requirements of IF and FOF 
Based on the opinion of the SCF (2003b), Directive 2006/141/EC provides for minimum and 
maximum biotin contents in IF and FOF of 1.5 µg/100 kcal and 7.5 µg/100 kcal, respectively. 
6.25.2. Biotin content of human milk 
The average content of biotin in human milk is around 5 μg/L (0.8 µg/100 kcal) (EFSA NDA Panel, 
2014c). 
6.25.3. Biotin requirements of infants 
In the Panel’s previous opinion on nutrient requirements and dietary intakes of infants and young 
children in the European Union (EFSA NDA Panel, 2013a), the Panel concluded that a biotin intake of 
4 µg/day and 6 µg/day was adequate for the majority of infants in the first half and in the second half 
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of the first year of life, respectively. These values are in line with the more recent opinion of the Panel 
on DRVs for biotin (EFSA NDA Panel, 2014c). 
6.25.4. Biotin intakes of infants 
Assuming a human milk intake of 0.8 L/day and a biotin content of 5 µg/L, an exclusively breast-fed 
infant would consume 4 µg biotin per day during the first six months of life. No information on biotin 
intakes in infants from birth to six months living in Europe is available. For infants from 6 to < 12 
months of age, data are available from one study only (DGE, 2008), which reported median biotin 
intakes of around 20-23 µg/day. 
6.25.5. Health consequences 
Biotin is a cofactor for the enzymes acetyl-CoA carboxylase, propionyl-CoA carboxylase, 
β-methylcrotonyl-CoA carboxylase and pyruvate carboxylase, which play critical roles in the synthesis 
of fatty acids, the catabolism of branched-chain amino acids and gluconeogenesis. Dietary biotin 
deficiency is rare and does not occur in breast-fed infants. It is characterised by fine, scaly dermatitis, 
hair loss, conjunctivitis, ataxia and delayed child development. Biotin deficiency has been observed in 
patients receiving long-term TPN without biotin supplementation and in patients with biotinidase 
deficiency, as well as in people who had consumed large amounts of raw eggs. The SCF estimated that 
no UL could be established for biotin (SCF, 2001b). 
6.25.6. Recommendations 
Assuming an average energy intake of an infant below six months of age of 500 kcal/day and taking as 
a basis the intake levels of biotin considered adequate by the Panel for this age group of 4 µg/day 
based on biotin intakes from breast milk, this converts into a minimum biotin content in formulae of 
0.8 µg/100 kcal (rounding up to 1 µg/100 kcal). 
Therefore, the Panel proposes a minimum biotin content in IF and FOF of 1 µg/100 kcal 
(0.24 µg/100 kJ). 
6.26. Folate 
6.26.1. Current compositional requirements of IF and FOF 
Directive 2006/141/EC provides for minimum and maximum folate contents in IF and FOF of 
10 µg/100 kcal and 50 µg/100 kcal, respectively. In its opinion, the SCF (2003b) recommended 
minimum and maximum contents of folate in IF and FOF of 10 µg/100 kcal and 30 µg/100 kcal, 
respectively. 
6.26.2. Folate content of human milk 
The average content of folate in human milk was found to be around 80 μg/L (12.3 µg/100 kcal) (Lim 
et al., 1998; Mackey and Picciano, 1999; Kim et al., 2004; Khambalia et al., 2006; Houghton et al., 
2009; West et al., 2012). 
6.26.3. Folate requirements of infants 
Because the absorption efficiency of folates varies depending on their chemical form, dietary folate 
equivalents (DFE) have been defined by IoM (1998) as 1 DFE = 1 µg food folate = 0.6 µg folic acid 
from fortified food or as a supplement consumed with food = 0.5 µg of a folic acid supplement taken 
on an empty stomach. In the Panel’s previous opinion on nutrient requirements and dietary intakes of 
infants and young children in the European Union (EFSA NDA Panel, 2013a), the Panel concluded 
that a folate intake of 65 µg DFE/day and 80 µg DFE/day was adequate for the majority of infants in 
the first half and in the second half of the first year of life, respectively. This is in line with a more 
recent draft opinion of the Panel on DRVs for folate (EFSA NDA Panel, 2014b) released for public 
consultation. 
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6.26.4. Folate intakes of infants 
Assuming a human milk intake of 0.8 L/day and a folate content of 80 µg/L, an exclusively breast-fed 
infant would consume 64 µg folate per day during the first six months of life. None of the surveys 
conducted in infants below six months of life reported folate intakes as DFE. For infants from 6 to 
< 12 months only, the German VELS study (Verzehrsstudie zur Ermittlung der Lebensmittelaufnahme 
von Säuglingen und Kleinkindern) (DGE, 2008) reported folate intakes as DFE. Median folate intakes 
in this study were 62 µg and 78 µg DFE per day in girls and boys, respectively. 
6.26.5. Health consequences 
Folate is essential for one-carbon transfer reactions, including those involved in glycine/serine and 
homocysteine/methionine interconversion, and in purine and pyrimidine synthesis. Folate deficiency 
impairs de novo DNA synthesis and consequently cellular replication. Folate deficiency has also been 
associated with irritability, forgetfulness, neuropathy and depression. Poor folate status in the 
periconceptual period increases the risk of neural tube defects. Folate deficiency has not been reported 
in breast-fed infants, even in the infants of mothers with low folate status. Excess dietary folate is 
mainly excreted in the urine. Consumption of high amounts of folic acid by subjects deficient in 
cobalamin increases the risk of neurological damage by masking the haematological manifestations of 
cobalamin deficiency. The SCF noted that, in nearly all studies showing neurological damage, the 
folic acid dose was ≥ 5 mg folic acid/day, which was taken to represent the Lowest Observed Adverse 
Effect Level (LOAEL). Using an uncertainty factor of 5, the UL for adults was set at 1 mg/day. The 
UL for folic acid for children aged one to three years of 200 μg/day was derived by extrapolation 
based on body weight (SCF, 2000d). A UL for food folate was not set. 
6.26.6. Recommendations 
Assuming an average energy intake of an infant below six months of age of 500 kcal/day and taking as 
a basis the intake levels of folate considered adequate by the Panel for this age group of 65 µg 
DFE/day based on folate intakes from breast milk, this converts into a minimum folate content in 
formulae of 13 µg/100 kcal (rounded up to 15 µg/100 kcal). 
The Panel proposes a minimum folate content in IF and FOF of 15 µg DFE/100 kcal (3.6 µg 
DFE/100 kJ). 
6.27. Cobalamin (vitamin B12) 
6.27.1. Current compositional requirements of IF and FOF 
Based on the opinion of the SCF (2003b), Directive 2006/141/EC provides for minimum and 
maximum cobalamin contents in IF and FOF of 0.1 µg/100 kcal and 0.5 µg/100 kcal, respectively. 
6.27.2. Cobalamin content of human milk 
The mean value in breast milk of a group of 24 healthy Californian women, most of whom had 
consumed supplements containing 6 µg cobalamin/day during pregnancy, was 1.2 µg/L 
(0.18 µg/100 kcal) (range 0.2–5.0 µg/L (0.03-0.77 µg/100 kcal)) (Lildballe et al., 2009). In a recent 
longitudinal study, the cobalamin concentration of breast milk from 25 Danish mothers was measured 
at two weeks, four months and nine months of lactation (Greibe et al., 2013). Most women were 
taking daily multivitamin supplements providing 1.0–4.5 µg cobalamin. Median (range) 
concentrations of cobalamin in hindmilk were 1.03 (0.28–2.55), 0.39 (0.19–0.94) and 0.60 (0.22–2.63) 
µg/L at two weeks, four months and nine months, respectively. The corresponding concentrations per 
100 kcal were 0.16 (0.04-0.39), 0.06 (0.03-0.14) and 0.09 (0.03-0.40) µg/100 kcal. 
6.27.3. Cobalamin requirements of infants 
In the Panel’s previous opinion on nutrient requirements and dietary intakes of infants and young 
children in the European Union (EFSA NDA Panel, 2013a), the Panel concluded that a cobalamin 
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intake of 0.4 µg/day and 0.5 µg/day was adequate for the majority of infants in the first half and in the 
second half of the first year of life, respectively. 
6.27.4. Cobalamin intakes of infants 
Assuming a human milk intake of 0.8 L/day and a cobalamin content of 0.5 µg/L, an exclusively 
breast-fed infant would consume 0.4 µg cobalamin per day during the first six months of life. 
Mean/median cobalamin intakes in mostly formula-fed infants from birth to six months were reported 
to range from around 1.3 to 1.8 µg/day (Noble and Emmett, 2006; Fantino and Gourmet, 2008; 
Lennox et al., 2013) and in infants aged 6 to < 12 months from around 1.2 to 3.6 µg/day (Noble and 
Emmett, 2001; de Boer et al., 2006; DGE, 2008; Fantino and Gourmet, 2008; Marriott et al., 2008; 
Thorsdottir et al., 2008; Lennox et al., 2013). 
6.27.5. Health consequences 
In humans, cobalamin is required as a coenzyme for two reactions: the isomerisation of 
methylmalonyl-CoA to succinyl-CoA by mitochondrial methylmalonyl-CoA mutase and the 
methylation of homocysteine to methionine by methionine synthase. Cobalamin deficiency is rare in 
infants but can occur in infants breast fed by vegan mothers with (subclinical) cobalamin deficiency. 
In infants, cobalamin deficiency results in cerebral atrophy and symptoms of encephalopathy with 
developmental retardation. No adverse effects have been associated with excess cobalamin intake 
from food or supplements in healthy individuals. No UL could be established by the SCF for 
cobalamin (SCF, 2000f). 
6.27.6. Recommendations 
Assuming an average energy intake of an infant below six months of age of 500 kcal/day and taking as 
a basis the intake levels of cobalamin considered adequate by the Panel for this age group of 
0.4 µg/day based on cobalamin intakes from breast milk, this converts into a minimum cobalamin 
content in formulae of 0.08 µg/100 kcal (rounded up to 0.1 µg/100 kcal). 
Therefore, the Panel proposes a minimum cobalamin content in IF and FOF of 0.1 µg/100 kcal 
(0.02 µg/100 kJ). 
6.28. Vitamin C 
6.28.1. Current compositional requirements of IF and FOF 
Based on the opinion of the SCF (2003b), Directive 2006/141/EC provides for minimum and 
maximum vitamin C contents in IF and FOF of 10 mg/100 kcal and 30 mg/100 kcal, respectively. 
6.28.2. Vitamin C content of human milk 
Mean vitamin C concentrations in human milk are reported to range from 35 to 90 mg/L 
(5.4-13.8 mg/100 kcal) (EFSA NDA Panel, 2013e). The amount of vitamin C excreted via breast milk 
depends on the vitamin C status of the mother, and the vitamin C content in human milk reflects 
maternal vitamin C intake more than the infant’s requirement (WHO/FAO, 2004). 
6.28.3. Vitamin C requirements of infants 
In the Panel’s previous opinion on nutrient requirements and dietary intakes of infants and young 
children in the European Union (EFSA NDA Panel, 2013a), the Panel concluded that a vitamin C 
intake of 20 mg/day is adequate for the majority of infants. 
6.28.4. Vitamin C intakes of infants 
Assuming a human milk intake of 0.8 L/day and a vitamin C content of 60 mg/L, an exclusively 
breast-fed infant would consume 48 mg vitamin C per day during the first six months of life. 
Mean/median vitamin C intakes in mostly formula-fed infants from birth to six months are reported to 
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range from around 40 to 90 mg/day (Hilbig, 2005; Noble and Emmett, 2006; Fantino and Gourmet, 
2008; Lennox et al., 2013) and in infants aged 6 to < 12 months from around 33 to 94 mg/day (Noble 
and Emmett, 2001; Hilbig, 2005; de Boer et al., 2006; DGE, 2008; Fantino and Gourmet, 2008; 
Marriott et al., 2008; Thorsdottir et al., 2008; Lennox et al., 2013). 
6.28.5. Health consequences 
Vitamin C (L-ascorbic acid and dehydroascorbic acid) is an enzyme cofactor for biochemical reactions 
catalysed by mono-oxygenases, dioxygenases and mixed function oxygenases. Vitamin C plays an 
important role in the biosynthesis of collagen, is essential for the synthesis of carnitine and 
catecholamines and is also involved in the metabolism of cholesterol to bile acids. Vitamin C in 
aqueous solution readily scavenges reactive oxygen and nitrogen species, as well as singlet oxygen 
and hypochlorite, and is part of the antioxidant network of the body (EFSA NDA Panel, 2013e). Frank 
vitamin C deficiency leads to scurvy but has been observed only after the sixth month of life in infants 
fed a diet consisting of cow’s milk with no fruits and vegetables. Vitamin C is of low acute toxicity 
and available data on adverse effects are limited. No UL has been set by the Panel, but available 
human data suggest that supplemental daily doses of vitamin C up to about 1 g in addition to normal 
dietary intakes in adults are not associated with adverse effects (EFSA, 2004). 
6.28.6. Recommendations 
Assuming an average energy intake of an infant below six months of age of 500 kcal/day and taking as 
the basis the intake levels of vitamin C considered adequate by the Panel for this age group of 
20 mg/day, based on three times the amount known to prevent scurvy, this converts into a minimum 
vitamin C content in formulae of 4 mg/100 kcal. 
Therefore, the Panel proposes a minimum vitamin C content in IF and FOF of 4 mg/100 kcal 
(0.96 mg/100 kJ). 
7. Maximum content of micronutrients in IF and FOF 
As the different protein and fat sources used in the manufacture of formulae and the water used to 
reconstitute powdered formulae contribute to the total nutrient content of a formula in varying 
amounts, maximum contents of nutrients have been established in order to ensure the safe use of 
formulae while limiting technological manipulations of the natural nutrient content of food 
constituents used in the production of formulae. 
From a nutritional point of view, the minimum contents proposed by the Panel cover the nutritional 
needs of virtually all healthy infants born at term and there is no need to exceed these amounts in 
formulae, as nutrients which are not used or stored have to be excreted, and this may put a burden on 
the infant’s metabolism. Therefore, the Panel emphasises that maximum amounts should be 
interpreted not as target values but rather as upper limits of a range which should not be exceeded. 
Specifications for the currently permitted maximum amounts of micronutrients in formulae were 
mostly calculated as three to five times the minimum amounts established at the time, took into 
account established history of apparent safe use (Codex Stan 72-1981, Codex Stan 156-1987, 
Directive 2006/141/EC and the SCF (2003b)), and were not based on scientific evidence for adverse 
effects owing to the lack of such evidence for most nutrients. 
The Panel notes that there are no reports of any adverse effects associated with the use of formulae 
complying with the current specifications as laid down in Directive 2006/141/EC, although there are 
no studies available which were designed to investigate the short- or long-term health consequences of 
consumption of formulae containing the currently permitted maximum amounts of micronutrients in 
IF or FOF. 
The Panel acknowledges that the scientific data available to derive ULs for infants remain scarce for 
most micronutrients and a UL for infants could be set only for vitamin D (EFSA NDA Panel, 2012d). 
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For magnesium, zinc, selenium, iodine, molybdenum, vitamin A, niacin, vitamin B6 and folic acid, 
ULs for children aged one to three years have been established (SCF, 2000g, 2000d, 2000c, 2000b, 
2001a, 2002b, 2002c, 2002d, 2002a). Assuming an energy intake from formula of 500 kcal/day 
(average of the AR for energy of boys and girls aged three to four months), regular consumption of a 
formula by an infant containing the currently permitted maximum amounts of zinc, iodine, vitamin A 
and folate (if the whole amount is provided in the form of folic acid) would imply that the ULs would 
be exceeded for these nutrients. Assuming an energy intake from formula of 700 kcal/day (highest 
observed mean energy intakes in infants below six months of age), intakes of selenium would also 
exceed the UL. The Panel acknowledges that the ULs used in this estimation were those derived for 
young children and there is considerable uncertainty with respect to the extrapolation to infants. 
8. Specifications for other ingredients in IF and FOF 
8.1. Choline 
Choline is currently mandatory in IF, and Directive 2006/141/EC provides for minimum and 
maximum choline contents of 7 mg/100 kcal and 50 mg/100 kcal, respectively. In its opinion, the SCF 
(2003b) concluded on minimum and maximum contents of choline in IF of 7 mg/100 kcal and 
30 mg/100 kcal, respectively. 
In human milk, choline is found as free choline, phosphocholine, glycerophosphocholine, 
sphingomyelin and phosphatidylcholine, all of which are available to the nursing infant. Total choline 
concentrations in human milk are influenced by maternal choline intake, length of lactation and 
genetic polymorphisms. The concentration of total choline in mature milk is 160-210 mg/L 
(25-32 g/100 kcal) (Holmes-McNary et al., 1996; Holmes et al., 1996). In one study (reported in two 
publications), mean choline levels were found to range between 144 and 170 mg/L 
(22-26 mg/100 kcal) and to increase from 70 mg/L (11 mg/100 kcal) in colostrum to 151 mg/L 
(23 mg/100 kcal) (range 57-318 mg/L (9-49 mg/100 kcal)) in mature milk (Ilcol et al., 2005; Allen, 
2012). In a second study (Fischer et al., 2010) comparing breast milk concentrations in 
unsupplemented and supplemented mothers, the average choline content in breast milk amounted to 
125 and 149 mg/L (19 and 23 mg/100 kcal), respectively. The average total choline concentration in 
mature human milk can be taken to be around 160 mg/L (20 mg/100 kcal). 
Choline is predominantly provided via the diet, but the human body can also form choline de novo via 
two pathways that both lead to phosphatidylcholine. The extent to which choline is a required dietary 
constituent under normal circumstances is not clear. However, in conditions of increased need or of 
impaired synthesis, choline is considered to be conditionally indispensable. Choline has a number of 
important functions: it is a precursor of phospholipids, platelet-activating factor, betaine and the 
neurotransmitter acetylcholine and it is involved in the metabolism and transport of lipids. Dietary 
deficiency of choline in adults has been reported to cause liver steatosis (Buchman et al., 1995) and 
liver (Zeisel et al., 1991) and muscle damage (Fischer et al., 2007). Choline was not considered in the 
derivation of ULs in the EU. A UL for choline of 1 g/day for children aged one to three years has been 
set by IoM (1998). The UL was extrapolated from the UL of adults based on relative body weights. 
The UL for adults was based on a case report of hypotension and several studies involving cholinergic 
effects and fishy body odour after oral administration of large doses of choline. No UL for infants was 
derived owing to the lack of data and concerns about the infant’s ability to handle excess amounts. 
In the Panel’s previous opinion on nutrient requirements and dietary intakes of infants and young 
children in the European Union (EFSA NDA Panel, 2013a), the Panel concluded that a choline intake 
of 130 mg/day was adequate for the majority of infants below six months of age and of 150 mg/day 
for infants aged 6 to < 12 months. 
Assuming an average energy intake of an infant below six months of age of 500 kcal/day and taking as 
a basis the intake level of choline considered adequate by the Panel for this age group of 130 mg/day 
based on choline intakes from breast milk, this converts into a minimum choline content in formulae 
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of 26 mg/100 kcal (rounded down to 25 mg/100 kcal). Therefore, the Panel proposes a minimum 
choline content in IF of 25 mg/100 kcal (6.0 mg/100 kJ). There is no necessity to add choline to FOF. 
There are no reports of adverse effects occurring with the current specifications of choline in IF. 
8.2. Inositol 
Inositol is currently mandatory in IF, and Directive 2006/141/EC provides for minimum and 
maximum inositol contents of 4 mg/100 kcal and 40 mg/100 kcal, respectively, in line with the SCF 
(2003b). 
In addition to sugars such as lactose, glucose, galactose and mannose, human milk also contains sugar 
alcohols/polyols, in particular inositol, mostly as myo-inositol, either free or in phosphorylated forms. 
The myo-inositol concentration has been found to be higher in colostrum and reaches a relatively 
stable concentration of around 130-325 mg/L (20-50 mg/100 kcal) in mature human milk (Cavalli et 
al., 2006; Jóźwik et al., 2013). Inositol plays a role in many important biological functions including 
the regulation of cell osmolality, processes of cell signalling, as structural components of the 
developing neural system and in the production of the phospholipids for pulmonary surfactant. 
Endogenous de novo synthesis of inositol appears to be efficient in newborn infants. Together with 
inositol provided by human milk, this makes it unlikely that healthy, term, breast-fed infants could 
become depleted of inositol (Brown LD et al., 2009). However, it is not known if endogenous inositol 
synthesis is sufficient in the absence of dietary inositol. 
Considering that it is unknown if endogenous synthesis of inositol in newborns is sufficient in the 
absence of dietary inositol, the Panel proposes to maintain the minimum inositol content in IF of 
4 mg/100 kcal (0.96 mg/100 kJ) proposed in 2003 by the SCF. The Panel considers that there is no 
necessity to add inositol to FOF, as the supply from complementary food is sufficient in older infants. 
There are no reports of adverse effects occurring with the current specifications of inositol in IF. 
8.3. Taurine 
The addition of taurine to IF and FOF is currently permitted by Directive 2006/141/EC on a voluntary 
basis up to a maximum of 12 mg/100 kcal. Taurine concentrations in milk from mothers of term 
infants have been found to be around 4.7 mg/100 kcal (Zhang et al., 2013), with highest observed 
taurine concentrations of around 12 mg/100 kcal (Rassin et al., 1978). 
It has been suggested that taurine plays a role in intestinal fat absorption, hepatic function and auditory 
and visual development in pre-term or low-birth weight infants. However, clinical data on long-term 
effects on neurological development in these infants are lacking (Verner et al., 2007), as is evidence 
that the addition of taurine to IF has any clinical benefits for term infants. 
Taking into account the lack of convincing evidence for a benefit of the addition of taurine to IF 
and/or FOF, the Panel considers that there is no necessity to add taurine to IF or FOF. 
There are no reports of adverse effects occurring with the current specifications of taurine in formulae. 
8.4. L-Carnitine 
The addition of L-carnitine at an amount of at least 1.2 mg/100 kcal is currently mandatory for IF 
containing ISP or protein hydrolysates but not for IF based on cow’s or goat’s milk protein, as the 
latter are considered to provide L-carnitine naturally from the milk source. 
L-Carnitine is considered an indispensable nutrient for newborn infants because of a temporarily 
insufficient synthesising capacity. In studies investigating L-carnitine concentrations in milk from 
different species, mean total carnitine concentrations have been reported to be in the range 
0.9-1.6 mg/100 kcal in human milk (Sandor et al., 1982; Penn et al., 1987; Ferreira, 2003), 
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4.1-6.7 mg/100 kcal in cow’s milk (Sandor et al., 1982; Penn et al., 1987; Ferreira, 2003) and 
3.2-4.4 mg/100 kcal in goat’s milk (Sandor et al., 1982; Penn et al., 1987). The natural carnitine 
content of animal milks may be decreased by dilution or fractionation of the milk source when cow’s 
and goat’s milk proteins are used in the manufacture of IF. Therefore, a minimum L-carnitine content 
should be also set for IF based on milk protein. 
The Panel notes that no new data have become available since the opinion of the SCF (2003b) which 
would indicate that a minimum content of L-carnitine of 1.2 mg/100 kcal in IF is insufficient to ensure 
adequate growth and development of infants. The Panel proposes a minimum L-carnitine content in IF 
of 1.2 mg/100 kcal (0.3 mg/100 kJ), irrespective of the protein source used, which is an amount 
similar to the content of L-carnitine in human milk. The Panel considers that there is no necessity to 
add L-carnitine to FOF, as the supply from complementary food and from endogenous synthesis is 
sufficient in older infants. 
8.5. Nucleotides and nucleosides 
The addition of nucleotides to IF and FOF is currently permitted by Directive 2006/141/EC on a 
voluntary basis up to a maximum of 5 mg/100 kcal. If added, the maximum nucleotide content is 
regulated to be cytidine 5′-monophosphate (CMP) 2.5 mg/100 kcal, uridine 5′-monophosphate (UMP) 
1.75 mg/100 kcal, adenosine 5′-monophosphate (AMP) 1.50 mg/100 kcal, guanosine 5′-
monophosphate (GMP) 0.50 mg/100 kcal and inosine 5′-monophosphate (IMP) 1.00 mg/100 kcal. 
Nucleotides and nucleosides are dispensable nutrients synthesised de novo in human metabolism. 
Nucleotides are structural components of ribonucleic acid (RNA) and DNA. Nucleotides, such as 
ATP, transfer chemical energy. Other nucleotides are involved in the synthesis of proteins, lipids and 
carbohydrates (e.g. NAD, FAD) (SCF, 2003b). 
Human milk contains free nucleosides, free nucleotides, RNA and DNA. The concentrations of “total 
potentially available nucleotides”, defined by some authors as the sum of free nucleosides, free 
nucleotides, nucleotide-containing adducts (such as NAD and uridine diphosphate (UDP) glucose) and 
nucleotide polymers, were reported to be around 10.5-11.0 mg/100 kcal in milk from Asian, American 
and European mothers. The major sources were nucleotide polymers, primarily RNA (around 
43-48 %), free nucleotides (around 36-40 %) and free nucleosides (around 6.5-8 %) (Leach et al., 
1995; Tressler et al., 2003). Average concentrations of nucleotides in human milk were observed to be 
in the range 0.7-4.5 mg/100 kcal for CMP, 0.3-2.3 mg/100 kcal for UMP, 0.05-1.9 mg/100 kcal for 
GMP, 0.2-1.7 mg/100 kcal for AMP and 0-1.4 mg/100 kcal for IMP (Gil and Sanchez-Medina, 1982; 
Janas and Picciano, 1982; Leach et al., 1995; Thorell et al., 1996; Tressler et al., 2003; Liao et al., 
2011), with four studies out of six reporting IMP concentrations below the limit of detection. 
It should be noted that the presence of nucleotides and nucleosides in human milk does not necessarily 
indicate a specific benefit for the infants as they may also be by-products of milk formation that reflect 
metabolic activity of the mammary gland tissue, shedding of somatic cells and occurrence of 
microorganisms, without having a specific function for the infant (SCF, 2003b). 
Nucleotides have been studied in healthy, term infants with respect to their effect on clinically relevant 
outcomes such as antibody titres after vaccination (Pickering et al., 1998; Yau et al., 2003; Schaller et 
al., 2004; Hawkes et al., 2006), the incidence or severity of infections (Carver et al., 1991; Brunser et 
al., 1994; Yau et al., 2003), the incidence of diarrhoea (Brunser et al., 1994; Yau et al., 2003; Singhal 
et al., 2008) and growth (Carver et al., 1991; Pickering et al., 1998; Lasekan et al., 1999; Yau et al., 
2003; Schaller et al., 2004; Singhal et al., 2010). The Panel notes that, although effects on some of the 
antibody titres measured in the studies were observed, these effects were not consistent and that no 
effects of nucleotides on the incidence or severity of infections, on the incidence of diarrhoea or on 
growth were observed. 
Taking into account the lack of convincing evidence for a benefit of the addition of nucleotides to IF 
and/or FOF, the Panel considers that there is no necessity to add nucleotides to IF or FOF. 
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There are no reports of adverse effects occurring with the current specifications of nucleotides in 
formula. 
8.6. “Probiotics” and “synbiotics” 
The addition of live microorganisms to IF and FOF is not mentioned in the relevant Directives, except 
for production of acidified IF and FOF, for which the use of non-pathogenic L-(+)-lactic acid- 
producing bacterial cultures is permitted (Regulation (EC) No 1333/2008). However, according to 
Directive 2006/141/EC, IF and FOF may contain food ingredients other than those listed in Annexes I 
and II, provided those ingredients have been shown to be suitable for infants through a systematic 
review of the available data or, when necessary, by appropriate studies (Articles 5 and 6). 
IF and FOF with added live bacteria and claiming to confer health benefits (generally referred to as 
“probiotics”) have been introduced into the EU market. Several bacterial strains included in IF and 
FOF have been evaluated with regard to safety and potential beneficial health effects to date. These 
include Bifidobacterium animalis subsp. lactis CNCMI-3446 (also named B. bifidum and B. lactis 
Bb12), alone or in combination with either Streptococcus thermophilus or with both S. thermophilus 
and Lactobacillus helveticus, L. johnsonii La1, B. longum BL999 plus L. rhamnosus LPR, 
L. rhamnosus GG, L. reuteri ATCC 55730, L. salivarius CECT5713 and L. fermentum CECT5716 
(Braegger et al., 2011; Gil-Campos et al., 2012; Maldonado et al., 2012; Mugambi et al., 2012). 
The health outcomes evaluated in RCTs include growth, gastrointestinal infections/diarrhoea, 
respiratory tract infections/symptoms, colic/irritability, allergic manifestations, stool frequency and 
consistency and antibody production (Braegger et al., 2011; Gil-Campos et al., 2012; Holscher et al., 
2012; Mugambi et al., 2012; Szajewska and Chmielewska, 2013). 
The most recent systematic reviews (Mugambi et al., 2012; Szajewska and Chmielewska, 2013) 
concluded that many of the studies conducted with IF and FOF supplemented with “probiotic” bacteria 
did not find significant physiological or health effects compared with non-supplemented formulae. 
These reviews also revealed uncertainty regarding the beneficial effects reported for formulae 
supplemented with some of the strains through lack of consistency across studies, to methodological 
limitations and to the existence of data from single studies only (Braegger et al., 2011; Szajewska and 
Chmielewska, 2013). Such uncertainty applies to the effects of IF supplemented with B. animalis 
subsp. lactis CNCMI-3446 (alone or in combination) on diarrhoea, which were not consistent across 
studies with substantial methodological limitations and also applies to the effects of other strains 
evaluated only in single studies such as L. johnsonii La1 and L. salivarius CECT5713 on diarrhoea, L. 
salivarius CECT 5713 on respiratory tract infections, and L. rhamnosus LGG on defecation frequency 
and stool consistency (Braegger et al., 2011). 
A couple of recent studies have evaluated the effects of the strain L. fermentum CECT 5716, isolated 
from human milk, added to GOS containing IF compared with the same IF without the bacterium. The 
first study was designed to evaluate the safety and tolerance of the IF supplemented with L. fermentum 
CECT 5716 in infants of one to six months of age and, as secondary outcomes, also evaluated 
infections, reporting reductions in the incidence of gastrointestinal infections, but not of respiratory or 
total infections (Gil-Campos et al., 2012). The second study was conducted on healthy six-month-old 
infants and reported a reduced incidence rate of gastrointestinal and upper respiratory tract infections, 
but not of lower respiratory tract infections, otitis, urinary tract infections or febrile episodes, between 
the ages of 6 and 12 months in the L. fermentum CECT 5716 group compared with the control group 
(Maldonado et al., 2012). The Panel notes that the two studies were not consistent regarding the 
effects on respiratory tract infections and that one of the studies on gastrointestinal infections was 
designed not for this purpose, but for evaluating safety. Another recent single study reported that 
B. animalis subsp. lactis CNCMI-3446 added to formula containing partially hydrolysed whey protein 
increased anti-poliovirus-specific immunoglobulin A (IgA) concentration (p < 0.05) but not anti-
rotavirus-specific IgA, following immunisation, and only in a sub-group of infants delivered by 
caesarean section (Holscher et al., 2012). 
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IF and FOF containing “probiotics” have also been studied in relation to any potential untoward 
effects, such as delayed growth, diarrhoea and allergic reactions (Braegger et al., 2011; Gil-Campos et 
al., 2012; Maldonado et al., 2012; Azad et al., 2013). It has been generally concluded that currently 
evaluated “probiotic”-supplemented IF do not raise safety concerns with regard to growth or other 
adverse effects, although in many studies adverse events were inconsistently reported (Azad et al., 
2013) and further evaluations of safety in long-term studies are needed (Braegger et al., 2011). 
A few studies have been conducted with IF or FOF supplemented with combinations of “probiotics” 
and “prebiotics” (named “synbiotics”) on growth, infections, asthma/wheezing, crying and stool 
frequency/constipation (reviewed by Braegger et al., 2011; and Azad et al., 2013). The synbiotics 
evaluated in RCTs in infants include B. longum BL999 plus GOS/FOS, B. longum BL999 plus 
L. rhamnosus LPR plus GOS/FOS, B. longum BL999 plus L. paracasei ST11 plus GOS/FOS, L. 
paracasei subsp. paracasei plus B. animalis subsp. lactis plus GOS and B. breve M-16V plus 
GOS/FOS. The evidence on the effectiveness is very limited and only data from single studies are 
available. These have reported effects on increased stool frequency for three of the synbiotics tested 
(B. longum BL999 plus GOS/FOS, B. longum BL999 plus L. rhamnosus LPR plus GOS/FOS and 
L. paracasei subsp. paracasei plus B. animalis subsp. lactis plus GOS) (reviewed by Braegger et al., 
2011) and on parent-reported asthma-like symptoms, but not on total serum IgE and specific IgE 
against aeroallergens (van der Aa et al., 2011 reviewed by Azad et al., 2013). 
Safety of “synbiotics” added to IF and FOF has also been evaluated and it was concluded that they do 
not give rise to concerns with regard to growth or other adverse effects, although the evidence is 
limited (Braegger et al., 2011). 
The Panel notes that the evidence available so far on beneficial effects of IF or FOF supplemented 
with “probiotics” and “synbiotics” on infant health mainly comes from single studies and studies with 
methodological limitations, or it is inconsistent across the few studies that are comparable. Therefore, 
the Panel considers that there is insufficient information to draw conclusions on beneficial effects on 
infant health of “the probiotics strains” added to IF and FOF under the conditions of use investigated 
so far in humans and even less in the case of the “synbiotics” tested (detailed above). There is no 
evidence that gives rise to concerns about the safety of the tested “probiotics” or “synbiotics”. 
Taking into account the lack of convincing evidence for a benefit of the addition of the “probiotics” or 
the “synbiotics” evaluated in humans so far added to IF and/or FOF, the Panel considers that there is 
no necessity to add those “probiotics” and/or “synbiotics” to IF or FOF. 
9. Use of formulae by young children 
The Panel was also asked to advise the Commission with respect to the appropriate age range of use 
and the essential composition of so-called “growing-up milks” or young-child formulae. 
In its previous opinion (EFSA NDA Panel, 2013a), the Panel considered that, despite the fact that an 
adequate amount of energy and nutrients can be supplied by a balanced and varied diet, intakes of 
ALA, DHA, iron, vitamin D and iodine in some infants and young children living in Europe are low 
and some sub-groups in this population may be at risk of inadequacy. This consideration was based on 
assessment of nutrient intake data and on studies investigating the nutrient status of infants and young 
children living in Europe. 
In the same opinion, the Panel noted that formulae, including young-child formulae, are one of several 
means to increase intakes of these critical nutrients in infants and young children living in Europe with 
inadequate or at risk of inadequate status of these nutrients. However, other means, such as fortified 
cow’s milk, fortified cereals and cereal-based foods, supplements or the early introduction of meat and 
fish into complementary feeding and their continued regular consumption, are efficient alternatives to 
increase intakes of these nutrients. The selection of the appropriate form and vehicle through which 
these nutrients are provided in the diet will depend on national dietary habits, health authorities, the 
regulatory context and caregivers’ preference. 
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The Panel concluded that no unique role of young-child formulae with respect to the provision of 
critical nutrients in the diet of infants and young children living in Europe can be identified, so that 
they cannot be considered as a necessity to satisfy the nutritional requirements of young children when 
compared with other foods that may be included in the normal diet of young children. The median 
content of ALA, DHA (if added), iron, vitamin D and iodine in currently marketed young-child 
formulae is within the range of permitted concentrations in FOF and, except for iron, also in IF. The 
Panel notes that formulae consumed during the first year of life can continue to be used by young 
children. Therefore, the Panel does not consider it necessary to propose specific compositional criteria 
for formulae consumed after one year of age. 
10. Recommendations for further research 
The Panel emphasises: 
 the necessity to generate reliable analytical data on the amino acid pattern of human milk 
protein at different stages of lactation; 
 the necessity for appropriate studies to fill the gaps in the knowledge of protein requirements 
of infants in the second half of the first year of life; 
 the lack of human studies evaluating the safety and adequacy of most IF and FOF presently on 
the market containing protein hydrolysates; 
 the necessity to generate data on the decrease of bioavailability of certain amino acids through 
different methods of processing; 
 the lack of non-digestible oligosaccharides that mimic those present in human milk and the 
lack of appropriate human studies evaluating the safety and potential health benefits of non-
digestible oligosaccharides and bacteria whose growth in the infant’s gut is promoted by 
breast milk. 
CONCLUSIONS 
The Panel concludes that: 
 There is consensus that breast milk is the preferred food for all healthy infants and provides an 
adequate supply of all nutrients to support growth and development (with the exception of 
vitamin K during the first weeks of life and of vitamin D). 
 All formulae intended for infants must be safe and suitable to meet the nutritional 
requirements and to promote growth and development of infants born at term when used as a 
sole source of nutrition during the first months of life and when used as the principal liquid 
element in a progressively diversified diet after the introduction of appropriate complementary 
feeding. Nutrients and substances should be added to formulae for infants only in amounts that 
serve a nutritional or other benefit. 
 The minimum content of a nutrient in formulae proposed in this opinion is derived from the 
intake levels the Panel had considered adequate for the majority of infants in the first half of 
the first year of life in its previous opinion and an average amount of formulae consumed 
during this period (500 kcal/day). From a nutritional point of view, the minimum contents 
proposed by the Panel cover the nutritional needs of virtually all healthy infants born at term 
and there is no need to exceed these amounts in formulae, as nutrients which are not used or 
stored have to be excreted, and this may put a burden on the infant’s metabolism and/or 
physiological functions. 
 Specifications for the currently permitted maximum amounts of micronutrients in formulae 
were mostly calculated as three to five times the minimum amounts established at the time and 
took into account an established history of apparent safe use (Codex Stan 72-1981, Codex 
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Stan 156-1987, the Directive 2006/141/EC, and SCF (2003b)) and were not based on scientific 
evidence of adverse effects owing to the lack of such evidence for most nutrients. It is 
emphasised that maximum amounts should be interpreted not as target values but rather as 
upper limits of a range which should not be exceeded. 
 There are no reports on any adverse effects associated with the use of formulae complying 
with the current specifications for micronutrients as laid down in Directive 2006/141/EC, 
although there are no studies available which were designed to investigate the short- or long-
term health consequences of consumption of IF or FOF containing the currently permitted 
maximum amounts of micronutrients. Assuming an energy intake from formula of 
500 kcal/day (average of the AR for energy of boys and girls aged three to four months), 
regular consumption of a formula by an infant containing the currently permitted maximum 
amounts of zinc, iodine, vitamin A and folate (if the whole amount is provided in the form of 
folic acid) would imply that the ULs would be exceeded for these nutrients. Assuming an 
energy intake from formula of 700 kcal/day (highest observed mean energy intakes in infants 
below six months of age), intakes of selenium would also exceed the UL. The Panel 
acknowledges that the ULs used in this estimation were those derived for young children and 
there is uncertainty with respect to the extrapolation to infants. 
 Cow’s milk, goat’s milk and ISP are safe and suitable protein sources for use in IF and FOF 
based on intact protein. The use of other protein sources in IF and FOF and/or the introduction 
of new technologies need clinical evaluation and their safety and suitability should be 
established in the target population prior to their general use in IF and FOF. 
 Formulae containing protein hydrolysates are insufficiently characterised by the declared 
protein content even if they fulfil regulatory criteria concerning amino acid patterns and 
contents; therefore, the safety and suitability of each specific IF or FOF containing protein 
hydrolysates has to be established by clinical evaluation. 
 The use of a default conversion factor of 6.25 to calculate the protein content from the total 
nitrogen content is proposed, irrespective of the protein source. 
 IF and FOF should provide on an energy basis indispensable and conditionally indispensable 
amino acids in amounts at least equal to the reference protein (i.e. breast milk), irrespective of 
the protein source and the following reference pattern is proposed:  
Amino acid g/100 g protein mg/100 kcal mg/100 kJ 
Cysteine 2.1 38 9 
Histidine 2.2 40 10 
Isoleucine 5.0 90 22 
Leucine 9.2 166 40 
Lysine 6.3 113 27 
Methionine 1.3 23 5 
Phenylalanine 4.6 83 20 
Threonine 4.3 77 18 
Tryptophan 1.8 32 8 
Tyrosine 4.2 76 18 
Valine 4.9 88 21 
 
 The sum of methionine and cysteine and the sum of tyrosine and phenylalanine in IF may be 
used for calculation purposes. If the ratio of methionine to cysteine or the ratio of tyrosine to 
phenylalanine exceeds 2, this must be justified by clinical evaluation. For FOF, no restrictions 
with respect amino acid ratios need to apply, because complementary foods will contribute to 
amino acid intakes and the metabolism of older infants is more mature with respect to the 
capacity to convert methionine to cysteine and phenylalanine to tyrosine. 
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 The following composition of IF and FOF based on intact cow’s and goat’s milk protein is 
proposed:  
  
Range  
 
Range 
 
Unit IF FOF Unit IF FOF 
Energy kcal/100 mL 60-70 kJ/100 mL 250-293 
Protein g/100 kcal 1.8-2.5 g/100 kJ 0.43-0.60 
Total fat g/100 kcal 4.4-6.0 g/100 kJ 1.1-1.4 
LA mg/100 kcal 500-1 200 mg/100 kJ 120-300 
ALA mg/100 kcal 50-100 mg/100 kJ 12-24 
DHA
(a) 
mg/100 kcal 20-50 mg/100 kJ 4.8-12 
TFA FA% ≤ 3 FA% ≤ 3 
Carbohydrates g/100 kcal 9-14 g/100 kJ 2.2-3.3 
Lactose, unless g/100 kcal ≥ 4.5 g/100 kJ ≥ 1.1 
"lactose-free" g/100 kcal ≤ 0.01 g/100 kJ ≤ 0.0024 
Sucrose, fructose 
and sugars from 
honey 
% of total CHO 0 ≤ 20 % of total CHO 0 ≤ 20 
Glucose g/100 kcal 0 0 g/100 kJ 0 0 
Starches 
≤ 2 g/100 mL, not more than 30 % of total CHO for IF, unrestricted 
within maximum amounts as long as free of gluten 
  
Minimum 
 
Minimum 
 
Unit IF FOF Unit IF FOF 
Calcium mg/100 kcal 50 mg/100 kJ 12 
Phosphorus mg/100 kcal 25 mg/100 kJ 6 
Magnesium mg/100 kcal 5 mg/100 kJ 1.2 
Sodium mg/100 kcal 25 mg/100 kJ 6 
Chloride mg/100 kcal 60 mg/100 kJ 14.3 
Potassium mg/100 kcal 80 mg/100 kJ 19.1 
Iron mg/100 kcal 0.3 0.6 mg/100 kJ 0.07 0.14 
Zinc mg/100 kcal 0.5 mg/100 kJ 0.12 
Copper µg/100 kcal 60 µg/100 kJ 14.3 
Selenium µg/100 kcal 3 µg/100 kJ 0.72 
Iodine µg/100 kcal 15 µg/100 kJ 3.6 
Molybdenum µg/100 kcal 0.4 µg/100 kJ 0.1 
Manganese µg/100 kcal 1 µg/100 kJ 0.24 
Vitamin A
(b)
 µg/100 kcal 70 µg/100 kJ 16.7 
Vitamin D µg/100 kcal 2 µg/100 kJ 0.48 
Vitamin E
(c) mg α-TE/100 kcal 0.6 mg α-TE/100 kJ 0.14 
Vitamin K µg/100 kcal 1 µg/100 kJ 0.24 
Thiamin µg/100 kcal 40 µg/100 kJ 9.6 
Riboflavin µg/100 kcal 60 µg/100 kJ 14.3 
Niacin
(d) 
mg/100 kcal 0.4 mg/100 kJ 0.10 
Pantothenic acid mg/100 kcal 0.4 mg/100 kJ 0.10 
Vitamin B6 µg/100 kcal 20 µg/100 kJ 4.8 
Biotin µg/100 kcal 1 µg/100 kJ 0.24 
Folate µg DFE/100 kcal 15 µg DFE/100 kJ 3.6 
Cobalamin µg/100 kcal 0.1 µg/100 kJ 0.02 
Vitamin C mg/100 kcal 4 mg/100 kJ 0.96 
Choline mg/100 kcal 25 NN mg/100 kcal 6 NN 
L-Carnitine mg/100 kcal 1.2 NN mg/100 kJ 0.3 NN 
Inositol mg/100 kcal 4 NN mg/100 kJ 0.96 NN 
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(a) The amount of EPA should not be higher than the amount of DHA.  
(b) Pre-formed vitamin A.  
(c) Vitamin E activity of RRR-α-tocopherol.  
(d) Pre-formed niacin. 
NN, not necessary; CHO, carbohydrates. 
 For IF and FOF containing hydrolysed protein, the same requirements as for formulae based 
on intact cow’s and goat’s milk protein should apply, except for the minimum protein content, 
which cannot be proposed, and the adequacy of the protein content of a specific IF or FOF 
containing hydrolysed proteins needs to be established based on clinical evaluation. The 
maximum protein content should, however, not exceed 2.8 g/100 kcal (0.67 g/100 kJ). 
 Furthermore, for IF and FOF containing ISP, the same requirements as for formulae based on 
intact cow’s and goat’s milk protein should apply, except for a minimum and maximum 
protein content of 2.25-2.8 g/100 kcal (0.54-0.67 g/100 kJ), a minimum phosphorus content of 
30 mg/100 kcal (7.2 mg/100 kJ), a minimum iron content of 0.45 mg/100 kcal 
(0.11 mg/100 kJ) for IF and of 0.90 mg/100 kcal (0.22 mg/100 kJ) for FOF and a minimum 
zinc content of 0.75 mg/100 kcal (0.18 mg/100 kJ). There should be no requirement for a 
minimum lactose content in IF and FOF containing ISP. 
 The minimum content of nutrients in IF and FOF proposed by the Panel is identical with the 
exception of iron. If the same formula is to be used from the first months of infancy, and is to 
be suitable for the whole first year of life, the minimum iron content should be 
0.6 mg/100 kcal (0.14 mg/100 kJ) for formulae based on intact cow’s and goat’s milk protein 
and formulae containing protein hydrolysates, and 0.9 mg/100 kcal (0.22 mg/100 kJ) for 
formulae containing ISP. 
 There is no necessity to add ARA, EPA, chromium, fluoride, taurine, nucleotides, non-
digestible oligosaccharides, “probiotics” or “synbiotics” to IF and FOF. There is also no 
necessity to use PL as a source of LCPUFAs instead of TAG in IF and FOF or to use TAG 
with palmitic acid predominantly esterified in the sn-2 position in IF and FOF instead of TAG 
from other fat sources. For FOF, in contrast to IF, the addition of L-carnitine, inositol and 
choline is not necessary. 
 As formulae consumed during the first year of life can continue to be used by young children, 
the Panel did not consider it necessary to propose specific compositional criteria for formula 
consumed after one year of age. 
DOCUMENTATION PROVIDED TO EFSA 
Evidence report related to an extensive literature search and review as preparatory work for the 
evaluation of the essential composition of infant and follow-on formulae and growing-up milks 
provided by Pallas Health Research and Consultancy following a procurement procedure. 
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ABBREVIATIONS 
AAP American Academy of Pediatrics 
AI Adequate Intake 
ALA alpha-linolenic acid 
AMP adenosine 5′-monophosphate 
AOS acidic oligosaccharides 
AR Average Requirement 
ARA arachidonic acid 
ATP adenosine triphosphate 
BMD bone mineral density 
BMI body mass index 
BSID Bayley Scales of Infant Development 
CD coeliac disease 
CLA conjugated-linoleic acid 
CMP cytidine 5′-monophosphate 
CoA coenzyme A 
DFE dietary folate equivalent 
DHA docosahexaenoic acid 
DNA deoxyribonucleic acid 
DPA docosapentaenoic acid 
DRV Dietary Reference Value 
DXA dual-energy X-ray absorptiometry 
E % percentages of the total energy intakes 
EPA eicosapentaenoic acid 
ESPGHAN European Society for Paediatric Gastroenterology Hepatology and 
Nutrition 
FA % percentage of total fatty acids 
FAD flavin adenine dinucleotide 
Essential composition of infant and follow-on formulae  
 
EFSA Journal 2014;12(7):3760 105 
FADS fatty acid desaturase 
FMN flavin mononucleotide 
FOF follow-on formulae 
FOS fructo-oligosaccharides 
GMP guanosine 5′-monophosphate 
GOS galacto-oligosaccharides 
HDL high-density lipoprotein 
HLA human leucocyte antigen 
IDD iodine deficiency disorders 
IF infant formula(e) 
Ig immunoglobulin 
IGF insulin-like growth factor 
IGFBP IGF-binding protein 
IMP inosine 5′-monophosphate 
IQ intelligence quotient 
ISP isolated soy protein 
LA linoleic acid 
LC long-chain 
LOAEL Lowest Observed Adverse Effect Level 
MCFA medium-chain fatty acid 
MDI Mental Developmental Index 
MUFA monounsaturated fatty acid 
NAD nicotine adenine dinucleotide 
NADP NAD phosphate 
NE niacin equivalents 
NEPSY A Developmental NEuroPSYchological Assessment 
NPN non-protein nitrogen 
PDI Psychomotor Development Index 
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PL phospholipid 
PPVT-III Peabody Picture Vocabulary Test, 3rd edition 
PPVT-R PPVT, revised 
PRI Population Reference Intake 
PUFA polyunsaturated fatty acid 
RCT randomised controlled trial 
RE retinol equivalents 
RI Reference Intake range for macronutrients 
RNA ribonucleic acid 
SCF Scientific Committee on Food 
SCFA short-chain fatty acid 
SD standard deviation 
SFA saturated fatty acid 
SNP single-nucleotide polymorphism 
T1DM type 1 diabetes mellitus 
TAG triacylglycerol 
TDI Tolerable Daily Intake 
TE tocopherol equivalents 
TFA trans-fatty acid 
ToR Terms of Reference 
TPN total parenteral nutrition 
UDP uridinediphosphate 
UL Tolerable Upper Intake Level 
UMP uridine 5′-monophosphate 
VELS Verzehrsstudie zur Ermittlung der Lebensmittelaufnahme von 
Säuglingen und Kleinkindern 
WPPSI-R Wechsler Preschool and Primary Scale of Intelligence Revised 
WHO World Health Organization 
 
